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FOREWORD
The question of how much health care contributes to the health of populations has been
debated for several decades. Writing in the 1970s, Professor Thomas McKeown argued that
its contribution had been minor, as much of the decline in mortality in industrialised
countries took place before effective health care was available. Instead, he emphasised the
role of broader social policies, leading to changes such as better nutrition and cleaner water.
However, as several commentators have noted, McKeown was describing a period in which
health care still had relatively little to offer. It was only in the 1960s and 1970s that safe
and effective drugs for many chronic diseases became widely available. 
In the 1980s, several researchers, including Professor Walter Holland, the Nuffield Trust’s
1997 Rock Carling lecturer, began work on what was variously termed avoidable or
amenable mortality. This involved looking at deaths that should not occur in the presence
of effective and timely health care. This work suggested that health care was indeed having
an impact on premature mortality at the population level. 
While this work led to much interest at the time, the concept of avoidable mortality has
recently received rather less attention. Yet there are now several reasons why we should
revisit it. One is the growing international interest in comparing the performance of health
systems, exemplified by the World Health Organization’s 2000 World Health Report, with
its controversial rankings of health systems. Another is the growing interest in the complex
relationship between the health and wealth of nations, exemplified by the report of the
Commission on Macro-Economics and Health. 
The Nuffield Trust's purpose is to communicate evidence and encourage an exchange
around developed or developing knowledge in order to illuminate recognised and emerging
issues. As such, it is entirely appropriate that it should contribute to these discussions. One
way that it has done this is by publishing this important book, which describes the findings
of a study co-funded by the Trust and by Merck & Co., in association with the European
Observatory on Health Care Systems. 
The authors, Ellen Nolte and Martin McKee, have done an excellent job in assembling the
extensive literature that now exists on avoidable mortality, bringing the definitions up to
date, and then applying them to patterns of mortality in a range of industrialised countries.
They confirm that health care has made an appreciable difference to population health,
while showing that the impact varies among countries. 
This work bridges two of the Trust’s key themes, public health and quality in health care,
and I commend it to health service researchers and health policy makers interested in
benchmarking the performance of health systems.  
John Wyn Owen C.B.
Secretary, Nuffield Trust
February 2004
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EXECUTIVE SUMMARY
Does health care save lives? Commentators such as McKeown and Illich, writing in the
1960s, argued that it played very little part, and might even be harmful. However they were
writing about a period when health care had relatively little to offer compared to today.
Since then, several writers have described often quite substantial improvements in death
rates from conditions for which effective interventions have been introduced. But the
debate continues, with some arguing that health care is making an increasingly important
impact on overall levels of health while others contend that it is in the realm of broader
policies, such as education, transport and housing, that we should look to for future
advances in health. Inevitably this is to a considerable extent a false dichotomy. Both are
important. But how much does health care contribute to population health?
One way in which this question has been addressed previously is to look at deaths that
should not occur in the presence of effective and timely health care, so-called ‘avoidable’
mortality. However much of this work was undertaken in the 1980s and early 1990s, since
when health care has advanced considerably. In addition, ‘avoidable’ deaths were often
limited to those before, for example, the age of 65, a figure that seems inappropriately low
in the light of life expectancies that are now about 80 in many countries. 
In this review we have traced the evolution of the concept of ‘avoidable’ mortality from its
inception in the 1970s. We have undertaken a detailed methodological critique of this
concept, examining questions of attribution, issues relating to comparisons over time and
place, and relationships with other indicators of health service provision. To help future
researchers we have produced a comprehensive, annotated review of the work that has been
undertaken worldwide so far. 
We note that ‘avoidable’ mortality was never intended to be more than an indicator of
potential weaknesses in health care that can then be investigated in more depth. We
describe examples of where this approach has been successful, drawing attention to
problems that might otherwise have been missed. 
In contrast, many of the critics of ‘avoidable’ mortality, or more specifically, mortality
amenable to health care (amenable mortality), have asked that it do something it was not
intended to do, to be a definitive source of evidence of differences in effectiveness of health
8
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care. Thus, it is not unexpected that studies seeking to link amenable mortality with health
care resources have failed to do so, especially when undertaken within countries, although
it is notable that where gross differences exist, as between western and eastern Europe, the
gap in amenable mortality is especially high. For these reasons, it seems justifiable to
continue and extend the extensive body of research that has already been undertaken to
look at ‘avoidable’ mortality, updating the list of conditions included to reflect the changing
scope of health care and extending the age limit to reflect increasing expectation of life.
However it must be recognised that the concept of ‘avoidable’ mortality does have
important limitations, relating to comparability of data, attribution of causes, and coverage
of the range of health outcomes. 
Comparisons of health system performance are now firmly on the international policy
agenda, especially since the publication of the 2000 World Health Report. Incorporation of
the concept of mortality amenable to health care into the methodology used to generate the
rankings of health systems in that report would be an advance on the current situation. We
show how, within Europe, this would lead to different rankings from those based on overall
disability adjusted life expectancy, which is used in the current rankings. 
However, any approach based on aggregate data would not address one of the major
criticisms of such comparisons, that they do not indicate what needs to be done when faced
with evidence of sub-optimal performance. This requires a more detailed analysis of the
specific issues facing health systems. Here we propose a new method, in which analyses of
amenable mortality identify areas of potential concern that are then examined in more
detail by studying the processes and outcomes of care for tracer conditions, selected on the
basis of their ability to assess a wide range of health system components. 
The second part of the review applies the refined method of amenable mortality analysis to
patterns of mortality in the countries of the European Union over the past two decades.
This shows that deaths that could be prevented by timely and effective care were still
relatively common in many countries in 1980. Reductions in these deaths contributed
substantially to the overall change in life expectancy between birth and age 75 during the
1980s. The largest contribution was from falling infant mortality but in some countries
reductions in deaths among the middle aged was equally or even more important. These
countries were Denmark, The Netherlands, the United Kingdom, France (for men) and
Sweden (for women). 
In contrast, during the 1990s, reductions in amenable mortality made a somewhat smaller
contribution to improved life expectancy, especially in the northern European countries.
However they remained important in southern Europe, especially in Portugal and Greece,
where the initial death rates had been higher. 
These findings provide clear evidence that improvements in access to effective health care
have had a measurable impact in many countries during the 1980s and 1990s, in particular
through reductions in infant mortality and in deaths among the middle aged and elderly,
especially women. However the scale of impact has, to a considerable extent, reflected the
starting point. Thus, those countries where infant mortality was relatively high at the
beginning of the 1980s, and which had the greatest scope for improvement, such as Greece
and Portugal, unsurprisingly saw the greatest reductions in amenable mortality in infancy.
In contrast, in countries with infant mortality rates that had already reached very low rates
by the beginning of the 1990s, such as Sweden, the scope for further improvement was
small.
Similarly, the scope for improvement in amenable deaths in adulthood was greatest in those
countries where initial rates were highest. The corollary of this is that as rates fall in all
countries, the extent of variation decreases. As a consequence, it seems likely that, in the
21st century, the ability to compare health system performance using mortality data at the
aggregate level is likely to be limited, simply because the differences will be relatively small.
This does not, however, mean that there is not scope for analyses that use amenable
mortality rates to screen for potential problems that can then be explored in more depth. It
also does not exclude the use of amenable mortality to gain new insights into inequalities
in access to care within populations. 
D O E S  H E A LT H  C A R E  S A V E  L I V E S ?   A V O I D A B L E  M O R T A L I T Y  R E V I S I T E D
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BACKGROUND
The publication by the World Health Organisation (WHO) of the 2000 World Health
Report1, with its rankings of the performance of health care systems, as well as subsequent
methodological work by the OECD, has placed the issue of health system performance on
the international health policy agenda.2
As defined by the WHO, health system performance has three dimensions, health
attainment, responsiveness, and fairness of financing. Health attainment is defined as
healthy life expectancy, or the length of time that someone in the country in question can
expect to live in good health. This measure has the advantage that it can be obtained for
many countries, although it should also be noted that the adjustment of life expectancy for
levels of health in most cases involves a process of estimation and, in a majority of
countries even life expectancy must be estimated because of the absence of comprehensive
mortality data. However it also has an important weakness. Overall health attainment will
reflect the influence of very many different factors, only some of which lie within the health
care system. Thus, for example, in western Europe there is a significant correlation between
overall health attainment, as reported in the World Health Report, and national levels of
consumption of fruit and vegetables, as an indicator of a healthy diet. 
Yet it is apparent from everyday experience that health care has some influence on levels of
health. Many conditions that would once have been fatal can now be cured, such as
common childhood infections. The discovery of insulin has transformed juvenile onset
diabetes from what was once an acute, rapidly fatal disease of childhood into one that is
compatible with a normal lifespan. The crucial question is not whether health care
contributes to population health but how much it does? Is its effect only marginal or does
it play a more important role? And, in the debate about health system performance, is it
possible to build on what is known about this relationship to create a more refined measure
of health system performance that can inform international comparisons?
The question of whether health services make a meaningful contribution to population
health has long been debated.3 Several authors, writing from a historical perspective in the
late 1970s, argued persuasively that health care had contributed little to the decline in
mortality that had occurred in industrialised countries from the mid nineteenth to mid
twentieth century. They proposed that this improvement was most likely to be due to the
B A C K G R O U N D
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influence of factors outside the health care sector, in particular nutrition, but also
improvements in the environment.4,5,6 Indeed some, such as Illich, have argued that
developments in health care in the 1950s and 1960s were actually damaging health,
introducing the word iatrogenesis.7
The name of Thomas McKeown is perhaps that most closely identified with the argument
that health care contributed little to population health.4 His study of the decline in
mortality in England and Wales between 1848/54 and 1971 provided some memorable
images, in particular how the largest part of the decline in mortality from tuberculosis
predated the introduction of immunisation or effective chemotherapy (Figure 1).
Figure 1 Mortality from respiratory tuberculosis in England and Wales 
(source: McKeown4)
Yet while this representation is accurate, it is also true that the introduction of
chemotherapy had a quite remarkable impact on death rates from tuberculosis among young
people, as can be seen in Figure 2, which shows the year on year decline in mortality from
tuberculosis in England and Wales at different ages between 1945 and 1955, the period
during which chemotherapy was being introduced.
Figure 2 Death rates from tuberculosis in successive years between 1945 and 1955 in
England and Wales by age group
(source: Office for National Statistic mortality data)
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McKeown’s arguments have been embraced enthusiastically, in particular by groups seeking
to challenge the perceived emphasis given to health care in the debate about the
determinants of health, with arguments implying that, as in the late nineteenth and early
twentieth centuries, health care continues to contribute little to population health. However,
as the example of tuberculosis shows, the reality is not quite so simple. Thus, Mackenbach
has examined changing mortality over a similar period, 1875/79 and 1970, in The
Netherlands, and come to a somewhat different conclusion.8 He accepts that antibiotics
were only introduced after mortality from infectious diseases had already fallen substantially
but he showed how their use was associated with acceleration in the rate of decline. Thus,
between 1921 and 1939, when only some sulphonamides were available in The
Netherlands, the annual decline of mortality from infectious diseases was 4% per annum,
whereas subsequently, when antibiotics such as penicillin became widely available, mortality
from infectious disease declined by 10% per annum. Setting an (arbitrary) cut-off point at
1946 to mark the general introduction of antibiotics in The Netherlands, he estimated, on
the basis of the known effects of antibiotics on specific infectious diseases, that between 1.6
and 4.8% of the total decline in infectious disease mortality between 1875/79 and 1970
could be attributed to medical care. Further analyses also examined the potential impact of
the decline in mortality from common surgical conditions, such as appendicitis and
cholecystitis, resulting from improvements in surgery and anaesthesia from around 1930,
and from perinatal conditions, reflecting improvements in antenatal and perinatal care since
the 1930s. Taking account of all of these factors he estimated that between 5 and 18.5% of
the total decline in mortality between 1875/79 and 1970 in The Netherlands could be
attributed to health care.
More recently there have been a series of reviews of the contribution of health care to health
and there is now consensus that McKeown was correct to the extent that “curative medical
measures played little role in mortality decline prior to mid-20th century.”9 However the
rapidly changing scope and nature of health care does not mean that this can be assumed
still to be the case.
Indeed, the scope of health care has changed enormously in the second half of the twentieth
century. The change is not only in the more obvious areas such as new pharmaceuticals and
technology but also in new and more effective ways of organising care, such as the
introduction of multi-disciplinary stroke units or integrated screening programmes, and in
the development of evidence-based care, enabling traditional but ineffective treatments to be
discarded while innovative and effective ones are adopted and diffused more rapidly. Thus,
while health care may have made little contribution to population health in the past it may
now be playing a rather more important role.  
Several approaches have been developed in attempts to quantify this contribution. The most
widely used makes use of the ready availability of mortality data at a population level and is
based on the concept of deaths from certain causes that should not occur in the presence of
timely and effective health care.  This has given rise to the development of a variety of terms
including “avoidable mortality” and “mortality amenable to medical/health care”.  
B A C K G R O U N D
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Although attempts to systematically assess the quality of medical care using routine data of
vital statistics go back to the 1950s10 and the actual term “avoidable mortality” has been
used since at least the 1960s11, its origins in the form in which it is commonly understood
date from the work of Rutstein and co-workers to develop a measure of the quality of
medical care in the mid-1970s. This concept has been commented on and/or reviewed by
several authors, most notably Holland, Mackenbach and Westerling.12,13,14  However much
of this work dates from the late 1980s and early 1990s and it has received relatively little
recent attention. Indeed, as the 2000 World Health report shows, the concept has been
overlooked in some influential recent studies. In addition, the rapid increase in the pace of
change in health care, as well as increasing expectation of a healthy life, make it important
to revisit this concept. Does ‘avoidable’ mortality still offer a means of assessing health
system performance and is the list of causes of death previously deemed to be avoidable still
valid? 
This publication is in three parts. Part I reviews the existing literature on ‘avoidable’
mortality to create a framework for analysis that takes account of contemporary
circumstances and part II applies this framework to routinely available mortality data in
European countries. Part III provides a comprehensive, annotated review of empirical
studies of ‘avoidable’ mortality that have been undertaken worldwide so far.
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PART I:
THE CONCEPT OF ‘AVOIDABLE’ MORTALITY
A LITERATURE REVIEW
Methods
Literature on “avoidable mortality” was identified from a variety of sources. The main ones
were MEDLINE and HMIC. These were searched for the years 1966 (Medline) or 1979
(HMIC) to the present, using the search terms “amenable mortality”, “avoidable mortality”,
“amenable causes”, “avoidable causes”, “unnecessary deaths”, “untimely deaths”, “quality of
health care”, “health care and (health) outcome”. References cited in papers identified by
this search were followed up. The review concentrates on literature published in peer-
reviewed journals and includes empirical studies as well as conceptual papers. In addition,
the series of European Community (EC) publications on avoidable deaths were included as
they have made a major contribution to the conceptual development of ‘avoidable’ mortality.
Therefore, related literature, although not necessarily peer-reviewed, was also included
whereas national statistical reports, some of which touched on the concept of avoidable
mortality, were not included. The only exceptions were one study published by the Centers
for Disease Control (CDC), which formed the basis for subsequent studies on ‘avoidable’
mortality in the USA. In addition, a conference paper presented by Mackenbach that
updated his earlier work was used as was a report commissioned by the UK Department of
Health that reviewed and extended further the list of ‘avoidable’ causes of death that had
formed the basis for the EC studies of avoidable deaths. Studies looking at selected causes
of ‘avoidable’ death such as tuberculosis or cervical cancer only were excluded as were those
using the term avoidable death or mortality in a broader sense without referring particularly
to the underlying concept of “avoidable mortality”. Finally, the review is limited to work
published in English, French or German.
The first section looks specifically at the evolution of the concept of ‘avoidable’ mortality
and how it has changed over time. This is followed by an overview of the findings of studies
applying this concept at the population level. The third section will examine the conceptual
problems that arise when using “avoidable mortality” as an indicator of quality of care, and
is followed by a concluding section that will explore alternative approaches. 
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Evolution of the concept of ‘avoidable’ mortality
The concept of “avoidable mortality” as it has been used over the last 25 years, stems from
the Working Group on Preventable and Manageable Diseases led by David Rustein of
Harvard Medical School in the USA in the 1970s.15 They introduced the notion of
‘unnecessary untimely deaths’ by proposing a list of conditions from which death should
not occur in the presence of timely and effective medical care. Medical care was defined in
its broadest sense as prevention, cure and care, and including “the application of all relevant
medical knowledge [...], the services of all medical and allied health personnel, institutions
and laboratories, the resources of governmental, voluntary, and social agencies, and the co-
operative responsibility of the individual himself”. Using this broad definition, the Working
Group selected over 90 conditions as ‘sentinel health events’ since cases of disease, disability
or death from these conditions were considered to be preventable and/or treatable by
appropriate and timely medical care. 
Whilst acknowledging that the chain of responsibility to prevent the occurrence of such a
disease or death may be complex (Box 1), and that the physician cannot be solely
responsible for failures that result in a sentinel health event, the authors argue that the
physician nevertheless has a crucial role as being the “one competent to provide the
leadership and the professional guidance” to inform (community) action to prevent such
events. Information on sentinel health events may therefore serve as an index of the quality
of care delivered by particular providers, agencies, and institutions or by particular health
care sectors. Following this line of reasoning, the list includes not only conditions where
the role of medical care appears to be obvious, as for example in the case of appendicitis,
but also conditions where the contribution of medical care is usually believed to be small,
such as lung cancer. 
The conditions thus identified were separated into those where even a single case of disease
or disability or untimely death justifies an immediate enquiry into the question ‘Why did it
happen?’ as, for example in cases of botulism or death from cervical cancer (‘clear-cut’
indicators or ‘single case index’) and conditions where not every single case is considered
preventable or manageable but in which appropriate medical care should be associated with
a lower incidence of that condition, such as the vascular consequences of treated or
untreated hypertension (‘index based on rates’). In addition, each condition was categorised
as to whether the unnecessary disease or disability or untimely death is treatable and/or
preventable. Thus, diphtheria is considered a disease preventable by immunisation whereas
unnecessary untimely death from this condition may be both preventable, again by
immunisation, and treatable, by administering antitoxin and antibiotics. However, lung
cancer is considered preventable only, by means of actions such as reducing or eliminating
exposure to cigarette smoking, asbestos and some other occupational factors, as treatment is
rarely successful once the disease has arisen. In addition, some conditions were considered
sentinel only at certain ages, for example deaths from acute respiratory infections under age
50.
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Box 1 Health care related factors influencing health outcome
“The unnecessary case of diphtheria, measles, or poliomyelitis may be the responsibility of
the state legislature that neglected to appropriate the needed funds, the health officer who
did not implement the program, the medical society that opposed community clinics, the
physician who did not immunize his patient, the religious views of the family, or the mother
who didn’t bother to take her baby for immunization [...] Death from cancer of the lung may
be due to the patient’s unwillingness or inability to give up cigarette smoking, the reassuring
statements put out by the advertiser or manufacturer, the absence of an effective health-
information program in the public schools and in the community, or, more rarely, from an
error in diagnosis or from poor surgical care.”15 
In 1996 Westerling reviewed published evidence of avoidable factors influencing death.16 He
showed that of the studies included 45% identified inadequate diagnosis and 51%
inadequate treatment as avoidable factors. Other important factors identified were delay in
diagnosis (22%) or treatment (31%), failure in preventing, recognising or treating
complications (34%), deficiencies in management of care, such as coordination of different
levels of care (17%) as well as some patient characteristics, especially psychosocial factors
and health care seeking behaviour (20%). These factors varied according to outcome,
however, with, for example, avoidable factors for trauma death being related, mainly, to
hospital care, e.g. delay in diagnosis of injury, failure to recognise injury severity, lack or delay
of surgical treatment and failures in the management of complications. The overall proportion
of trauma deaths potentially avoidable was estimated at 27%. In contrast, about half of
deaths from asthma were identified as having avoidable factors, largely delays in seeking
professional help, attributable to lack of information and education but also to poor access to
care in remote areas and inadequate assessment or treatment of asthma episodes.
The flowchart shown overleaf illustrates some main factors related to health care that have a
potential impact on the health outcome.
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Box 1 Health care related factors influencing health outcome - continued 
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Disease/risk
presentation
Diagnosis
Treatment
Outcome
Access to care:
- GP density
- Travel time
- Opening hours
- Waiting/contact time
Management of
complications:
- recognition 
- availability of treatment
- adequacy of treatment 
- timeliness
Treatment:
- facility availability 
- adequacy
- timeliness
- follow-up
Medical misconduct
Prevention of complications
Recognition of condition
Diagnosis:
- availability
- accuracy
- sensitivity
- timeliness
Coverage / co-payment
Cooperation / integration of
services
Access to care: eligibility
Public health programme
Community programme
Coverage / co-payment
Cooperation / integration of
services
Individual and social characteristics
determining likelihood of contracting
disease and/or health seeking
behaviour: education/social class;
health beliefs, level of concern, costs
of diagnosis/ screening/treatment
Organisation of 
health care: care level
Organisation of 
health care: system level
Rutstein et al.’s original work was undertaken in the mid 1970s, when the 8th revision of
the International Classification of Diseases (ICD), used to classify causes of death, was in
use. Consequently, in 1977 and 1980 revisions of the lists of unnecessary untimely disease,
disability and death were undertaken to take account of the recently introduced 9th
revision, as well as to consider certain advances in health care.17,18 These lists have formed
the basis for practically all subsequent studies on ‘avoidable mortality’.
A first empirical application of this concept was undertaken by Adler in 1978 who used
conditions that were considered single case markers by Rutstein et al. to “demonstrate the
usefulness of this approach” to measure the quality of medical care by evaluating
preventable mortality in the USA in 1968-1971.19 However Charlton et al. were the first to
apply this concept at the population level to analyse regional variation in mortality in
England and Wales in 1974-78, also introducing the terms “avoidable deaths” and
“[conditions] amenable to medical intervention”.20 Based on Rutstein’s list they selected 14
disease groups chosen to reflect different aspects of health care including primary care,
general practice referrals to hospitals and hospital care.21 However conditions whose
avoidance was considered to be outside the scope of medical care, such as lung cancer and
causes of death that were very rare, were excluded (Table 1). Age limits were set within
which each cause was deemed potentially avoidable, most often 5-64 years. Table 1 also
lists, for each condition, those health care providers and related interventions that were
considered relevant to prevent untimely death. 
Using various modifications of their original list of avoidable conditions that, following the
findings of the Hypertension Detection and Follow-up Program Co-operative Group
subsequently also included cerebrovascular disease, Charlton et al. extended their work to
examine trends in mortality amenable to medical intervention at the national22,23 and
international level, for example in England & Wales, USA, France, Japan, Italy and Sweden
between 1956 and 1978.24
A subsequent study to assess the impact of health care or health services using the concept
of ‘avoidable mortality’ was undertaken by Poikolainen and Eskola who looked at trends in
Finland between 1969 and 1981.25 Their list of conditions considered amenable to health
services was also based on the work by Rutstein and co-workers and covered a total of 22
conditions or groups of conditions, including five causes of perinatal death (Table 2).
Similar to Charlton et al.20 their list included conditions such as tuberculosis, cervical
cancer, hypertensive disease and asthma and excluded conditions such as lung cancer
whose prevention, they argued, depended mainly on efforts outside the health services.
Again, as with Charlton et al., they defined an upper age limit, which was usually 65 years,
although for some conditions such as diabetes or asthma this limit was set lower, at age 50.
However acknowledging that there had been innovations in health care, they also analysed a
separate set of seven “partly amenable” conditions that had become amenable during the
study period. These included ischaemic heart disease, non-melanoma skin cancer and
meningitis.
In a further study that compared 25 developed countries, Poikolainen and Eskola extended
their original list, covering in total more than 70 amenable conditions and another 20
partly-amenable conditions (Table 2), thus expanding the concept of “avoidable mortality” 
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Cause of death 20,21 ICD 8 ICD 9 Age Health care providers Intervention
Hypertensive disease † 400-404 401-405 5-64 primary care, hospital Case detection, anti-hypertensive 
medication
Cancer of cervix uteri 180 180 5-64 primary care, hospital, Screening, surgery, radiation therapy
community health services,
pathological services
Pneumonia & bronchitis 480-486, 490 480-486, 490 5-49 primary care, hospitals Antibiotics, early detection of complications
Tuberculosis (excl. silico) ‡ 011-019 010-018 5-64 public health programme, Immunisation, contacts tracing, antibiotics
primary care, hospital
Asthma 493 493 5-49 primary care, hospital Therapy, casualty department care
Chronic rheumatic 393-398 393-398 5-44 primary care, hospital Case detection of streptococci, antibiotics, 
heart disease prophylaxis
Acute respiratory disease 460-466, 470-474 400-466, 470-474 5-49 primary care, hospital Early detection of complications, antibiotics
Bacterial infections* 004, 034, 320, 004, 037, 320-322, 5-64 primary care, public health Early detection of complications, antibiotics
381-383, 390-392, 382-384, 390-392, programmes, hospital
680-686, 710, 720 680-686, 711, 730 
Hodgkin’s disease 201 201 5-34 primary care, hospital, Case detection, chemotherapy
pathological services and radiation therapy
Abdominal hernias 550-553 550-553 5-64 primary care, hospital Case detection, surgery prior to complications
Acute & chronic cholecystitis 574-575 574-575.1 5-64 primary care, hospital Case detection, surgery prior to complications
Appendicitis 540-543 540-543 5-64 primary care, hospital Case detection, surgery prior to complications
Maternal deaths 630-678 630-676 10-44
Deficiency anaemias 280-281 280-281 5-64 primary care, hospital, Case detection, laboratory services
pathological services
Perinatal mortality - -
Table 1 Amenable causes of death: Charlton et al
† subsequently combined with cerebrovasuclar disease (ICD8,9: 430-438; age 35-64); ‡ Silico tuberculosis excluded in ICD8; not separately identified in ICD9
* mismatch of codes: ICD8 034 = streptococcal sore throat, ICD9 037= tetanus; no explanation by authors
considerably.26 They also drew up an explicit list of “not amenable” conditions. Importantly,
this list of not amenable conditions included cerebrovascular disease, a condition that had
just been added to the list of conditions considered amenable to health care by Charlton et
al.24 Also in contrast to other work, chronic rheumatic heart disease was considered only
partly amenable to medical care. Reasons for this selection were not, however, given. 
At the same time, building on the work by Charlton et al.20, the EC Concerted Action
Project on Health Services and ‘Avoidable Deaths’, established in the early 1980s, adopted
and modified the concept of avoidable mortality, resulting in the publication of the
European Community Atlas of ‘Avoidable Death’ in 1988, a major work that has since been
updated twice.27,28,29,30,31 The first edition and the first volume of the 2nd edition each
cover 17 disease groups, which were considered to be effectively treatable or preventable by
health care services (Table 3). Health care services were interpreted as to include primary
care, hospital care, and collective health services such as screening and public health
programmes, e.g. immunisation. The conditions were chosen on the basis of having
“identifiable effective interventions and health care providers”. Named ‘avoidable death
indicators’ these causes intended to “provide warning signals of potential shortcomings in
health care delivery”.27
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Cause of death25,26 ICD 8 (A-List) Age 1986 1988
Amenable to medical care
Infectious diseases (1986) A1-12, 16-17, 20, 22-26, 0-64 ✔
34-38, 42, 78, 119, 123
Infectious diseases (1988) A1-20, 22-26, 28, 31, 0-64 ✔
33-43, 119, 123
Malignant neoplasm of cervix uteri A55 0-64 ✔ ✔
Diabetes mellitus A64 0-49 ✔ ✔
Goitre, thyrotoxicosis, avitaminoses A62, 63, 65 0-64 ✔ ✔
& nutritional defiencies
Epilepsy A74 0-64 ✔ ✔
Inflammatory diseases of eye, A75-78 0-64 ✔
cataract, glaucoma
Active rheumatic fever A80 0-64 ✔ ✔
Hypertensive disease A82 0-64 ✔ ✔
Venous thrombosis and embolism A87 0-64 ✔
Acute respiratory infections; A89-92 0-49 ✔ ✔
influenza; pneumonia
Bronchitis, emphysema & asthma A93 0-49 ✔ ✔
Hypertrophy of tonsils; A94-95 0-49/64 ✔
empyema & abcess of lung
Diseases of teeth and supporting structures A97 0-49 ✔
Peptic ulcer A98 0-64 ✔ ✔
Table 2 Amenable causes of death: Poikolainen & Eskola 
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Cause of death25,26 ICD 8 (A-List) Age 1986 1988
Amenable to medical care
Gastritis & duodenitis A99 0-64 ✔
Appendicitis A100 0-64 ✔ ✔
Intestinal obstruction & hernia A101 0-64 ✔ ✔
Cholelithiasis & cholecystitis A103 0-64 ✔ ✔
Acute nephritis A105 0-64 ✔
Diseases of genito-urinary system A107-110 0-64 ✔
Complications of pregnancy, A112-118 0-64 ✔ ✔
childbirth & the puerperium
Diseases of skin; arthritis A120, 121, 122 0-64 ✔
& spondylitis; rheumatism
Cleft palate and cleft lip A129 0-64 ✔
Birth injury & difficult labour A131 0 ✔ ✔
Conditions of placenta & cord A132 0 ✔
Haemolytic disease A133 0 ✔ ✔
Anoxic & hypoxic conditions A134 0 ✔ ✔
Other causes of perinatal A135 0 ✔ (1)
morbidity & mortality
Partly amenable to medical care
Meningococcal infection A19 0-64 ✔ (2)
Other bacterial/viral disease, A21, 29, 44 0-64 ✔
all other infective/parasitic disease
Malignant neoplasm of buccal A45 0-64 ✔ ✔
cavity and pharynx
Malignant neoplasm of larynx A50 0-64 ✔
Malignant neoplasm of skin A53 0-64 ✔ ✔
Benign neoplasm & unspec. A61 0-64 ✔
Other endocrine and metabolic disease A66 0-64 ✔
Other diseases of blood A68 0-64 ✔
& blood-forming organs
Meningitis A72 0-64 ✔ ✔
Other diseases of nervous system A79 0-64 ✔
& sense organs
Chronic rheumatic heart disease A81 0-64 ✔ ✔
Ischaemic heart disease; other heart disease A83-84 0-64 (3) ✔
Other diseases of circulatory system A88 0-64 ✔
Other diseases of respiratory system A96 0-64 ✔
Other diseases of digestive system A104 0-64 ✔
Other diseases of genito-urinary system A111 0-64 ✔
Other diseases of musculoskeletal system A125 0-64 ✔
Symptoms and other ill-defined conditions A137 0-64 ✔
Table 2 Amenable causes of death: Poikolainen & Eskola (continued)
(1)  partly amenable only;  (2) amenable to medical care, see above; (3) IHD only     
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Volume
Cause of death 27-31 ICD 9 Age 1988/91 1993 1997 Health care providers Intervention
Infectious diseases
Typhoid 001 5-64 ✔ Public health programme, Case detection, 
Whooping cough 033 0-14 ✔ primary care, hospital immunisation,
Tetanus 037 0-64 ✔ treatment of  complications
Measles 055 1-14 ✔
Osteomyelitis 720 1-64 ✔
Intestinal infections 001-009 0-14 ✔ Public health programme, Case detection, immunisation
primary care, hospital treatment of  complications
Tuberculosis 010-018, 5-64 ✔ ✔ Public health programme, Screening, early detection 
137 primary care, hospital of cases, immunisation
contact tracing, antibiotics
Malignant neoplasm of breast 174 25-64 ✔ Public health programme: Case finding, screening,
screening in ages 50-64, surgery, radiotherapy,
primary care, hospital chemotherapy
Malignant neoplasm of skin 173 35-64 ✔ Public health programme, Primary prevention,
primary care, hospital case finding, surgery, radio
therapy
Malignant neoplasm 180 15-64 ✔ ✔ Community health services, Screening, cytology,
of cervix uteri* primary care, hospital surgery, radiotherapy
Malignant neoplasm of cervix 179, 180, 15-54 ✔ ✔ Community health services, Screening, cytology, surgery,
uteri and body of the uterus* 182 primary care, hospital radiotherapy
Malignant neoplasm of testis 186 0-64 ✔ Public health programme, Case finding, surgery, 
primary care, hospital chemotherapy, radiotherapy
Hodgkin’s disease 201 5-64 ✔ ✔ Primary care, hospital, Case detection, chemotherapy,
pathological services radiotherapy
Leukaemia 204-208 0-44 ✔ Hospital Chemotherapy, radiotherapy,
bone marrow transplant
Table 3 Amenable causes of death: European Community atlas of ‘avoidable death’ 
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Table 3 Amenable causes of death: European Community atlas of ‘avoidable death’ (continued)
Volume
Cause of death 27-31 ICD 9 Age 1988/91 1993 1997 Health care providers Intervention
Chronic rheumatic heart disease 393-398 5-44 ✔ ✔ Primary care, hospital Case detection of streptococci,
antibiotics, prophylaxis, 
valve replacement surgery
Ischaemic heart disease 410-414, 429.2 35-64 ✔ ✔ Primary care, hospital, Primary prevention
health education
Hypertensive & cerebrovascular 401-405 35-64 ✔ ✔ Primary care, hospital Case detection, antihyperten-
disease 430-438 sive medication, treatment of
complications of hypertensive
disease
All respiratory diseases 460-519 1-14 ✔ ✔ Primary care, hospital Early detection of
complications, antibiotics
Asthma 493 5-44 ✔ ✔ Primary care, hospital Casualty department care,
treatment, early referral of
status asthmaticus
Peptic ulcer 531-534 25-64 ✔ ✔ Primary care, hospital Anti-ulcer drugs, surgery for
complications
Appendicitis 540-543 5-64 ✔ ✔ Primary care, hospital Case detection, surgery
Abdominal hernia 550-553 5-64 ✔ ✔ Primary care, hospital Case detection, surgery prior
to complications
Cholelithiasis & cholecystitis 574-575.1, 576.1 5-64 ✔ ✔ Primary care, hospital Case detection, surgery prior
to complications
Congenital cardiovascular anomalies 745-747 1-14 ✔ Hospital Drugs, surgery
Maternal deaths (all causes) 630-676 All ages ✔ ✔ Primary care, hospital Antenatal care, obstetric care
Perinatal mortality All causes < 1wk +  ✔ ✔ Primary care, hospital Antenatal care, obstetric care, 
stillbirths paediatric neonatal care
The indicators were designed to illustrate
different components of health care provision:
primary, secondary and preventive, and to assess
the outcome of health services for the residents
of defined geographical areas. Three disease
groups included in the list were considered
“primary prevention indicators”, as their
avoidability was believed to be more dependent
on actions outside the direct control of health
services. For the remaining 14
conditions/groups of conditions it was believed
that it was “reasonably certain” that effective
treatment or secondary prevention is available.
The 2nd edition, published in 1991 was
supplemented by a second volume in 1993,
covering a further eight conditions, reflecting
advances in medical knowledge and “extensions
of the abilities of the health services and their
technical infrastructures.”30 However, compared
with the 14 causes covered earlier, the role of
health services in the reduction of mortality
from these eight conditions was less certain. The
authors believed it “reasonably certain that
effective treatment or primary or secondary
prevention could be provided by health services,
although there is considerable controversy over
the avoidability of death from, for example,
congenital anomaly.” Consequently it was
assumed that while not all deaths from these
causes would be avoidable, health services could
contribute substantially to minimising mortality.
As with the concept of ‘partly amenable’
conditions developed by Poikolainen and
Eskola25, the supplemented list included
ischaemic heart disease and skin cancer. 
Finally, the 3rd edition of the EC Atlas of
‘Avoidable Death’ used a combination of causes
from the 17 plus eight conditions included in
earlier editions, resulting in a total of 16
conditions (Table 3). 
Similar to Charlton et al.20 age limits were set
for each condition to improve the “validity of
mortality as an indicator of health service
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outcome”, set at under 65 for most causes.27 As noted above, the conditions selected were
intended to cover a range of different health services. The authors did, however, emphasise
that they did not include all conditions for which death is avoidable by medical intervention
or that every death from some of the selected causes would be avoidable but they expected
that a proportion could be prevented. Finally, and unlike Charlton et al.20, the EC group
also included conditions whose control mainly depends on policies of primary prevention
(health policies) as noted earlier, namely lung cancer, liver cirrhosis, and motor vehicle
accidents.27,29 These conditions were, however, no longer included in the most recent
edition.31
Work on the EC Atlas of ‘Avoidable Death’ has stimulated a number of country-specific
analyses by participating research groups in Europe, such as in Belgium32, France33, The
Netherlands34, Ireland35 and Scotland36 and beyond in Sweden37, Spain38, the former
German Democratic Republic39,40, Greenland41, New Zealand42, Canada43, the USA44 and
Singapore.45 The list of causes of death considered avoidable has, however, varied between
studies with even those originating from the work on the EC Atlas using a more or less
modified selection of amenable conditions and varying age ranges. For example, in their
case study in France, Jougla et al., based on the work by the EC, extended this list to
include cancer of the oral cavity, nephritis and a larger list of infectious diseases. They also
extended the age range of infectious diseases to cover ages 5-64.33
In an early review of work on avoidable mortality, looking at 11 papers that had been
published until the late 1980s, Mackenbach and co-workers noted that this variation in
what is included is likely to reflect different views on the avoidability of death from certain
conditions as well as the availability of mortality data and variation in the frequency of
death of certain conditions in certain countries.13 Thus some authors include conditions
that are considered particularly relevant in the respective study region, for example
meningitis and diabetes mellitus in New Zealand46 while others explicitly exclude certain
conditions because of their low frequency as for example with hypertension and asthma in
Greenland.41 Adopting Rutstein’s broad definition of medical care15 this last study did,
however, include causes such as boat injuries, suicide and alcohol-related injuries as they
were considered important causes of death in Greenland. This example illustrates the point
made earlier on the variation in opinions as to whether a particular condition is to be
classified as avoidable or not. However, the reasons used are often not made explicit as
noted by Mackenbach et al.13 who reported that a sound discussion of reasons for the
inclusion or exclusion of specific causes of ‘avoidable’ death is almost always lacking.
In an attempt to quantify more specifically the contribution of medical care to changing
mortality in The Netherlands, Mackenbach and colleagues linked trends in mortality to
specific innovations in medical care.47 Based on Rutstein’s list15 they selected a range of
conditions that were considered to reflect all medical care innovations for which the
positive impact on disease incidence or case fatality was relatively undisputed (Table 4). In
contrast to Rutstein, however, they used a more restricted definition of medical care as “the
application of biomedical knowledge through a personal service system”, adapted from
McDermott.48 As with Charlton et al.20 their list thus excluded conditions for which
effective intervention is considered to be outside the direct control of the medical care
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Cause of death47 ICD 9* Medical care Innovation
Diseases of the thyroid 240-246 Specific medical therapies, e.g. 
Diabetes mellitus 250 introduction of insulin [1922]
Pernicious anaemia 281.0
Other anaemia Remainder of 281
Peptic ulcer 531-534 Improvements in surgery/anaesthetics,  
Appendicitis 540-543 e.g. introduction of intravenous fluid 
Cholelithiasis & cholecystitis 574-575.1, 576.1 therapy [around 1930]
Abdominal hernia 550-553
Ileus without hernia 560
Benign prostatic hyperplasia 600 (222.2)
Maternal causes (630-676) Improvements in antenatal and perinatal
Complications mainly related to pregnancy 640-648 care [since ca. 1930]
Complications occurring mainly 660-669
in the course of labour and delivery
Complications of the puerperium 670-676
Perinatal causes
Diseases of the mother 760
Birth injury 761-763, 767
Haemolytic disease 773
Other Remainder of 
760-779
Tuberculosis 010-018, 137 Chemotherapeutics, e.g. sulphonamides 
Pneumonia/influenza 480-487 [1936], and antibiotics, e.g. penicillin 
Septicaemia 038 [1947]
Infections of the urinary system
Other infectious diseases
Congenital digestive anomalies (749), 750, 751 Surgical repair of congenital anomalies 
Congenital cardiovascular anomalies 745-747 [since ca. 1950]
Rheumatic heart disease 393-398 Prophylaxis [since ca. 1950]; heart valve
surgery [ca. 1965]
Diphtheria/whooping cough/ 032, 033, Mass immunisation [since 1953]
tetanus/poliomyelitis 037, 045
Nephritis and nephrosis 580-589 Haemodialysis [since ca. 1960]
Hypertensive disease 401-405 Hypertension detection and treatment 
Cerebrovascular disease 430-438 [since ca. 1960]
Cancer of lip 140 Improvements in cancer treatment, 
Cancer of skin 173 esp. combination chemotherapy 
Cancer of kidney 189 [since ca. 1970]
Hodgkin’s disease 201
Cancer of testis 186
Leukaemia 204-208
Cancer of cervix uteri 180 Mass screening [since 1976]
Table 4 Amenable causes of death: Mackenbach et al. 
system, including many forms of primary prevention. However mass immunisation and
screening were considered integral part of the medical care system. In addition, whilst many
studies of avoidable mortality published thus far had analysed data within only a designated
age range, Mackenbach et al. could not identify clear evidence as to whether effects of
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* ICD codes assigned by EN
medical care were limited to certain age groups only and thus did not apply age limits. The
only exceptions were diabetes mellitus (<25 years) because improved survival had been
shown to be limited to young ages only, as well as renal cancer (<15 years) and leukaemia
(<15 years) because these diseases involve different pathological process in children and in
adults, with markedly different responses to treatment.
In a recent update of their work Mackenbach extended their original list of amenable
conditions to account for advances in medical care, with substantial innovations in, for
example, treatment of ischaemic heart disease, such as thrombolytic therapy, as well as
rectal cancer and hip fracture.49
More recent work on avoidable mortality has increasingly focused on differentiating more
clearly between causes that are amenable to medical intervention, through secondary
prevention and treatment (‘treatable’ conditions) and those amenable to interventions that
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Cause of death50,51 ICD 9 1993* 1996*
Medical care indicators
Malignant neoplasms of large intestine, except rectum 153 ✔ ✔
Malignant neoplasms of rectum 154 ✔ ✔
and rectosigmoid junction
Malignant neoplasms of cervix uteri 180 ✔ ✔
Hodgkin’s disease 201 ✔
Diabetes 250 ✔
Meningitis, bacterial 320 ✔
Chronic rheumatic heart disease 393-398 ✔
Hypertensive and cerebrovascular disease 401-405, 430-438 (1) ✔
Chronic bronchitis and emphysema 491, 492 ✔ ✔
Pneumonia other than viral ICD 8: 481, 486 ✔
Asthma 493 ✔ ✔
Gastric and duodenal ulcer 531, 532 ✔ ✔
Appendicitis, abdominal hernia, 540-543, 550-553, ✔
cholelithiasis & cholecystitis 574-575.1, 576.1
Congenital malformations of heart ICD 8: 746 ✔
Certain causes of perinatal mortality ICD 8: 760-778 ✔
Health policy indicators
Malignant neoplasms of trachea, bronchus and lung 162 ✔ ✔
Liver cirrhosis 571 ✔ ✔
Motor vehicle accidents E810-E825 ✔ ✔
Malignant neoplasms of oesophagus 150 ✔
Other
Suicide and self-inflicted injury, E950-E959, E980-E989 ✔
incl. injury undetermined whether 
accidentally or purposely inflicted
Malignant neoplasms of mammae 174 ✔
Table 5 Amenable causes of death: Westerling 
(1) cerebrovascular disease only; * age range 1993: 0-64; 1996: 21-64
are usually outside the direct control of the health services, through healthy public policies
(‘preventable’ conditions). This distinction was made by both Rutstein and colleagues15 and
the EC working group on avoidable deaths.27 However Westerling was the first to explicitly
compare ‘treatable’ conditions and ‘preventable’ conditions and to apply this approach
empirically and systematically to data from Sweden, using various selections of causes of
death, based on the work of both Rutstein and the EC group (Table 5).14,50,51
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Cause of death57 ICD 9 Age group
Medical care indicators
Infectious diseases
Intestinal infections 001-009 0-14
(other than typhoid, diphtheria)
Typhoid, diphtheria, tetanus, septicaemia, 001, 002, 032, 037, 0-74
poliomyelitis, osteomyelitis 038, 045, 730
Whooping cough 033 0-14 
Measles 055 1-14
Tuberculosis 010-018, 137 0-74
Malignant neoplasm of skin 173 0-74
Malignant neoplasm of breast 174 0-74
Malignant neoplasm of cervix uteri 180 0-74
Malignant neoplasm of testis 186 0-74
Hodgkin’s disease 201 0-74
Leukaemia 204-208 < 15
Diseases of the thyroid 240-246 0-74
Diabetes mellitus 250 0-49
Rheumatic heart disease 393-398 0-44
Hypertensive disease 401-405 0-74
Cerebrovascular disease 430-438 0-74
All respiratory diseases (excluding pneumonia /influenza) 460-479, 488-519 1-14
Pneumonia/influenza 480-487 0-74
Peptic ulcer 531-533 0-74
Appendicitis 540-543 0-74
Abdominal hernia 550-553 0-74
Cholelithiasis (& cholecystitis) 574-575.1 0-74
Nephritis and nephrosis 580-589 0-74
Benign prostatic hyperplasia 600 0-74
Maternal deaths 630-676 all ages
Perinatal deaths all causes excluding stillbirths 760-779 all ages
Congenital cardiovascular anomalies 745-747 1-14
Ischaemic heart disease* 410-414 0-74
Primary prevention (national health policy) indicators
Malignant neoplasm of trachea, bronchus, and lung 162 0-74
Cirrhosis of liver 571 0-74
Motor vehicle accidents E810-825 all ages
Table 6 Amenable causes of death: Nolte et al. 
* partly medical care indicator, partly primary prevention (national health policy) indicator
A similar approach was adopted by Benavides and co-workers to analyse avoidable mortality
in Valencia, Spain, using indicators proposed by the EC working group and divided into
‘primary prevention indicators’, i.e. lung cancer, liver cirrhosis, motor vehicle injuries, and
‘secondary prevention indicators’, consisting of the remaining 14 causes (Table 3).52 
Using various selections of conditions, mostly based on the EC list of avoidable deaths, this
approach was subsequently adopted in studies of avoidable mortality in Lithuania53,
Valencia, Spain54, Belgium55, Korea56 and, with some modification that also took account of
Mackenbach’s work47, in Germany and Poland (Table 6).57
A slightly different approach was chosen by Simonato et al. who undertook a further
differentiation of ‘avoidable’ causes into (1) those amenable to primary prevention, i.e.
health and wider societal policies, (2) those amenable to early detection and treatment and
(3) those amenable to improved treatment and medical care (Table 7).58 These groups were
defined as:
1. Causes avoidable through primary prevention, i.e. by reducing the incidence of the
disease. This category includes causes whose aetiology is in part attributable to lifestyle
factors (such as alcohol and/or tobacco consumption) and/or to occupational risk factors. It
also includes deaths from injury and poisoning, which are influenced in part by legal and
societal measures such as traffic safety and crime reduction policies.
2. Causes amenable to secondary prevention through early detection and treatment. This
group includes causes of death for which “screening modalities have been established” such
as cancer of breast and cervix, as well as causes for which death is avoidable through early
detection combined with adequate treatment, such as skin cancer.
3. Causes amenable to improved treatment and medical care. This group includes infectious
diseases, deaths from which are ‘avoidable’ largely through antibiotic treatment and
immunisation as well as causes that require medical and/or surgical intervention such as
hypertension, appendicitis, deaths of which are related to “complex interactions within the
health care system, such as accurate diagnosis, transport to hospital, adequate medical and
surgical care.”
Tobias and Jackson refined this approach further by not classifying each condition as
entirely ‘avoidable’ by either primary or secondary or tertiary prevention but by partitioning
causes among these three categories, using an ‘expert consensus’ method.59 Thus each
condition considered ‘avoidable’ was assigned relative weights reflecting the scale of its
potential preventability within each category. For example, the relative proportions of
preventability by measures of primary, secondary or tertiary prevention assigned to
hypertensive disease were determined to be 0.3, 0.65 and 0.05, respectively. According to
this definition hypertension is thus considered to be largely amenable to secondary
prevention measures. Tobias and Jackson also substantially broadened the number of
conditions potentially ‘avoidable’ by reviewing the literature in the light of advances in
health care since the early 1980s. Their final list thus included 56 conditions or groups of
conditions, 24 of which were considered largely being ‘avoidable’ by primary prevention
(preventing condition to develop), 16 mainly by secondary prevention (early detection and
intervention intended to delay progression of disease or recurrence of events) and 16 mainly
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Cause of death58 ICD 7 ICD 8 ICD 9
Group 1 Causes avoidable through primary prevention
Malignant neoplasms of upper airways and digestive tract 140-150, 161 140-150, 161 140-150, 161
Malignant neoplasms of the liver 155 155 155.0
Malignant neoplasms of trachea, bronchus and lung 162-163 162 162
Malignant neoplasms of the bladder 181 188 188
Circulatory disturbances of the brain 330-334 430-438 430-438
Chronic liver disease and cirrhosis 581 571 571
Injury and poisoning 800-999 800-999 800-999
Group 2 Causes avoidable through early detection and treatment
Malignant neoplasms of the skin 
(melanoma and non-melanoma) 190-191 172-173 172-173
Malignant neoplasms of the female breast 170 174 174
Malignant neoplasms of the cervix uteri 171 180 180
Malignant neoplasms of the uterus 172-174 182 179, 182
Group 3 Causes avoidable through improved treatment and medical care
Infectious and parasitic diseases 001-138 001-136 001-139
Malignant neoplasms of the testis 178 186 186
Hodgkin’s disease 201 201 201
Leukaemia 204 204-207 204-208
Chronic rheumatic heart disease 410-416 393-398 393-398
Hypertensive disease 440-447 400-404 401-405
Diseases of respiratory system 470-527 460-519 460-519
Gastric and duodenal ulcer 540-541 531-533 531-533
Appendicitis 550-553 540-543 540-543
Abdominal hernia 560-561, 570 550-553, 560 550-553
Cholelithiasis or other gallbladder disorder 584-585 574-575 574-575.1
Maternal mortality 640-689 636-678 630-676
Table 7 Amenable causes of death: Simonato et al. 
by tertiary prevention (reducing case-fatality by medical or surgical treatment) (Table 8).
They also increased the age limit from 65 to 75 to reflect improvements in life expectancy as
well as improved cause of death coding for the elderly. 
However, in contrast to the ‘traditional’ concept of avoidable mortality the broader
conception used by Tobias and Jackson was intended mainly to “measure the theoretical
scope for further population health gain, not what may be considered feasible given current
technology, available resources and competing values.” Thus the usefulness of this more
comprehensive indicator as a measure of the quality of contemporary health care is
somewhat limited. 
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Conditions involved59 ICD 9 CM PAM* SAM TAM
Diarrhoeal diseases 001-999 0.7$ 0.1 0.2
Tuberculosis 010-018, 137 0.6 0.35 0.05
Diphtheria, whooping cough, tetanus, polio, 032-033, 037, 045, 320.0, 0.9 0.05 0.05
Hib, measles, rubella 055-056, 320.0, 771.0, 771.3
HIV/AIDS 042 0.9 0.05 0.05
Hepatitis A, B, C, D, E; primary liver cancer 070, 155 0.7 0.1 0.2
Syphilis, gonorrhoea + other STDs, 090-099, 614.0-614.5, 0.8 0.1 0.1
ectopic pregnancy 614.7-616.9, 633
Other infectious: brucellosis + other zoonoses, 023-031, 034-6, 084, 0.3 0.4 0.3
streptococcus, malaria, meningitis, congenital 771.1-2, 771.4-9
320, 320.1-9, 770.0, 
Lip cancer, melanoma, other skin cancer 140, 172, 173 0.6 0.1 0.3
Stomach cancer 151 0.4 0.2 0.4
Colorectal cancer 153-154 0.4 0.5 0.1
Malignant neoplasm mouth, pharynx, larynx 141, 143-6, 148-9, 161 0.8 0.1 0.1
Malignant neoplasm trachea, bronchus, lung 162 0.95 - 0.05
Breast cancer 174 0.15 0.35 0.5
Cervical cancer 180 0.3 0.5 0.2
Cancer of uterus 179, 182 0.1 0.4 0.5
Cancer of testis 186 - 0.3 0.7
Eye cancer 190 - - 1
Thyroid cancer 193 0.1 0.2 0.7
Hodgkin’s disease 201 - 0.1 0.9
Lymphoid leukaemia 204 0.05 0.05 0.9
Benign cancers 210-234 - - 1
Goitre, thyrotoxicosis, hypothyroidism 240-242, 244 0.1 0.7 0.2
Congenital hypothyroidism, CAH, PKU, 
galatosaemia 243, 255.2, 270.1, 271.1 - 0.8 0.2
Diabetes 250 0.3 0.5 0.1
Nutritional deficits including anaemia 260-9, 280, 281 1 - -
Psychosis, alcoholism, cardiac, gastric or liver 
damage due to alcohol 291, 303, 305.0, 425.5, 0.9 - 0.1
535.3, 571.0-5
Epilepsy 345 - 0.9 0.1
Otitis media and mastoiditis 381-383 0.1 0.7 0.2
Acute rheumatic fever, heart disease 390-398 0.3 0.6 0.1
Hypertensive disease 401-405, 437.2 0.3 0.65 0.05
Ischaemic heart disease 410-414 0.5 0.25 0.25
Intracerebral haemorrhage or occlusion 431, 433, 434, 436 0.3 0.5 0.2
Respiratory infections including pneumonia 460-466, 480-487 0.4 0.5 0.1
and influenza
Chronic bronchitis and emphysema 490-492, 496 0.8 0.1 0.1
Asthma 493 0.1 0.7 0.2
Gastric and duodenal ulcer 531-534 0.05 0.75 0.2
Appendicitis 540-543 - - 1
Table 8 Amenable causes of death: Tobias & Jackson
Empirical studies of ‘avoidable’ mortality
Scope and nature
The literature search identified 72 studies that have empirically applied the concept of
avoidable mortality. Two studies that summarised findings of the EC Concerted Action
Project on avoidable deaths only, without elaborating on it with additional analyses were
excluded from the review.12,60 Studies were analysed using a structured protocol, extracting
information on (1) study region, (2) time period under investigation, (3) aim of study and
definition of ‘avoidable mortality’, (4) causes of death and age group(s) under study, (5)
analytical design and (6) main results. This information was drawn together in form of an
annotated bibliography (see part III of this report). 
As noted earlier, studies vary substantially regarding the selection of ‘avoidable’ causes but
also in terms of methodological approach, study region, time period covered, selection and
application of explanatory variables and, more generally, quality. In addition, there is
considerable variation regarding terminology. As indicated above, some studies used the
expression ‘avoidable’ deaths to denote mortality from conditions amenable to medical
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Conditions involved59 ICD 9 CM PAM* SAM TAM
Intestinal obstruction and hernia 550-553, 560 - - 1
Gallbladder disease 574-576.9 0.2 - 0.8
Acute renal failure 584 0.1 0.2 0.7
Complications of pregnancy 630-632, 634-676 0.2 0.5 0.3
Skin, bone and joint infections 680-686, 711, 730 0.2 0.5 0.3
Congenital anomalies of brain and spinal cord 740-742 0.6 0.2 0.2
Congenital cardiac, digestive, genito-urinary, 743-746.6, 746.8-747.9, 0.1 0.2 0.7
muskuloskeletal anomalies 749-757
Prematurity, low birthweight, respiratory 764-765, 769, 770.7 0.5 0.1 0.4
disease from prematurity
Birth trauma and asphyxia 767-768, 770.1, 772.0, 772.3 0.1 0.4 0.5
Other perinatal conditions: respiratory disease, 766, 769, 770.2-6, 770.8-9, 0.3 0.2 0.5
haemolytic disease, jaundice, etc. 772.1-2, 772.4-9, 773-779
Sudden infant death 798.0 1 - -
Road traffic injury E810-829 0.6 - 0.4
Poisoning E850-869 0.6 - 0.4
Swimming pool falls and drownings E883.0, E910.5, E910.6 0.8 - 0.2
Falls from playground equipment, sport injury E884.0, E884.5, E886.0, 0.6 - 0.4
EE917.0, E927
Burns and scalds E890-899 0.8 - 0.2
Drowning E910-910.4, E910.7-910.9, 0.8 - 0.2
E984
Suicide E950-959, E980-989 0.6 0.3 0.1
Complications of treatment E870-879 - 0.2 0.8
Table 8 Amenable causes of death: Tobias & Jackson (continued)
* PAM – primary avoidable mortality; SAM – secondary avoidable mortality; TAM – tertiary avoidable mortality
$ proportion in each category
intervention20,46 while others using this term referred to the more broadly defined concept
of medical care as proposed by Rutstein et al.15,41,56 Buck and Bull used ‘preventable’
mortality to refer to deaths from causes amenable to medical treatment,61 while Westerling
and others reserved this term for conditions amenable to primary prevention
measures.13,45,53 Westerling also introduced the term ‘medical care indicators’, which refers
specifically to conditions amenable to medical intervention, as opposed to ‘health policy
indicators’, referring to conditions responsive to measures of primary prevention, i.e. wider
health policies.50 Most recent studies tended to adopt this last terminology54 or some
variation, for example using “treatable” or “amenable” mortality to refer to conditions
amenable to medical care.45,53,57 For clarity these meanings will be used in subsequent
sections of this review. 
The variation in what is actually meant by ‘avoidable’ mortality also highlights another
point that is rarely discussed, namely what is actually meant by ‘medical care’. Although
most studies that looked at amenable conditions refer to ‘medical care’, ‘medical
intervention’, ‘medical treatment’, ‘medical management’ or ‘therapeutic care’ only few have
provided a precise definition, for example Rutstein et al.15 and Mackenbach et al.47 as
described in the preceding section. The EC Concerted Action Project on Health Services and
‘Avoidable Deaths’ refers more broadly to ‘health care services’, which were interpreted to
include primary care, hospital care, community health services and public health
programmes27 while others used terms such as ‘health services’, ‘health care’ or ‘health care
delivery services’ more interchangeably with for example ‘medical care’.25,62 Yet others fail to
make an explicit link to ‘care’ or ‘services’ but more generally refer to ‘medical knowledge’
or ‘[medical] technology’.63 This raises important questions about what ‘avoidable’
mortality is actually meant to measure, an issue that will be examined in more detail below. 
In general, the comparability of studies is rather limited. However two main types of studies
can be distinguished: those adopting a cross-sectional approach, by analysing ‘avoidable’
mortality at a particular point (or period) in time and studies that examine time trends.
Using this definition, of 70 studies included in the review 30 were cross-sectional, 31
analysed trends, a further seven undertook both cross-sectional and trend analyses, while
one study applied a case control design and one a prospective-observational design. Studies
classified as cross-sectional mainly examined geographical variation of ‘avoidable’ mortality
within and/or between regions/countries (n=24) or the distribution of ‘avoidable’ mortality
according to socioeconomic and/or demographic factors such as ethnicity, usually within
one region or country (n=9). Four studies examined ‘avoidable’ mortality at the regional or
national level only. Studies that looked at changes in ‘avoidable’ mortality over time mostly
analysed trends at the national and/or regional level (n=15), eleven studies compared trends
in different regions or countries, and a further five specifically analysed trends in different
socioeconomic and/or ethnic population groups. 
Studies have included a wide range of high-income countries, or regions within them,
mostly western Europe including Scandinavia and the Mediterranean countries, as well as
the USA, Canada, Australia, New Zealand, Japan, Singapore and Korea, whereas five studies
looked specifically at (selected) former communist countries of central and eastern Europe.
Most studies were set in the 1970s and 1980s, especially those classified as cross-sectional.
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Six trend analyses examined changes from the 1950s or early 1960s onwards, usually up to
the mid-1980s. Analyses of the more recent period were less frequent (n=10), generally
focusing on the first half of the 1990s. 
As noted earlier, studies of ‘avoidable’ mortality generally used this concept as a means to
assess the quality of medical/health care. However a number of studies also addressed the
question as to whether mortality rates from conditions amenable to medical intervention
can indeed be interpreted as an indicator of the quality or effectiveness of medical/health
care.13 Many analyses of geographical variations thus explicitly related amenable mortality
to indicators of health services and/or to other factors, mostly socioeconomic indicators
and/or indicators of morbidity whereas in analyses of variation by socioeconomic or
demographic factors or changes in amenable mortality over time this link is usually more
implicit. The following sections will look specifically at these issues and highlight some
major findings of the studies being reviewed. More specific information on the studies
summarised below is given in the appendix.
Variation between places
In their review of aggregate studies of ‘avoidable’ mortality Mackenbach et al.13 summarised
the findings of eight studies of geographical variation that had analysed the association
between amenable mortality and indicators of health care/services resources and/or other
(explanatory) variables.20,26,32,33,34,64,65,66 They controlled for socio-economic and
demographic  factors and found that associations with indicators of health care provision
were generally rather weak and inconsistent. For example, in their study of regional
variation of amenable mortality in The Netherlands, Mackenbach et al. found only few
associations that were statistically significant, and often not in the expected direction, for
example mortality from tuberculosis was positively associated with the number of hospital
beds.66 In contrast, associations between ‘avoidable’ mortality and socioeconomic factors
were generally found to be stronger and consistently negative. 
These associations between ‘avoidable’ mortality and socio-economic factors are also seen in
more recent studies. For example, analysing ‘avoidable’ mortality by region in Québec,
Canada, in the 1980s, Pampalon identified statistically significant geographical variation for
three causes considered amenable to medical care, i.e. tuberculosis, hypertensive disease and
perinatal mortality.43 Much of this variation was explained by socioeconomic indicators,
mainly low educational level and unemployment. Perinatal mortality alone was also related
to an indicator of health services, namely the consultation rate with general practitioners
(GPs) although, again, socioeconomic factors explained a substantial larger part of the
variation, at 83%, compared with the health services indicator that explained a ‘mere’ 5%. In
contrast, in their cross-country analysis of amenable mortality, analysing 17 developed
countries in the early 1970s, Buck and Bull identified significant negative correlations
between amenable deaths and public investment in health facilities (Spearman Rho = 
-0.49).61 However their analysis did not control for possible confounding through, for
example, socioeconomic factors. This was partly taken account of in one other cross-
country analysis by Mackenbach who examined the association between amenable mortality
and per capita health expenditure in eleven of then EC Member states in 1980-84.67 His
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analysis showed that while regional diversity in amenable mortality remained high even
after adjustment for gross domestic product (GDP), there was no association between
indicators of amenable mortality and the level of health care expenditure. Buck and Bull’s
study also looked more specifically at regional variation in amenable mortality and its
association with indicators of health services in England and Wales in 1974/75-1977/78,
using measures of general practitioner training, such as percentage of recent trainees passing
exam.61 They showed that only one of 13 measures was significantly associated with
amenable mortality. However, in a multiple regression model that also took account of
socioeconomic factors, these indicators explained 10% of the geographical variation in
amenable mortality. 
Taken together these findings suggest that there is, if any, only little evidence for an
association between geographical variation in amenable mortality and differences in the
quality or quantity of health services, at least as measured by easily available quantitative
data. Rather, geographical variation in amenable mortality seems to be more closely related
to socioeconomic conditions13, which may in turn reflect differences in timely access to
effective care. However it is not possible to examine this issue further at an aggregate level.
Variation between social groups 
The usual rationale behind studies of variation of amenable mortality by socioeconomic
and/or socio-demographic factors is to explore the contribution of health services to
inequalities in health, based on the assumption that differences in health status between
different social groups in society may be due, in part, to differences in access to and/or
quality of health services. 
Several studies of racial disparities in amenable mortality, mainly undertaken in the USA,
consistently showed considerable differences between African-Americans and white
Americans. For example, in their study of amenable mortality in California in 1978,
Woolhander and colleagues demonstrated significant excess mortality amongst African-
Americans from several amenable conditions such as hypertension and its complications
and acute pulmonary infections as well as considerably elevated death rates from cervical
cancer, diabetes and peptic ulcer.68 Similar findings were reported from a study in Texas,
showing that in the 1980s standardised mortality ratios for amenable conditions were more
than three times higher amongst African-Americans than in the white American population,
mainly tuberculosis, hypertension, cervical cancer, appendicitis and asthma.69 A US study in
1980-1986 also reported substantial racial disparities with death rates from twelve amenable
causes 4.5 times higher amongst African-Americans than white Americans.70 Rates were
again found to be highest for tuberculosis (8.9 times), hypertension (6.5 times), asthma (4.4
times) and cervical cancer (2.6 times). These findings were further supported by a study in
New York State in 1983 that, using hospital discharge data, calculated age-adjusted case-
fatality ratios for a series of amenable conditions.63 Rates were substantially higher amongst
African-Americans compared with white Americans for many amenable conditions, for
example vascular complications of heart or brain associated with hypertensive disease
(143.3 per 1000 discharges compared with 104.3), cervical cancer (69.4 vs. 55.4), diabetes
(81.7 vs. 69.7) or Hodgkin’s disease (122.1 vs. 78.1). 
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This consistent finding of racial inequalities in mortality from amenable conditions in the
USA has also been found with disadvantaged population groups elsewhere. For example,
three studies looked specifically at the distribution of amenable mortality amongst the
native Maori-population compared to the non-Maori majority in New Zealand. Malcolm
estimated the potential gain in life expectancy when preventable conditions, i.e. conditions
‘avoidable’ by primary or secondary prevention were excluded (1985-87).42 This showed
that removal of secondary preventable (i.e. amenable) conditions would result in Maori men
gaining an additional 1.2 years in life expectancy compared with one year for non-Maori
men (women: 1.7 and 1.0 years), with the ‘true’ gain for Maori and hence the difference
between Maori and non-Maori New Zealanders possibly being even higher due to
underestimation of Maori mortality. Tobias and Jackson also reported a considerable ethnic
gap in ‘avoidable’ mortality in New Zealand in 1996-97, with mortality rates from
conditions amenable to measures of secondary prevention being about 2.5 times higher
amongst Maori people compared with European and other New Zealanders.59 The results of
these two studies further indicate that the gap in amenable mortality between Maori and
non-Maori has remained rather stable over time. Indeed, analysing trends in amenable
mortality, Malcolm and Salmond showed that between 1968 and 1987 there was only little
improvement in the excess mortality of Maori, with the Maori to non-Maori ratio in
amenable mortality declining from 2.3-2.5 to 2.0 in both sexes.71
Similar findings have also been reported from studies of socioeconomic variations in
amenable mortality. In their case-control study of social class differences in amenable
mortality in the City of Helsinki, Finland, in 1980-1986, Poikolainen and Eskola
demonstrated a significantly elevated risk of premature death for those in the lowest
occupational category compared with the highest category, with an odds ratio adjusted for
age, sex, marital status and region estimated at 5.8 (95% confidence interval: 6.9-10.6).72
Other studies, although using different study designs and indicators of socioeconomic
status, generally reported similar findings.56,73,74 The only exception is one study by
Westerling and colleagues who found only small differences in amenable mortality between
blue and white collar workers (SMR: 107 vs. 95) although there was an almost three-fold
difference in mortality from gastric and duodenal ulcer (SMR: 163 vs. 59), which was
statistically significant.51 However they also reported significantly higher death rates
amongst those not in work, which were three times those in the working population. 
In summary, despite differences in study design, definition of socioeconomic or
demographic factors, region and time period covered, these findings suggest a fairly
consistent pattern with those classified as being at social disadvantage because of ethnicity
or socioeconomic characteristics being at higher risk of death from amenable conditions.
Taken together, these findings support the view that health services can contribute to the
reduction of health inequalities. This is further illustrated by one study by Mackenbach and
colleagues of the potential impact of medical care on the widening of mortality differentials
between socio-economic groups between 1931 and 1981 in England and Wales and between
1952 and 1982 in The Netherlands.75 They showed that, in England and Wales between
1931 and 1961, amenable mortality declined faster than all-cause mortality and that this
decline was generally greater in higher social classes. This pattern was found to be less
consistent in the period 1961 to 1981 although for half of the conditions considered
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amenable to medical care the declines were larger in the higher social classes. Based on
these findings they concluded that medical care contributed to the observed widening of
mortality differences between socioeconomic groups. 
Variation over time
In their review of aggregate studies of ‘avoidable’ mortality mentioned earlier, Mackenbach
and colleagues13 also summarised findings from three studies of time trends in amenable
mortality.24,25,47 These studies reported considerable declines in mortality for most or all
conditions considered amenable to medical intervention in recent decades, pointing to the
potential impact of medical care. To account for the likely confounding effects of improving
socioeconomic conditions and ‘spontaneous’ declines in the incidence of a number of
amenable causes, they compared trends in amenable mortality with trends in mortality from
other conditions, generally demonstrating that mortality from amenable causes declined
much more rapidly than mortality from so-called ‘not amenable’ causes. For example, based
on the analysis by Mackenbach and co-workers47, the review estimated that between 1950
and 1984 amenable mortality in The Netherlands declined, on average, by 6 per cent per
year in both men and women whereas, among women, mortality from non-amenable
conditions fell by a mere 2 per cent per year only, and, among men, did not change at all. 
These conclusions receive support from more recent studies of changes in amenable
mortality. Table 9 summarises the findings of trend analyses, looking specifically at annual
changes in amenable mortality. It only includes studies that have examined mortality rates,
mostly age-standardised death rates and provided a summary estimate for all amenable
causes and also examined trends in mortality from causes considered not amenable to
medical care for comparison (n=16). The figures given in the table are calculated from per
cent changes given in the respective publications. The only exceptions were two studies that
provided direct estimates of the annual change in amenable mortality.53,76
The findings presented in Table 9 generally confirm the findings summarised by
Mackenbach et al.13 For example, examining mortality changes between the mid-1950s and
the mid-1970s Charlton and Velez and Boys and co-workers showed that, in western
industrialised countries, amenable mortality declined by 2.3% to 3.4% per year while
mortality from all other causes fell by a maximum of one per cent per year only.24,77 Studies
looking at changes between the 1960s/1970s and the 1980s/1990s generally reported similar
trends with mortality amenable to medical care again falling more rapidly than mortality
from other (not amenable) causes, by an annual 3-5% compared with 1-
2%.22,25,54,55,57,71,76,78,79,80,81 Differences in the pace of change between studies are likely to
be due, in part, to differences in the selection of causes of death considered amenable to
medical care. However these last findings seem to suggest that the decline in amenable
mortality accelerated during the 1970s and 1980s compared with the earlier period. This
view is supported by the analysis by Boys et al. who showed that the pace of the decline in
amenable mortality in, for example, England and Wales increased from 2.7% per year
between 1955/59 and 1970/74 to 3.6% per year between 1970/74 and 1985/87.77 These
trends were mainly observed in western industrialised countries. However similar rapid
declines were also reported from Singapore where, between 1965/69 and 1990/94, amenable
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causes amenable to medical care
causes amenable to
health policy
all other causes all causes
 
time period country no.
causes
(age)
% of all deaths total
change
(%)
change/
year (%)
total
change
(%)
change/
year (%)
total
change (%)
change/
year (%)
total
change (%)
change/
year (%)
note
Hungary 22
(0-64)
n.a.  -33.5
-2.2
 n.a. n.a.  -3.6 -0.2  -14.2 -0.9 SDRBoys et al.
199177
1955/59-
1970/74
Czechoslovakia   -28.3 -1.9    6.9 0.5  -4.0 -0.3 all other:
 Poland   -42.2 -2.8    -17.7 -1.2  -25.2 -1.7 not amenable
 GDR   - -    - -  n.a. - incl. IHD
 FRG   -42.5 -2.8    -2.5 -0.2  -14.2 -0.9  
 England &
Wales
  -40.4
-2.7
   1.8 0.1  -10.2 -0.7  
 Canada   -50.7 -3.4    -1.9 -0.1  -14.5 -1.0  
 USA   -46.4 -3.1    4.4 0.3  -8.7 -0.6  
           
Charlton &
Velez 198624
1956-1978 England &
Wales
10
(5-64)
1956: 17.3; 1978: 9.6  -51.3 -2.3  n.a. n.a.  -4.3 -0.2  -12.5 -0.6 SDR
France 1956: 15.3; 1978: 7.4 -64.0 -2.9 -19.1 -0.9 -26.0 -1.2
Italy 1956: 19.7; 1978: 11.3 -57.1 -2.6 -17.0 -0.8 -24.9 -1.1
Japan 1956: 33.3; 1978: 19.6 -72.3 -3.3 -43.2 -2.0 -52.8 -2.4
Sweden 1956: 15.8; 1978: 7.1 -60.9 -2.8 -2.9 -0.1 -12.4 -0.6
USA 1956: 17.8; 1978: 6.3 -67.1 -3.1 -8.7 -0.4 -17.9 -0.8
Simonato et
al. 199858
1955-1994 21 European
countries
12
(5-64)
1955/59: 22.0% (m+f) m -76.3 m -2.2 m -16.6 m -0.5 m -16.6 m -0.5 m -32.6 m -0.9 SDR
1990/94: 8.9% (f);
7.6% (m)
f -77.9 f -2.2 f -29.1 f -0.8 f -29.1 f -0.8 f -45.1 f -1.3
Bernat Gil &
Rathwell
198978
1960-1984 Spain 13
(5-64)
1960: 19.0; 1984: 8.9  -66.8  -2.8  n.a.  n.a.  -20.0  -0.8  -28.9  -1.2 SDR
Niti & Ng
200145
1965/69-
1990/94
Singapore 9
(5-64)
1964/94: 17.1 (m),
19.7 (f)
m -78.2 m -3.1 m -28.5 m -1.1 m -28.5 m -1.1 m -39.7 m -1.6 SDR
     f -67.8 f -2.7 f -34.2 f -1.4 f -34.2 f -1.4 f -42.8 f -1.7  
Poikolainen
& Eskola
198625
1969-1981 Finland 21
(0-64)
1969: 8.2 (m), 13.4 (f) m -63 -5.3  n.a. n.a. m -24 m -2.0 m -24 m -2.0
    1981: n.a. f -68  -5.7     f -29 f -2.4 f -34 f -2.8
Crude
DR/SDR; all
other: not
amenable excl.
violent causes
Table 9 Changes in amenable mortality over time: Summary of results from selected studies of ‘avoidable’ mortality
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causes amenable to medical care
causes amenable to
health policy
all other causes all causes
time period country no.
causes
(age)
% of all deaths total
change
(%)
change/
year (%)
total
change
(%)
change/
year (%)
total
change (%)
change/
year (%)
total
change (%)
change/
year (%)
note
Mackenbach
et al.
1988b76
1969-1984 The
Netherlands
13
(0-75)
1969: 18.4; 1984: 11.8  n.a.  -4.5  n.a.  n.a.  n.a.  n.a.  n.a.  -1.6 SDR; annual
decline
estimated by
authors
1968-1987 New Zealand n.a.         SDRMalcolm &
Salmond
199371 Maori
15
(0-64)
m -75.8 m -3.8  n.a. n.a. m -37.1 m -1.9   
all other: not
amenable
  f -72.8 f -3.6   f -46.1 f -2.3   causes
 Non-Maori  m -61.9 m -3.1   m -22.1 m -1.1    
     f -54.0 f -2.7     f -18.2 f -0.9      
Boys et al.
199177
1970/74-
1985/87
Hungary 22
(0-64)
n.a. -14.7 -1.1 n.a. n.a. 29.0 1.9 17.0 1.2 SDR
Czechoslovakia -28.2 -2.0 4.6 0.3 -3.2 -0.2 all other:
Poland -22.6 -1.6 16.5 1.1 7.3 0.5 not amenable
GDR -26.5 -1.9 2.9 - -3.8 -0.3 incl. IHD
FRG -61.6 -4.4 -19.0 -1.3 -27.3 -2.0
England &
Wales
-49.7 -3.6 -15.5 -1.0 -22.0 -1.6
Canada -60.1 -4.3 -22.9 -1.5 -28.4 -2.0
USA -51.2 -3.7 -21.7 -1.4 -26.2 -1.9
1970-1990 Lithuania 11
(0-64)
1970/90: 11.8 (m),
21.0 (f)
 n.a. m -0.7  n.a. m 0.9  n.a. m 0.9  n.a. m 0.2 SDR; annual
decline
estimated by
authors
Gaisaus-
kiene &
Gurevicius
199553
       f -0.9   f 1.3   f 1.3   f -0.2  
Hisnanick &
Coddington
199581
1972/79-
1980/87
USA: Am.
Indian/ Alaskan
Native
8
(5-75)
1972/87: 7.0 m -57.0 m -7.1  n.a. n.a. m -30.6 m -3.8   crude DR
     f -55.5 f -6.9     f -25.5 f -3.2      
Humblet et
al. 200055
1974/78-
1990/94
Belgium 13
(1-64)
1974/78: 7.3 (m), 20.8
(f)
m -53.0 m -3.3 m -30.8 m -1.9 m -30.8 m -1.9 m -23.9 m -1.5 mortality:
YPLL
    
1990/94: 4.4 (m); 20.0
(f)
f -29.7 f -1.9 f -26.7 f -1.7 f -26.7 f -1.7 f -26.7 f -1.7
 
Table 9 Changes in amenable mortality over time: Summary of results from selected studies of ‘avoidable’ mortality (continued)
T
H
E
 C
O
N
C
E
P
T
 O
F
 ‘A
V
O
ID
A
B
L
E
’ M
O
R
T
A
L
IT
Y
 —
 A
 L
IT
E
R
A
T
U
R
E
 R
E
V
IE
W41
causes amenable to medical care
causes amenable to
health policy
all other causes all causes
time period country no.
causes
(age)
% of all deaths total
change
(%)
change/
year (%)
total
change
(%)
change/
year (%)
total
change (%)
change/
year (%)
total
change (%)
change/
year (%)
note
Lakhani et
al. 198622
1974/78-
1979/83
England &
Wales
10
(0-64)
1974/78: 17.1 -23  -4.6  n.a.  n.a.  -6  -1.2  -9  -1.8 crude DR; all
other: not
amenable
Marshall et
al. 199379
1975/77-
1985-87
New Zealand
[men only]
12
(15-64)
1975/77: 5.1
1985/87: 4.2
 -30  -3.0  n.a.  n.a.  -14  -1.4  -15  -1.5 SDR; all other:
not amenable
1980-1990 Australia 6 n.a.  -50.7 -5.1  n.a n.a.  -9.8 -1   SDRKjellstrand
et al. 199880  Canada (5-64)  -37.4 -3.7    -13.7 -1.4    
 France   -36.5 -3.7    -9.6 -1.0    
 Germany (west)   -29.3 -2.9    -6.3 -0.6    
 Italy   -33.3 -3.3    -5.9 -0.6    
 Japan   -31.2 -3.1    +5.4 +0.5    
 New Zealand   -20.2 -2.0    -5.1 -0.5    
 Sweden   -38.6 -3.9    -14.8 -1.5    
 UK   -40.1 -4.0    -19.8 -2.0    
 USA   -26.9 -2.7    -10.3 -0.1    
  all    -34.4  -3.4      -9.0  -0.9      
Nolte et al.
200257
1980-1988 west Germany 29
(<75)
1980:14.9 (m), 26.8 (f) m -37.7 m -4.7 m -17.4 m -2.2 m -10.3 m -1.3 m -17.6 m -2.2 SDR
  1988:11.2 (m), 24.3 (f) f -25.7 f -3.2 f -8 f -1.0 f -16.5 f -2.1 f -18 f -2.3 all other: not
 east Germany  1980:18.8 (m), 29.8 (f) m -15.6 m -2.0 m 0 m 0.0 m -6.1 m -0.8 m -5.8 m -0.7 amenable excl.
  1988:15.9 (m), 28.3 (f) f -13.9 f -1.7 f 17.4 f 2.2 f -11.6 f -1.5 f -9.6 f -1.2 IHD 
1983-1988 Poland  1983:16.5 (m), 30.0 (f) m -5.9 m -1.2 m +5.7 m 1.1 m 2.3 m 0.5 m +3.8 m 0.8  
  1988:15.0 (m), 28.4 (f) f -6 f -1.2 f +5.8 f 1.2 f -1.6 f -0.3 f -0.9 f -0.2  
1992-1997 west Germany  1992:10.5 (m), 23.7 (f) m -8.5 m -1.7 m -8.8 m -1.8 m -6.7 m -0.8 m -9 m -1.8  
  1997:10.6 (m), 23.4 (f) f -8.6 f -1.7 f -2.3 f -0.5 f -7.5 f -0.9 f -7.7 f -1.5  
 east Germany  1992:12.5 (m), 24.5 (f) m -17 m -3.4 m -14.3 m -2.9 m -18.2 m -2.3 m -17.7 m -3.5  
  1997:12.6 (m), 23.2 (f) f -24.4 f -4.9 f -9.6 f -1.9 f -20.8 f -2.6 f -20.6 f -4.1  
1991-1996 Poland  1991:14.0 (m), 26.8 (f) m -0.4 m -0.1 m -8.8 m -1.8 m -9.9 m -2.0 m -12 m -2.4  
    1996:15.8 (m), 27.9 (f) f -8.3 f -1.7 f -2.6 f -0.5 f -13.6 f -2.7 f -11.9 f -2.4  
Table 9 Changes in amenable mortality over time: Summary of results from selected studies of ‘avoidable’ mortality (continued)
mortality among men fell by 3.1% per year (women: 2.7%) compared with mortality from
all other causes, at 1.1% year (1.4%).45 Comparable trends were also reported from former
communist countries of central and eastern Europe, although with declines at a lower rate,
with amenable mortality falling by about 1-2 per cent per year between the mid-1970s and
mid-1980s while non-amenable mortality remained more or less stable or even increased as,
for example, in Hungary, Poland and Lithuania.53,77 
A more recent study that looked specifically at changes in amenable mortality in east
Germany before and after the political transition in 1990 demonstrated a substantial
acceleration in the decline in amenable mortality, from 1.7-2 per cent per year between 1980
and 1988 to 3.4-4.9 per cent per year between 1992 and 1997.57 There was also acceleration
in the decline of non-amenable mortality but at a lower level, from 0.8-1.5% per year to 2.3-
2.6% per year. This was not, however, observed in Poland. In fact, non-amenable mortality
seemed to have fallen more rapidly in the 1990s, after the political transition, than in the
1980s when the communist system was still in place, and the decline was also at a faster
rate than amenable mortality, at 2-2.7 per cent per year between 1991 and 1996 compared
with 0.1-1.7 per cent per year. These differential trends were largely attributed to the slow
pace of change in health care in Poland in the 1990s compared with the very rapid changes
observed in east Germany after its unification with west Germany in October 1990.
In summary, analysis of changes in amenable mortality published thus far paint a rather
consistent pattern of substantial declines in amenable mortality that have generally been
much more rapid than declines in mortality from other causes. Due to these changes, the
number of amenable deaths as proportion of all deaths has fallen considerably in all
countries under study, again with some variation between countries, largely because of the
selection of causes of death included. These findings suggest that “at least part of the
mortality decline from amenable conditions is due to improvements in health care.”13
Conceptual problems
Whilst many authors who have used the concept of ‘avoidable’ mortality have highlighted
its potential value as a measure to assess the quality or effectiveness of health care it has
also faced considerable criticism, in particular because of its apparent lack of association
with measures of health care provision, as noted above. The following sections will briefly
recap on some of the main limitations that have been identified, ordered according to major
themes emerging from the literature, although some overlap between sections will be
inevitable. 
Relationship to health care inputs
As noted earlier, there is as yet little evidence for an association between observed
geographical variations in amenable mortality and other measures of health care provision,
findings that have elicited strong criticism as to the actual usefulness of ‘avoidable’ mortality
as a measure of the quality or effectiveness of health care.64 Mackenbach and co-workers
found only few “possibly meaningful relationships” between amenable mortality and
medical supply characteristics such as general practitioner density or number of hospital
beds.66 Kunst et al. also reported that levels of health care supply added “little to the
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explanation of regional differences” in mortality from selected ‘avoidable’ conditions in EC
countries in the 1970s.34  In particular the observed lack of specific intercorrelations
between causes of death that broadly reflect the same type of medical care, for example
appendicitis and hernia, seemed to suggest that differences were not determined by a
common medical care factor. They thus concluded that the supply of health care within EC
countries is likely to be above a level at which an effect on case fatality would be seen and
other factors, such as inter-regional patient flows and random variation could account for
observed differences. However as with Mackenbach et al.66 they also concluded that the
level of health care supply per se was perhaps not an adequate measure as it merely reflects
quantity rather than quality of care.34
Indeed, most studies identified in the present review have looked mainly at resources or the
supply of health services, using measures such as health expenditure (e.g. % of GDP spent
on health)26,61, number of health care professionals (per defined population, per capita, per
patient)26,34, proportion of specialists33, number of hospital beds34,43 or presence of
regional, acute and/or university hospital.33 Only few studies also looked at some process
indicators such as hospitalisation rates43, consultation rates with general practitioners
and/or specialist consultations32 or acceptance rates for dialysis/renal transplantation80
although associations with amenable mortality using these measures were not consistent. 
The lack of a demonstrable association with health care resources is, however, not entirely
surprising. First, available data reflect only what is measurable and not necessarily what is
important. Second, any relationship between quantity and quality is likely to be inexact.
Third, geographical level of analysis may be insufficiently detailed to identify any real
differences. Finally, there may be unspecified lags between changes in resources and changes
in mortality. However, the rather more frequently observed association with adverse
socioeconomic factors has focused attention to timely access to medical care. Consequently,
Mackenbach et al. suggested that further studies at the population level should use
indicators of more specific aspects of medical care delivery, perhaps with further insights to
be gained by analysing how supply is organised, whether it conforms to quality standards,
and how accessible it is to the population.13
However, whilst direct evidence in the form of a clear association between amenable
mortality and measures of health service provision may be lacking in western Europe, there
is growing, albeit indirect, evidence from studies from the former communist countries of
central and eastern Europe in support of a link between resources and outcomes. The scale
of the gap in performance between the two parts of Europe in the 1980s is likely to have
been very much greater than between regions of western European countries. It has been
estimated that higher death rates from amenable causes accounted for 24% of the east-west
gap in Europe of 4.2 years in male life expectancy between birth and age 75 in 1988.82 In
women, the corresponding figure was 39% (gap: 2.3 years). These differences have been
explained, in part, by the relative isolation of those countries from many modern health care
developments. This is illustrated by the marked reduction in deaths from testicular cancer
in the former German Democratic Republic (GDR) when modern chemotherapeutic agents
became available after unification.83 Other evidence suggests that shortages or inadequacies
in health care may have led to less effective treatment of certain conditions, with
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management of hypertension and treatment of congenital heart anomalies in the GDR being
cited specifically.84-86 
A related study showed that just after German unification in 1992, when the health care
system in east Germany was still in a major process of rebuilding, about 16% of the two
year east-west gap in male life expectancy between birth and age 75 was attributable to
conditions amenable to health care.57  In women, differences in amenable mortality
contributed 26% to the 0.8 year life expectancy gap in 1992. By 1997, the east-west gap in
life expectancy in Germany had narrowed considerably, largely due to falling death rates in
east Germany particularly among those aged 55 years and older.87 The contribution of
amenable conditions to the remaining health gap did not, however, change, suggesting that
one reason for east Germany still lagging behind the west is a difference in the effectiveness
of health care.57 However large improvements in neonatal mortality in east Germany since
1990 may be considered to be at least partly due to improvements in the quality of perinatal
care,88 as was also seen in the Czech Republic.89
In contrast, some countries of the former Soviet Union experienced a substantial
deterioration in the quality of health care, with a noticeable impact on aggregate mortality
rates, although care is needed to separate the effects of collapse of the health care system
from wider societal problems. One example is the observation of an eight-fold rise in deaths
from diabetes among young people in the Ukraine since 1990, largely due to individuals
experiencing a disruption in supplies of insulin and difficulties in obtaining specialised care
when complications arose.90 This example illustrates the usefulness of the concept of
‘avoidable’ mortality as an indicator of potential problems at the population level possibly
related to health care that may then be investigated further by in depth studies.
Interpreting trends in deaths from amenable mortality over time
Findings from longitudinal studies support the view that declining mortality from amenable
conditions in (western) industrialised countries is likely to reflect increased effectiveness of
health care. However, as noted earlier, declines in ‘avoidable’ mortality may have been
confounded by simultaneous changes in disease incidence. The challenge of disentangling
these two factors is well illustrated by the case of tuberculosis and some other infectious
diseases where observed declines in incidence in the early 20th century were largely
attributed to improving living conditions. McKee and Rajaratnam noted the potential
impact of cohort effects on observed falls in death rates from peptic ulcer, considered
amenable to medical care.91 This was based on findings in west Germany and Switzerland,
demonstrating that a decline in mortality from peptic ulcer between 1952 and 1980 among
the under 65s was matched by an increase among the elderly.92,93 This was largely attributed
to exposure to aetiological factors affecting the cohort in the past, with the improvements
seen in younger people possibly linked to declining rates of early infection with Helicobacter
pylori, reflecting improving social conditions.94 However a more recent analysis of trends in
peptic ulcer mortality in Europe showed that much of the decline between 1955 and 1989,
averaging 56%, occurred between 1974 and 1985.95 While the earlier decline in western
Europe was mainly related to the cohort effect mentioned above, the more recent falls were
interpreted as largely reflecting advances in treatment, exerting an effect especially since the
mid-1970s due to the introduction of H2-receptor antagonists.
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Most studies of amenable mortality over time have also reported substantial falls in
mortality from cerebrovascular disease20,37,96 although some authors did not consider this
condition as amenable to medical intervention.26 This discrepancy in part reflects the
continuing controversy about whether declining death rates from this condition can actually
be interpreted as an effect of medical care or rather reflect a spontaneous decline in
incidence, perhaps reflecting the delayed impact of factors acting in utero or early
childhood.97 Thus, in western industrialised countries mortality rates have been declining
particularly since the 1960s for reasons not fully understood.98,99 However there is now
considerable evidence of declining case-fatality rates, pointing to the potential impact of
medical interventions (see Box 2).98,100
Box 2 The decline in stroke mortality and its explanations
Improved survival after stroke is likely to have accounted for much of the decline in stroke
mortality in recent decades.99 Reductions in case fatality have been demonstrated in a variety
of settings100,101,102 although findings are not consistent across geographical areas.103 
There are several possible reasons for the observed increase in survival rates including,
among others, advances in treatment and management of acute stroke102,104,105,
improvements in supportive and rehabilitative care106,107, improved diagnostic procedures
detecting milder forms of stroke108, and lower severity of stroke.100,109 Differences in
treatment and/or management of stroke have also been put forward to explain geographical
variation in stroke survival110, at least in part.111,112 
One other reason for the decline in stroke mortality is, of course, declining incidence,
although there are some inconsistencies.99 Thus, falls in stroke incidence have been reported
in a number of regions, for example Perth/Australia113 and Finland114 during the 1980s and
early 1990s, but not in others.100,109,115 Some studies have noted an actual increase in incidence
rates such as in Rochester/Minnesota108 and northern Sweden (women)116 but this seems
partly to have been due to changes in diagnostic practice, with greater availability of diagnostic
procedures such as radiological imaging and the possible detection of milder cases of stroke.
Notwithstanding these exceptions, the frequently observed downward trend in stroke
incidence rates has been associated largely with improvements in underlying risk factors,
especially high blood pressure which is one of the factors most closely associated with
stroke. These have been explained, largely, by pharmacological treatment of high blood
pressure or reduced salt intake.
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Treatment was first considered an implausible explanation for declining mortality, mainly
because effective treatment had not been available until the 1960s whereas falls in stroke
mortality had been observed since the beginning of the 20th century.99 It was however
acknowledged that treatment of hypertension may have contributed to the accelerated
decline in stroke mortality beginning around 1970 although, again, its explanatory power
was considered relatively modest, mainly because of the perceived limited potential of the
then available antihypertensive treatments to exert a significant impact at the population
level.99,117 Conversely, in their study of amenable mortality in Finland, Poikolainen and Eskola
observed a rapid decline in mortality from hypertension between 1969 and 1981, which was
linked to an increase in pharmacological treatment. This was estimated to have prevented
approximately 500-800 deaths per year in the middle-aged population in Finland during the
1970s.25 However other evidence from Finland suggests a considerable contribution of
changes in dietary habits since the late 1970s, mainly reduced salt intake but also increased
intake of polyunsaturated fats.118
Recent findings from the WHO MONICA Project demonstrated a significant decline in mean
systolic blood pressure levels among the middle-aged in populations in 21, mainly western
industrialised countries between 1979 and 1996.119 These declines showed a strong
association with stroke event rates in women, explaining 38% of the variation in event rate
trends in 15 populations, taking account of a 3-4 year time lag.120 However no such
association was seen in men.
Taken together these findings indicate that the decline in stroke mortality is still far from
being “fully explained”. However evidence assembled so far points to the potential impact of
health care on stroke mortality, both in terms of increasing survival after stroke and reducing
incidence, by means of better treatment of high blood pressure. Thus, one study of ‘avoidable’
mortality attributed 70% of the potential avoidability of stroke to measures of secondary
(antihypertensive treatment) and tertiary prevention (stroke units, rehabilitation, surgery)
whilst the remaining 30% were attributed to primary preventive measures, mainly addressing
smoking, diet, physical activities.59
To address the question of whether and to what extent observed changes in mortality can
actually be attributed to specific interventions, Mackenbach and colleagues examined how
changes in deaths from particular causes related to when various interventions were
introduced.47 They were able to show that the impacts of specific treatments were
observable as accelerating falls in mortality from the conditions they were intended to treat.
Based on this analysis they further calculated that in The Netherlands between 1950 and
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1984, changes in deaths from amenable causes added a total of 2.9 years to male life
expectancy at birth (women: 3.9 years) to what would otherwise have occurred. A recent
update of this analysis estimated that, between 1984 and 1995, continuing declines in
amenable mortality added a further 0.23 years to male life expectancy at birth (women: 0.41
years).49 Moreover, considering conditions for which there had been important medical
advances in the latter period the gain in life expectancy attributable to falling amenable
mortality would equal 1.1 years in men and 0.8 years in women.
In summary, when interpreting trends in mortality, whether amenable or otherwise, a degree
of caution is required because of factors such as changing disease incidence, which may
reflect changes in risk factors acting over prolonged periods. This raises the issue of
attribution of health outcomes to changes in health care, an issue that is examined in the
next section.
Selection of ‘avoidable’ conditions and the attribution of health outcomes 
Clearly any list of indicators of ‘avoidable’ mortality used is, to some extent, arbitrary as a
death from any cause is typically the final event in a complex chain of events. As noted
earlier the decision as to whether a particular cause of death be classified as ‘avoidable’ or
not depends upon the definition of medical/health care selected. The choice of category is
essentially based on a judgement about the relative effectiveness of different interventions
that might prevent death. This, however, requires a clear definition of what types of
intervention should be studied in relation to a particular cause of death as well as an
assessment of the relevant evidence of the possibility of influencing mortality by means of
that intervention. Thus, Walsworth-Bell and Allen questioned the inclusion of some
‘avoidable’ conditions as performance indicators for health services.121 They analysed eight
of fourteen conditions considered amenable in a selected area in England and Wales in
1981-1983 that Charlton et al.20 had identified as performing poorly in terms of amenable
mortality and, hence, medical care. Based on an analysis of case notes for each death from
these conditions they found “convincing” cases for ‘avoidability’ for hypertension and
cancer of the cervix only, identifying health care related factors that may, in most cases, have
altered the final outcome. For most other causes there was only little evidence of
inappropriate care and, hence, scope for averting death. The authors thus concluded that
only deaths from hypertension and cervical cancer appeared useful indicators for assessing
the quality of medical care. 
However the advocates of the original concept had accepted the limited usefulness of
analysis of aggregate data as a means of assessing quality of care. Rutstein and Charlton et
al. emphasised the need to supplement aggregate analyses with more detailed local enquiries
(Box 3).21,122 Holland and Breeze further stressed that ‘avoidable’ deaths should not be
interpreted as absolute measures of outcome and that they “do not provide definitive
evidence that a particular service is wrong.”123 Westerling also noted the risk of ‘false
warning signals’ that may be produced especially by small area analyses of amenable
mortality, due to random variation.50 In line with Rutstein122, Charlton et al.21 and others
he thus suggested using indicators of avoidable mortality for monitoring but limiting them
to acting as a starting point for in-depth analysis. 
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Box 3 Confidential enquiries
Building on the findings by Charlton et al.20, Holland and Breeze reported on two District
Health Authorities (DHA) in England and Wales that were identified as having high
standardised mortality ratios (SMRs) for certain avoidable deaths.123 Both DHAs looked, in
detail, into deaths from cervical cancer using patient records from local GPs and hospitals for
the period 1979-1984. As a result of this enquiry, DHA 1 identified shortcomings in the
screening system as a major explanation for the observed elevated death rate from cervical
cancer, in particular failures in following up abnormalities that were suspicious. DHA 2, in
contrast, did not find shortcomings in services as such but noted that the major obstacle in
curbing cervical cancer death rates was low uptake of screening services. This was believed to
reflect gaps in knowledge and other individual factors influencing health seeking behaviour
although poor accessibility and acceptability of services may have been important as well,
aspects that can be interpreted as a failure of the screening process to reach high risk
individuals.
Similarly, differences in levels of maternal mortality between European countries as
highlighted for example in the EC Atlas of ‘Avoidable Death’28 have prompted the formation
of the European Concerted Action on ‘Mothers’ Mortality and Severe morbidity’ (MOMS) .124
Their findings suggest that the higher level of maternal mortality rates in France compared to
its European neighbours may, in part, be attributed to substandard care related to obstetric
haemorrhage125,126, reinforcing similar findings from an earlier study on this topic.127 The
French team took this observation forward in a subsequent analysis that looked more
specifically into morbidity related to obstetric haemorrhage and showed that up to one-third
of patients received substandard or inappropriate care. This was attributed mainly to
organisational features, thus highlighting the need for re-organisation of obstetric services in
the areas under study.
The changing concept of avoidability
Importantly, most studies of amenable mortality were set in the 1970s and 1980s, often
using a shortened version of Rutstein’s list15 or some modification of the lists by Charlton et
al.20 and/or the EC group.28 These reflect consensus about what was considered achievable
by medical care at that time. However there have been substantial advances in the scope and
quality of health care since then, so that some causes of death previously considered not
being amenable can now be treated effectively. At the same time, progress in health care may
have made questionable the value of some conditions, previously considered as being
relatively ‘robust’ indicators of the quality of health care, such as perinatal mortality (Box 4).
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Box 4 The changing meaning of perinatal mortality
Studies of ‘avoidable’ mortality usually consider perinatal mortality as an important indicator
of the quality of health care.15,20,28 This indicator has, however, been criticised.128 As
industrialised countries in particular reach the limits of improvements in perinatal mortality
rates are increasingly based on very small numbers, which are “very dependent on precise
definitions of terms and variations in local practices and circumstances of health care and
registration systems.”129 Also, comparisons between countries are problematic because of
variations in definitions used and, in industrialised countries, the declining subset of perinatal
deaths that are actually amenable to medical care. For example, advances in obstetric
practice and neonatal care have led to improved survival of very preterm infants, resulting in
(varying) redefinitions of viability criteria. Outcomes are also affected by attitudes to viability
of preterm infants130 and thus to the appropriateness of strenuous efforts to save very ill
newborn babies rather than what may be seen as a more humane decision to withdraw
therapy.131 Legislation and guidelines concerning end-of-life decisions vary among countries,
from strong protection of human life in some to active intervention to end life in others, such
as The Netherlands.132
A related problem is variation in actual registration procedures and practices, which may be
considerable between countries, reflecting different legal definitions of the vital events to be
declared. One example is the delay permitted for registration of births and deaths, ranging
from three up to 42 days within western Europe.129 This is especially problematic for small
and preterm births with deaths occurring during the first day of life most likely to be under
registered where permitted delays are longest.
Congenital anomalies are an important factor contributing to perinatal mortality. However
improved ability of prenatal ultrasound screening to recognise congenital anomalies has
been shown to have affected perinatal mortality because of termination of pregnancy
following prenatal screening, thus shifting deaths of malformed fetuses from a registered
fetal or infant death to an induced abortion.128,129
This phenomenon increasingly explains international variation in infant deaths due to
congenital anomalies133 with, for example, a high rate (44%) in Ireland, which has limited
prenatal screening and legal prohibition of induced abortion, compared with France (23%),
where there is routine prenatal screening linked to ready access to induced abortion
throughout gestation, although the total number of deaths (aborted plus delivered) is
actually higher in France.134
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For these reasons the use of perinatal mortality as an indicator of the quality of health
services in international comparisons may be misleading unless these factors are being taken
into account, for example by applying common definitions. However evidence from perinatal
audits undertaken in a variety of settings suggests that notwithstanding the improvements in
antenatal and obstetric care achieved in western industrialised countries in recent decades,
current perinatal mortality could be reduced by up to 25% by further improvements in quality
of care.129 This implies that, as long as care is taken to ensure comparisons are valid,
perinatal mortality can still serve as a meaningful outcome indicator in international
comparisons. This conclusion receives further support from findings of a recent international
audit of perinatal deaths in regions of ten European countries (EuroNatal audit), which
showed that differences in perinatal mortality rates may, in part, be explained by differences
in the quality of antenatal and perinatal care.135 
Yet few studies analysing more recent periods have taken account of these changes. Thus, as
noted above, Mackenbach expanded his original list of amenable conditions to include
ischaemic heart disease, as the introduction of thrombolytic therapy had led to improved
survival of patients; rectal cancer because of the introduction of more effective combinations
of surgery and radiotherapy; and hip fracture, mortality from which has benefited from
more aggressive surgical treatment of elderly patients.49 One other example is a study by
McColl and Gulliford who developed twelve outcome indicators to assess the effectiveness
of (local) health services in addition to selected ‘avoidable death’ indicators as derived from
the work by Charlton et al.20,136 However their approach differed from the concept of
‘avoidable’ mortality in that they also included indicators of morbidity as well as process
oriented indicators such as immunisation rates. Tobias and Jackson went further by
updating Charlton’s original list to include 56 conditions or groups of conditions, so
substantially broadening the concept of ‘avoidable’ mortality.59 As noted above, their study
also categorised each ‘avoidable’ cause of death according to the level of intervention
involved, i.e. primary, secondary or tertiary intervention. This highlights one intrinsic
problem of ‘avoidable’ mortality, namely the attribution of health outcomes to specific
elements of health care.
This is especially apparent in the case of ischaemic heart disease (IHD). The contribution of
medical care to the decline in ischaemic heart disease mortality remains controversial
although accumulating evidence suggests its impact to be considerable. Beaglehole, for
example, calculated that 42% of the decline in deaths from cardiovascular disease in New
Zealand between 1974 and 1981 could be attributed to advances in medical care.137 Similarly,
a study in The Netherlands estimated the potential contribution of specific medical interventions
(treatment in coronary care units, post-infarction treatment and coronary bypass grafting) to
the observed decline in IHD mortality between 1978 and 1985 at 46%, while another 44%
were attributed to primary prevention efforts such as smoking cessation, strategies to reduce
cholesterol levels and treatment of hypertension.138 Using a computer-simulated state-
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transition model, Hunink et al. estimated that about 25% of the decline in IHD mortality in
the USA between 1980 and 1990 could be explained by primary prevention whereas another
72% was due to secondary reduction in risk factors or improvements in treatment of
patients with IHD.139 Including a variety of measures of primary (e.g. treatment of
hypertension) and secondary prevention (e.g. treatment following myocardial infarction)
Capewell et al. calculated that 40% of the decline in coronary heart disease mortality in
Scotland between 1975 and 1994 could be attributed to medical care.140 This was further
supported by another study in Auckland, New Zealand that, taking account of medical and
surgical treatments administered to patients with ischaemic heart disease and trends in
cardiovascular risk factors in the population and, in particular, smoking, cholesterol levels
and hypertension, estimated that 46% of an observed decline in IHD mortality of 23.4%
between 1982 and 1993 could be attributed to treatment while 54% was attributed to risk
factor reductions.141 This general picture receives further support from the WHO MONICA
project, linking changes in coronary care and secondary prevention practices to the decline
in adverse coronary outcomes between the mid-1980s and the mid-1990s.142
These findings suggest that a considerable proportion of IHD may be amenable to medical
care. Consequently, Tobias and Jackson have assigned 25% of the potential preventability to
measures of secondary prevention such as treatment of hypertension and high cholesterol
and a further 25% to tertiary prevention measures, mainly treatment of acute episodes and
surgery to unblock coronary arteries (see also Box 2).59 The estimates of the quantitative
attribution of health outcomes to specific components of health care were based on an
expert consensus process “in the absence of any more objective measure for assigning the
weights.” 59 Whilst, as the authors concluded, further research on this area is certainly
warranted it appears questionable whether it is feasible to assess the precise impact of
particular interventions on some conditions, given the multifactorial nature of many
chronic diseases and the phases involved in developing the actual condition. One might
even question whether this is actually desirable because such estimates would suggest a
degree of accuracy that is unlikely to be achievable, due to the nature of the approach and
the quality of data available.
Treatment or prevention
As noted earlier, various authors have distinguished conditions where death can be averted
by prevention (‘preventable’) or by treatment (‘amenable’, ‘treatable’). This concept can be
confusing so some clarification is required. Amenable conditions are defined as those from
which it is reasonable to expect death to be averted even after the condition has developed.
This covers diseases such as appendicitis and hypertension, where the clinical nature of the
intervention is apparent. It also includes causes of death susceptible to secondary
prevention through early detection and effective treatment, such as cervical cancer, for
which effective screening programmes exist, and such as tuberculosis where, although the
acquisition of disease is mainly driven by socio-economic conditions, timely treatment is
effective in preventing mortality.
Preventable conditions typically include those for which there are effective means of
preventing the condition from occurring. These include causes whose aetiology is, to a
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considerable extent, related to lifestyle factors, most importantly the use of alcohol and
tobacco (lung cancer and liver cirrhosis). This group also includes deaths amenable to legal
measures such as traffic safety (speed limits, use of seat belts and motorcycle helmets).
Where a condition is both preventable and amenable to treatment, then the amenability will
prevail. Thus, ‘preventable’ conditions, in this context, are actually a sub-set of those that
might otherwise be considered as being able to be prevented by public health measures and
are characterised by their relative lack of effective treatment once they have developed.
Clearly some conditions have features that place them on the interface between these
categories. Thus, declining mortality from cardiovascular and cerebrovascular diseases may
to a substantial part have been due to changes in diet and thus ‘preventable’, while
improvements in mortality from traffic accidents may also have been impacted by
substantial improvements in emergency services, and thus ‘treatable’ (similarly: HIV/AIDS).
A somewhat extreme illustration of this last example is the finding of a recent study on the
impact of medical care on death rates from homicide. Based on the observation that since
the 1960s the lethality of serious criminal assault in the USA has dropped substantially
despite a simultaneous increase in assault rates, Harris et al. examined time-series data on
criminological data on murder, manslaughter and assault as well as health data and data on
medical resources and facilities.143 They estimated that contemporary US homicide rates
would be up to five times higher than they would have been in the absence of advances in
medical technology and related health care support. 
In summary, some of the criticisms of amenable mortality have been based on a false
premise, proposing that it should deliver more than it was ever intended to. Measures of
amenable mortality can rarely, if ever, confirm the presence and nature of a problem.
Instead, they can act as an indicator of possible concern that should be investigated further.
In some cases there will be straightforward explanations, such as changing disease
incidence, but often problems related to the organisation or delivery of health care will be
identified. However when applying the concept of amenable mortality today it is important
to update the list of causes that are included to take account of recent advances in health
care. It is also important to be aware that the nature of attribution of an outcome to a
particular aspect of health care is intrinsically problematic because of the multi-factorial
nature of most outcomes. As a consequence, when interpreting findings a degree of
judgement must be applied, based on an understanding of the natural history and scope for
prevention and treatment of the condition in question.
Contribution of amenable conditions to overall mortality
Another criticism addresses the observation that conditions amenable to medical
intervention form only a small proportion of total mortality and analyses of trends are thus
likely to overemphasise the overall impact of health services.144 For example, applying the
concept of ‘avoidable’ mortality as used by the EC Concerted Action Project to Sweden in
1974-78 and 1980-84, Westerling and Smedby showed that ten out of 14 causes of death
that were considered indicators for the quality of medical care intervention occurred, on
average, less than 50 times per year37, in many cases reflecting the low level of mortality in
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Sweden. At the sub-national level, even when aggregating data over periods as long as five
years, expected rates would be small for most conditions. The authors thus concluded that
these indicators were of limited use for further studies on quality of health care in Sweden
and other countries where overall mortality is now very low.  
This criticism arises largely because the original advocates of this concept adopted the
somewhat arbitrary criterion that only deaths occurring under the age of 65 could be
considered amenable. This is inconsistent with life expectancies at birth in the high 70s or
low 80s in many industrialised countries and was addressed by Mackenbach et al. by
increasing the age limit to 75.47 This criticism also ignores the enormous changes in the
scope of health care, especially since the 1980s. 
Low age limits seem no longer justified in the light of new evidence regarding, for example,
hypertension and stroke. Two large studies, the Systolic Hypertension in the Elderly
Program (SHEP) and the Systolic Hypertension in Europe study (Syst-Eur), were able to
show the benefits of antihypertensive drug treatment for elderly patients with isolated
systolic hypertension (ISH) with respect to stroke and other major cardiovascular
events.145,146 The SHEP study demonstrated that, in a cohort of patients over 60 years of
age (mean age: 72 years), treatment of ISH reduced the total risk of stroke by 36%, the
incidence of cardiovascular disease in general by 32% and of coronary heart disease by
25%.147 Setting an age limit at 65 years for the ‘avoidability’ of mortality from hypertension
and stroke is likely therefore to underestimate the ‘true’ impact of health care.
Similarly, evidence from England and Wales of improved survival from certain cancers
during the 1990s, such as female breast cancer, cancer of the colon and rectum, the bladder
and malignant melanoma point to the potential for reducing mortality from these causes at
least up to age 75.148 Improved survival from female breast cancer was largely attributed to
a combination of earlier diagnosis and the introduction of a breast screening program as
well as improvements in treatment.149,150 However studies on cancer survival continue to
stimulate intense debates on whether improved survival indeed reflects advances in
treatment or rather obscures increased detection of early, “survivable” tumours and related
methodological problems.151,152
In summary, the choice of an upper age limit of 65 is no longer justified because of the
increase in life expectancy since the first studies were undertaken. 
Underlying disease incidence and disease severity at presentation
An intrinsic problem with the concept of ‘avoidable’ mortality is that it takes no account of
differences in the underlying incidence of disease, or of the severity of disease at
presentation. The latter is a function of health seeking behaviour and thus is partly outside
the scope of health services. However, it may also reflect access to care and should
therefore, at least in part, be amenable to health services. As the incidence of disease will
vary between places and over time, reflecting changes in the determinants of disease, some
of which may only exert their effects after many years, superficial comparisons of ‘avoidable’
mortality’ may be quite misleading. 
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Where studies have taken account of underlying disease incidence, usually using hospital
discharge data as proxy for incidence, they have unsurprisingly shown a positive correlation
between incidence and mortality for a number of amenable conditions.62,65 In these studies
differences in incidence have generally explained the greatest part of observed variation in
mortality between regions from selected amenable conditions although significant
heterogeneity remained even when this was taken into account. The only exception was
cervical cancer in the Netherlands where what had been a significant regional variation
disappeared once variation in incidence rates had been accounted for.62 A study in Sweden
looked at whether the proportion of deaths from selected causes occurring outside hospital
could explain regional variation in mortality from these causes, assuming that for certain
‘avoidable’ conditions acute medical management may have an important impact on the
outcome.153 However it found little evidence that this was the case. The only exceptions
were for diabetes and gastric ulcer in some predominantly isolated regions, where high
death rates outside hospital co-existed with high total death rates, indicating the need for
further in-depth studies in those areas.
In summary, it would be desirable to take disease incidence into account but this is often
not possible. However, it has been shown that variations in amenable mortality cannot
simply be explained by differences in disease incidence. 
Other limitations
Cause of death certification and coding
A further criticism of the concept of ‘avoidable mortality’ arises from the observation that
differences may be due, at least in part, to differences in diagnostic patterns, death
certification or coding of cause of death. This problem is common to all analyses that
employ geographical and/or temporal analyses of mortality data. However this must be set
against the advantages of mortality statistics, as they are routinely available in many
countries and as death is a unique event, in terms of its finality, so it is clearly defined.154
There are, of course, some important caveats regarding the quality of recording of causes in
the official statistics, which limits their suitability for epidemiological analysis. Thus,
mortality data inevitably underestimate the burden of disease attributable to low-fatality
conditions, such as mental illness, or many chronic disorders that may rarely be the
immediate cause of death but which do contribute to mortality, such as diabetes.154,155
Further problems arise from the different steps involved in the complex sequence of events
that leads to allocation of a code for cause of death.156,157 It has been argued that the WHO
rules for selecting the principal cause of death are open to varying interpretations and are
likely to pose considerable problems in certifying deaths at old age when multiple
conditions complicate the definition of a single underlying cause of death.158 In addition,
diagnostic habits and preferences of certifying doctors are likely to vary depending on
diagnostic techniques available, cultural norms, or even professional training. Simple
inaccuracies in completion of death certificates, such as errors in reporting the sequence of
events or illegible statements may also reduce data quality. Validity of the cause of death
statistics may also be affected by the process of assigning the ICD code to the statements
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given on the death certificate. Problems of comparability may also arise from differences in
the translation of ICD as has been observed for the German versions of ICD-8 and ICD-9 in
use in west Germany and the former GDR.159 Thus, cause-specific data are at risk of
misclassification from a variety of sources. This last point was emphasised by Carr-Hill et al.
who pointed to evidence suggesting a correlation between quality of medical records as
source of cause of death and quality of medical care.64
In summary, when interpreting data on amenable mortality, as with any studies using data
on cause of death, it is important to be aware of potential problems with disease
classification and coding.
Focus on mortality
Holland and Breeze further noted that “while careful examination of mortality from specific
causes can provide information on the outcome and effectiveness of health services,
mortality is not always an appropriate indicator.”123 They noted that mortality is at best an
incomplete measure of health service performance and is irrelevant for those services that
are focused primarily on relieving pain and improving quality of life. 
However reliable data on morbidity are still scarce and although progress has been made in
terms of setting up disease registries other than the more widely established cancer
registries, for example for conditions such as diabetes, myocardial infarction or stroke, these
often cover only some regions in a country. In contrast, routinely collected health service
utilisation data such as inpatient data or consultations of general practitioners and/or
specialists usually cover an entire region or country. But whilst potentially useful, utilisation
data, especially consultation rates, usually mainly reflect health care needs of those who
(actively) seek care and not necessarily those in need of care, which is largely socially
determined. 
Buck and colleagues also pointed to the importance of non-health outcomes of health
care.160 These would include, amongst others, the potential impact on the general well-
being (of society) of the redistributional effects of health care. Another issue is the intrinsic
value of the health care process itself (process utility), which is the potential benefit to
patients of being able to hand over responsibility for health care decision making - and any
potential risk related to that decision - to an agent, i.e. the doctor, so relieving themselves of
responsibility for a difficult decision and gaining the reassurance that results from the transfer
of expert information. A related benefit of organised health care, where this involves an element
of redistribution, is alleviation of the risk of impoverishment as a consequence of disease.160
Negative consequences of medical care
One final point that is rarely addressed in studies of ‘avoidable’ mortality is the potential
negative impact of medical care. This may be because, notwithstanding the work of Illich,
the concept of iatrogenesis has only relatively recently risen high on the policy agenda.
However it is now clearly recognised as a matter of concern, with a recent study estimating
that the annual number of deaths resulting from medical errors in the USA as up to 98,000
per year.161 Similarly, in the UK, the Bristol Inquiry into the management of care of children
receiving heart surgery162 has contributed to a growing “error prevention movement”163 as
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to reduce medical errors and their impact.164 Rutstein et al. did include surgical and medical
complications and misadventures, nosocomial infections and iatrogenic disease in their list
of unnecessary deaths.15 However, the only study of ‘avoidable’ mortality that has included
deaths related to medical error published so far is the analysis by Tobias and Jackson in
New Zealand.59
Alternative approaches to assess the contribution of medical care to
population health
Given the limitations of the concept of ‘avoidable’ mortality, it is necessary to examine
proposed alternative approaches to assessing the quality of health care at a population level.
Buck and colleagues reviewed various approaches to assessing the societal contribution of
health care.160 In addition to ‘avoidable’ mortality, they identified two other empirical
approaches, the inventory approach and the production function approach. 
The inventory approach
The inventory approach refers to analyses that looked at individual health services,
identifying the relevant population at whom they are aimed and quantified the associated
burden of disease. Examples include early work by McKinley and McKinley, who examined
the effect of chemotherapeutical and prophylactic interventions on the mortality decline in
the United States since 1900.6 Based on their analysis of the date of the introduction of each
intervention in relation to the decline in death rates from various infectious diseases they
estimated that 3.5% of the fall in infectious disease mortality since 1900 could be attributed
to medical interventions. Although criticised by others165, this estimate compares very well
with one study by Mackenbach mentioned earlier who calculated that of the total decline of
infectious disease mortality in The Netherlands between 1875/79 and 1970 between 1.6 and
4.8% can be attributed to medical care.8
Other studies employing the inventory approach include the work by Bunker and co-
workers166,167 as identified by Buck et al. and, more recently, Wright and Weinstein.168 Both
groups adopted an essentially similar approach, i.e. using published evidence on the
effectiveness of specific preventive and curative health services to estimate the potential gain
in life expectancy. Thus, examining the impact of 13 (clinical) preventive services such as
cervical cancer screening and 13 curative services, e.g. treatment of cervical cancer, Bunker
et al. arrive at an estimate of 1.5 years gain for preventive services with a potential further
gain of 7-8 months, while the gain for curative services was estimated at 3.5 to four years
(potential further gain: 1-1.5 years).166 Taken together these calculations suggest that about
five years (or 17%) of a total gain in life expectancy of 30 years in the USA during the 20th
century may be attributed to clinical preventive and curative services.167
The analysis by Wright and Weinstein looked more explicitly at specific interventions and
target populations, thus estimating that, for example, in 35-year olds with highly elevated
blood cholesterol levels of > 300 mg/dl the reduction of cholesterol to 200 mg/dl would
result in a life expectancy gain of 50-76 months in that particular group.168 In comparison,
targeting 35-year olds at average risk by helping them to quit smoking was estimated to
increase life expectancy by eight to ten months.  
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One limitation of these kinds of analyses is that they largely assume that health gains as
reported in clinical trials translate directly into health gains at the population level. This is
not necessarily the case.169 For example, evidence from randomised controlled trials shows
that the pharmacological treatment of high blood pressure reduces the risk of stroke. Yet the
application of this knowledge in primary care is hampered by a number of problems, for
example inaccuracies in the detection of people most likely to benefit from the treatment or
poor adherence to treatment by patients as well as poor adherence to established
management guidelines by professionals. Thus, assuming that hypertension treatment
reduces the stroke risk by 42%, that half of the hypertensive population are detected and of
those half are on treatment with only 50% being well controlled, Ebrahim calculated that
the efficacy of 42% will be reduced to 5% community effectiveness.170
More importantly, the approach chosen in the two sets of studies is intrinsically selective in
that they identify specific services that do not encompass the full scope of health services.
For example, the impact of a screening service for, for example, detecting the precursors of
cervical cancer will largely depend on how the actual screening programme is organized, i.e.
whether it is proactive and a defined population (e.g. community) is offered screening by
invitation, or opportunistic, which is restricted to patients who consult a health practitioner
usually for reasons other than screening. Also, by analysing each service individually, they
overlook possible interaction between services.160 One other drawback of this approach
relates to the focus on mortality, similar to studies of ‘avoidable’ mortality. Bunker and
colleagues tried to overcome this limitation by further assessing the potential impact of
medical care on quality of life.166 Again using published evidence on the effects of specific
treatments for a certain illness or condition but in the absence of formal quantitative
measures, they looked at an indicator “magnitude of relief in treated patients”, subsequently
translated into “potential years of relief per 100 population.”167 Looking at 19 conditions as
diverse as unipolar depression, terminal cancer (severe pain) and cataract it was thus
estimated that an individual has, on average, been relieved (from pain, by restoring
function, by preventing complications) from about five years of poor quality as a result of
medical care. Although providing different and potentially useful results, the underlying
approach is similar to the analysis of gains in life expectancy and thus subject to the same
methodological limitations. 
Finally, the inventory approach was also adopted in a recent study by Cutler and McClellan,
although from a slightly different angle that applied an economics perspective to the
estimated impact of technological advances in medical care on selected conditions.171 For
example, looking specifically at survival from heart attacks amongst Medicare beneficiaries
in the period 1984 to 1998 and changes in treatment and associated costs they estimate that
for every $1 spent on treatment there had been a health gain of $7. They thus concluded
that “(T)echnology increases spending, but the health benefits more than justify the added
costs.”171 Similar net benefits were estimated for low-birthweight infants, where a twelve-
year increase in life expectancy between 1950 and 1990, valued at $240,000, was found to
substantially outweigh the associated cost increase of advances in medical and non-medical
treatment of $40,000 during the same period. Improved treatment of depression and
cataract was also found to achieve net benefits when monetary values were applied to
improvements in quality of life, i.e. reduction in time spent depressed or improved vision.
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By also looking at cost of treatment these analyses certainly add a further important
dimension to assessing the contribution of health care to population health. One major
limitation of this last kind of analysis is, however, that it only provides information about
the potential health gain of those who have access to care. 
The production function approach
The production function approach describes “the production of health in terms of a
function of possible explanatory variables.”160 There is an abundance of research, mostly
from a (health) economics perspective that has adopted this approach, usually examining
factors indicative of health care (‘health care input’) and other explanatory variables for
their impact on some health measure (‘health care output’) through regression analysis. As
with the previously described studies that have looked more specifically at the association
between selected health care indicators and amenable mortality, these studies have produced
mixed findings. Thus, one early study by Cochrane and co-workers demonstrated in a
cross-sectional analysis that included 18 developed countries that, contrary to the
expectations, health care indices were not negatively associated with (age-specific) mortality
rates and moreover, a higher number of doctors per head was positively related to mortality
at young ages.172 In contrast, gross national product (GNP) per capita showed a strong and
consistent negative association with mortality. Others have also failed to identify strong and
consistent relationships between health care indicators such as health care expenditure and
health outcomes, usually (infant) mortality or life expectancy, after controlling for other
factors, whereas socioeconomic factors were found  to be powerful determinants of health
outcomes.173,174,175 
However, more recently Cremieux et al. showed that in within Canada lower health care
spending was associated with an increase in infant mortality and a decline in life expectancy,
and that this relationship was independent of a number of (socio)economic and lifestyle
variables.176 More specifically, they estimated that a 10% reduction in health care spending
was associated with higher infant mortality of about 0.5% and lower life expectancy of 6
months in men and 3 months in women. Also, in a recent cross-country analysis that
examined the determinants of health outcomes in 21 OECD countries, Or identified a
significant negative relationship between health expenditure and premature mortality
among women as measured in Potential Years of Life Lost (PYLL).177 However, for men this
association was, although negative, less strong and as with other studies, the impact of
wider environmental factors, especially socioeconomic indices, was found to be more
important than health care inputs. This was especially pronounced in a related analysis that
assessed the relative importance of medical and non-medical factors to the decline in
premature mortality in OECD countries between 1970 and 1992. It showed that of an
overall decline in premature mortality in all 21 OECD countries of 61.9% among women
(men: 52.7%), 13.5% (2.9%) was accounted for by rising in health care expenditures whereas
the rise in the employment share of white-collar workers accounted for 29.5% (27.1%). 
A subsequent analysis by the same author broadened the spectrum of health outcome
indicators and also took account of non-monetary health care input variables, i.e. number of
doctors per capita, as well as type of reimbursement (salary, fee-for-service, capitation) and a
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measure of access to services (gatekeeper).178 It showed a strong negative and statistically
significant association between the number of doctors and premature and infant mortality as
well as life expectancy at age 65, suggesting that a ten per cent increase in doctors - all else
being equal - would result in a reduction in premature mortality of almost 4% in women
and 3% in men. Only the association with occupational status was stronger whereas for men
GPD was an equally strong determinant. There was also evidence that a larger share of
public financing of health care was associated with lower rates of premature and infant
mortality, whereas the characteristics of the health care system, i.e. funding mechanisms
appeared to be less important. This last point was addressed in an analysis by Elola and
colleagues who examined the association between health care systems and selected health
outcomes, namely premature mortality (potential years of life lost, PYLL) and infant
mortality in 17 western European countries.179 They distinguished two basic forms of
health care systems: national health services (e.g. UK, Denmark, Ireland, Italy, Spain) and
social security systems (e.g. Germany, Austria, Netherlands). Controlling for socioeconomic
indicators such as Gini-coefficient their regression model predicted that countries with
national health services systems would have lower infant mortality rates at similar levels of
GDP and health care expenditures than social security systems. 
However while these last findings point to a role of health care for health that may be
greater than previously assumed, studies reported so far are subject to a number of
methodological problems. Apart from obvious limitations arising from data availability and
reliability, both in terms of health care resources and health outcomes, with models driven
largely by data availability, one major weakness relates to the cross-sectional nature of many
these analyses. The contribution of health care to population health is likely to operate over
a period of time, with potentially considerable time lags between intervention and outcome.
Yet, the usual approach is to associate contemporary inputs with current outcomes. This
was illustrated in an analysis by Gravelle and Backhouse who re-examined the work by
Cochrane et al.172 and, by lagging the explanatory variables were able to show that past
inputs are more significant in determining mortality than current ones.180 A related problem
is that of causality a cross-sectional design is ill-equipped to address adequately. Finally,
Gravelle and Blackhouse also highlighted the general problem of analyses operating at the
aggregate level within or between countries or regions as they are likely to miss important
relationships at the sub-national or regional level.180 Finally, these models often lack any
theoretical basis that might indicate what causal pathways existed.
Future directions 
This review has traced the evolution of the concept of “avoidable mortality” from its
inception in the 1970s. ‘Avoidable’ mortality was never intended to be more than an
indicator of potential weaknesses in health care that can then be investigated in more depth.
Notable examples include the studies that observed high death rates from cervical cancer
and from hypertension in English districts that, on further investigation, led to the
identification of shortcomings in health care12, or the study of diabetes in Ukraine where a
rapidly increasing death rate, that had not been identified by those responsible for reporting
on official statistics, led to the identification of a serious breakdown in the delivery of health
care.90 In contrast, many of the critics of ‘avoidable’ or, more specifically, amenable mortality
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have asked that it do something it was not intended to do, to be a definitive source of
evidence of differences in effectiveness of health care. Similarly, it is not unexpected that
studies seeking to link amenable mortality with health care resources have failed to do so,
especially when undertaken within countries, although it is notable that where gross
differences exist, as between western and eastern Europe, the gap in amenable mortality is
especially high. Thus, Holland’s statement that “[A]voidable deaths provide a valuable
measure of quality. [...] It has a valuable part to play in observing changes in performance
over time. The methodology can be applicable to other areas of concern, for example
alerting managers to variations in mortality within regions. [...] This technique can provide
indicators of areas where future research is necessary” remains valid.181 For these reasons, it
seems reasonable to continue and extend the extensive body of research that has already
been undertaken to look at amenable mortality, updating the list of conditions included to
reflect the changing scope of health care and extending the age limit to reflect increasing
expectation of life. However it must be recognised that the concept of amenable mortality
does have important limitations, relating to comparability of data, attribution of causes, and
coverage of the range of health outcomes. 
Comparisons of health system performance are now firmly on the international policy
agenda, especially since the publication of the 2000 World Health Report. Incorporation of
the concept of amenable mortality into the methodology used to generate the rankings of
health systems in that report would be an advance on the current situation. In contrast,
neither the inventory or production function approaches offer any benefit in this context.
However, this would not address one of the major criticisms of such comparisons, that they
do not indicate what needs to be done when faced with evidence of sub-optimal
performance. This requires a more detailed analysis of the specific issues facing health
(care) systems. 
One approach that shows promise is the concept of tracer conditions, in which selected
amenable causes are the focus of careful study of the responses of health systems. This was
proposed by the US Institute of Medicine (IoM) in the late 1960s as a means to evaluate
health policies.182 A similar approach was adopted by British researchers at St. Thomas
Hospital, London, at around the same time to assess the provision of health services in the
London Borough of Lambeth.183 The tracer concept as described by the IoM was borrowed
from natural sciences and translated for use within the health care delivery system. It was
based on the idea that certain tracer conditions or diseases would make it possible to
examine how the health care delivery was functioning, and so assess its quality. The tracer
conditions would have to be discrete and identifiable health problems and offer a means to
provide insight into how particular parts of the system work - not in isolation but in
relation to each other. The criteria proposed to provide a “rational and uniform basis” for
the selection of tracers were as follows:
 the health problem should have a definitive functional impact (i.e. treatment was
necessary and without appropriate treatment a functional impairment would result);
 it should be relatively well defined and easy to diagnose;
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 prevalence rates should be high enough to permit collection of adequate data from a
limited population sample;
 the the natural history of the condition should vary with utilisation and effectiveness of
medical care;
 techniques of medical management of the condition should be well defined for at least
one of the following processes: prevention, diagnosis, treatment, rehabilitation;
 there should be sufficient understanding of non-medical factors on tracer condition
(requiring a good understanding of the epidemiology of the tracer).
The IoM team defined a battery of 6 tracers rather than only one to enable evaluation of
(ambulatory) care received by a cross-section of the population (both sexes, different age
groups). They further categorised health service delivery into 5 major elements: prevention,
screening, evaluation (history and physical evaluation; laboratory; other testing), management
(chemotherapy; health counselling; speciality referral; hospitalisation) and follow-up case.
In summary, building on the evidence assembled it is possible to conceive of a means of
assessing performance of health care systems that has two stages. The first involves a broad
assessment of health outcomes that might identify topics deserving further attention. The
second stage involves an in-depth assessment of how the system deals with any issues of
potential concern identified in the first stage. 
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PART II:
AVOIDABLE MORTALITY IN THE
EUROPEAN UNION
Introduction
The review of the concept of ‘avoidable mortality’ in the first part of this report indicates
that, notwithstanding its many limitations, this concept has provided a means to examine
the quality of health care provided by a health care system and to identify topics for further
in-depth investigation. 
The second part of this report looks at its continuing potential to do so, building on what has
been done before and updating the list of conditions considered amenable to health care in
the light of more recent advances in medical knowledge and technology and extending the age
limit to reflect increasing expectation of life. This revised concept is then applied to routinely
available data from selected countries in the European Union to investigate the potential
impact of health care on changing life expectancy and mortality in the 1980s and 1990s.
Methods
Data
Mortality data were extracted from the World Health Organization mortality files for the
years 1980, 1989, 1990 and 1998.184 Data include deaths in each year, using the 8th
(abbreviated A-list), 9th (abbreviated basic tabulation list) and/or 10th revision of the
International Classification of Diseases (ICD) by sex and 5-year age band (with infant
deaths listed separately). Data for west Germany were only available to 1990 from this
source; additional data were thus obtained from the Statistical Office Germany.185 However,
from 1998 data collection at the federal level in Germany no longer distinguishes between
the former east and west but provides data at the level of federal states; as a consequence
separate data for east and west Berlin are no longer available and the pre- and post 1998
‘west’ (or ‘east’) are thus not strictly comparable. Thus, for consistency, the year 1997 was
chosen as the most recent year for west Germany. As with WHO, data included deaths by
sex and 5-year age band but using the detailed list of ICD9. Population numbers by sex and
age were obtained from the same sources. 
The analysis was limited to the larger member states of the European Union. It thus looks at
changes in amenable mortality in Austria, Denmark, Finland, France, Greece, west
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Germany, Italy, the Netherlands, Portugal, Spain, Sweden and the United Kingdom. Belgium
was not included as most recent data were only available for 1995. This is because mortality
statistics are collected at the community level in Belgium and the community of Brussels
has experienced long standing problems in implementing effective reporting systems.
Selection of causes of death
The selection of causes of death considered amenable to health care was based on our
earlier analysis of ‘avoidable’ mortality57 but took account of recent work by Tobias and
Jackson59 who provided an update of the list proposed by Charlton et al.20, and by
Mackenbach49 (Table 10). We thus included colorectal cancer where there is evidence from
randomised controlled trials on the impact on survival of intensive follow-up after curative
resection for colorectal cancer.186 Increasing evidence also points to the potential benefits of
screening for colorectal cancer for curbing mortality from this condition, although there is
still a lack of consensus on the effectiveness of population screening.187,188 We also included
epilepsy as a recent inquiry identified sub-optimal management of this condition in the UK,
which was related to an increased risk of premature death.189
As with the European Community Atlas of ‘Avoidable Death’28, we included ‘malignant
neoplasm of uterus, part unspecified’ (ICD-9 179) and of ‘body of uterus’ (ICD-9 182) in
addition to cancer of cervix uteri (ICD-9 180), as it has been reported that due to variation
in death certification and coding practices157 some countries could allocate cervical cancer
to any of these categories. A recent study confirmed that this is still largely the case. Thus,
Levi and colleagues demonstrated that 20-65% of deaths from uterine cancer in many of the
larger EU countries are still being certified as ‘uterus, unspecified’.190 They therefore
recommended that when analysing cervical cancer mortality across Europe to also include
ICD-9 179 and 182 for ages under 45 as most deaths from uterine cancer at that age arise
from cancer of cervix uteri. 
However, unlike Tobias and Jackson59 we did not include stomach cancer. The decline in
stomach cancer mortality during the past century has largely been due to declining
incidence, associated primarily with declining prevalence of infection with H. pylori,191
although with the effects also modulated by changing dietary patterns such as increased
fruit and vegetable consumption and decreasing salt intake, rather than improvements in
survival of those with cancer, which still remains poor.192 However we recognise that this
may be controversial as there is variation in survival after diagnosis of stomach cancer
between European countries, with for example England, Scotland and Poland somewhat
lower than the average European five-year survival rate whereas survival was found to be
significantly higher in Germany, Austria, France, Spain and Italy, with this mainly being
attributed to variation in stage at presentation, and, in a some cases, to differences in the
quality of care. In contrast, there is a large difference in survival from stomach cancer in
Japan, where survival is reported to be much higher than in Europe, at 47% vs. 21%.192 This
has been linked to more widespread use of endoscopy and development of mass screening,
centralised management of designated, highly experienced and skilled surgeons, as well as
the younger age at disease presentation in Japan.193 However this takes place in a country
where the incidence of stomach cancer is very much higher than in any western European
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country except Portugal and thus the costs and benefits of such a programme are unlikely
to apply in the rather different European setting. On balance, therefore, it was decided not
to include stomach cancer in this study.
A recent analysis of cancer mortality trends in the European Union between 1988 and 1997
showed a small decline in prostate cancer mortality especially after 1995 with appreciable
advances in survival being observed in the last few years that was attributed, in part, to
therapy including screening and thus early diagnosis as well as hormonal treatment.194
However the impact of screening on mortality from prostate cancer is still uncertain195,
especially as to whether the early detection of prostate cancer does indeed prolong life,
mainly because many cancers are indolent and remain asymptomatic at the time of death
from another cause.196 Prostate cancer was thus not included in our analysis.
Finally, although asthma has been considered amenable to health care20,28,197 we did not
include this condition, simply because the data format available, using the abbreviated form
of ICD-8 and ICD-9, did not make it possible to extract deaths from this condition. 
As with our earlier work, the conditions selected in the present analysis were considered
indicators of the impact of health care, i.e. secondary prevention or medical treatment, thus
amenable conditions. As with the EC working group on ‘avoidable deaths’ we interpret
health care (services) as to include primary care, hospital care, and collective health services
such as screening and public health programmes, e.g. immunisation. The conditions were
chosen on the basis of having identifiable effective interventions and health care providers.
They were, however, not intended to cover all causes that are possibly treatable. Rather, it
was assumed that while not all deaths from these causes would be ‘avoidable’, health
services could contribute substantially to minimising mortality.
To calculate the contribution of amenable conditions to changes in life expectancy, single
causes and cause groups were combined, with one exception. Ischaemic heart disease (IHD)
was treated separately as (1) the precise contribution of health care to reductions in deaths
from this condition is unresolved142, (2) IHD may be understood as an indicator of health
care but also of health policy, and, most importantly, (3) the very large number of deaths
involved means that any changes will obscure the impact of health care on diseases other
than IHD. Three cause groups were thus analysed: amenable conditions, IHD and ‘other
causes’, comprising the remaining causes of death.
As in our earlier work, an age-limit was set at 75 years as ‘avoidability’ of death and
reliability of death certification become increasingly questionable at older ages. We
recognise, however, that any upper age limit is essentially arbitrary, but this value is
consistent with life expectancy at birth in many western European countries. However the
logic of this would suggest a higher upper limit for women. We recognise this as an
important issue for debate but we do not feel that it has yet been resolved. 
Different age limits were set for diabetes mellitus (< 50) because the preventability of deaths
at older ages from diabetes, and in particular the effectiveness of good diabetic control in
reducing vascular complications, remain controversial. For some other causes a limit of <15
A V O I D A B L E  M O R T A L I T Y  I N  T H E  E U R O P E A N  U N I O N
65
Name of group Age ICD8 ICD9 ICD10
1 Intestinal infections30 0-14 000-009 001-009 A00-A09
2 Tuberculosis20,28 0-74 010-019 010-018, 137 A15-A19, B90
3 Other infectious 
(Diphtheria, Tetanus, Poliomyelitis)28 0-74 032, 037,  032, 037, 045 A36, A35,A80 
040-043
4 Whooping cough28 0-14 033 033 A37
5 Septicaemia47‡ 0-74 038 038 A40-A41
6 Measles28 1-14 055 055 B05
7 Malignant neoplasm of colon(‡) 0-74 153-154 153-154 C18-C21
and rectum49,59, 186,187,188
8 Malignant neoplasm of skin30,47(‡) 0-74 173 173 C44
9 Malignant neoplasm of breast30,136 0-74 174 174 C50
10 Malignant neoplasm of cervix uteri28 0-74 180 180 C53
11 Malignant neoplasm of cervix 0-44 182 179, 182 C54, C55
uteri and body of the uterus28,190
12 Malignant neoplasm of testis30,47,(‡) 0-74 186 186 C62
13 Hodgkin’s disease28,199,200(‡) 0-74 201 201 C81
14 Leukaemia30,47 0-44 204-207 204-208 C91-C95
15 Diseases of the thyroid47 0-74 240-246 240-246 E00-E07
16 Diabetes mellitus47,136 0-49 250 250 E10-E14
17 Epilepsy59,189 0-74 345 345 G40-G41
18 Chronic rheumatic heart disease28(‡) 0-74 393-396 393-398 I05-I09
19 Hypertensive disease28 0-74 400-404 401-405 I10-I13, I15
20 Ischaemic heart disease30 0-74 410-414 410-414 I20-I25
21 Cerebrovascular disease28 0-74 430-438 430-438 I60-I69 
22 All respiratory diseases 1-14 460-466, 460-479, J00-J09,
(excl. pneumonia/influenza)28 490-519 488-519 J20-J99
23 Influenza28 0-74 470-474 487 J10-J11
24 Pneumonia28 0-74 480-486 480-486 J12-J18
25 Peptic ulcer 30,47,136 0-74 531-533 531-533 K25-K27
26 Appendicitis28 0-74 540-543 540-543 K35-K38
27 Abdominal hernia28 0-74 550-553 550-553 K40-K46
28 Cholelithiasis & cholecystitis28 0-74 574-575 574-575.1 K80-K81
29 Nephritis and nephrosis47 0-74 580-584 580-589 N00-N07, N17-N19
N25-N27
30 Benign prostatic hyperplasia47 0-74 600 600 N40
31 Maternal deaths28 All 630-678 630-676 O00-O99
32 Congenital cardiovascular anomalies30 0-74 746-747 745-747 Q20-Q28
33 Perinatal deaths, all causes All 760-779 760-779 P00-P96, A33, 
excluding stillbirths28 A34
34 Misadventures to patients during All E870-E876, Y60-Y69,
surgical and medical care59 (‡) E878-E879 Y83-Y84
Table 10   Causes of death considered amenable to health care
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(‡) condition not included as ‘amenable condition’ in Denmark, Finland and Sweden (see text)
was set (intestinal infectious diseases, whooping cough, measles, childhood respiratory
diseases) as deaths other than in childhood from these causes are likely to reflect some
other disease process. However, unlike in our earlier study, the age limit for leukaemia was
extended to 44 years. This is mainly because of a recent study that has reported substantial
improvements in mortality from leukaemia in European Union countries.202 It showed that
between 1960/64 and 1995/97 death rates among children declined by over 70% and among
those aged 15-44 rates fell by about 40% in men and 45% in women. This was largely
attributed to advances in treatment. 
For countries that used the 8th revision of ICD the selection of amenable causes of death
had to be modified slightly. This was the case for Sweden (ICD8: 1980), Finland (1980) and
Denmark (1980, 1990). The data were presented according to the abbreviated version of
ICD-8 (A-list). The A-list does not, however, make it possible to extract some conditions
shown in Table 10.These included septicaemia, cancer of colon, cancer of skin other than
melanoma, cancer of testis, Hodgkin’s disease and misadventures during surgical/medical
care. For consistency, these conditions were thus excluded from the analysis of amenable
mortality in Sweden, Finland and Denmark. There were also some differences between ICD-
9 and ICD-10 that could affect intra-country comparisons involving The Netherlands and
Sweden, which changed from ICD-9 to ICD-10 in 1995 and 1996 respectively. For example,
the ICD-10 codes for cerebrovascular diseases do not include a diagnosis equivalent to ICD-
9 435 (“transient cerebral ischaemia”)203 although this is not expected to cause problems
because of the small numbers involved compared with the total number of deaths from
cerebrovascular disease. Similarly, the ICD-10 classification for perinatal causes (P00-P096)
does not include tetanus neonatorum, which has been reclassified as A33; however, the
equivalent ICD-9 code 771.3 is not identifiable as a single category in the ICD-9 basic
tabulation list. But again numbers involved in western Europe will be non-existent or
negligible and are not expected to causes any problems. There were, however, some
inconsistencies in the reported number of deaths from chronic rheumatic heart disease in
Denmark, Finland and Sweden, with some unusually high fluctuations coinciding with the
change from ICD-8 to ICD-9 or ICD-10. This condition was thus excluded from the analysis
of amenable mortality in the three Nordic countries. 
Analysis
The contribution of health care to changes in mortality trends in EU countries was
estimated by decomposing life expectancy by age and cause of death. This enables
separation of differences between life expectancies into contributions according to age and
cause of death, expressed in years gained or lost. Because of the age limit noted earlier, the
analyses were based on ‘temporary’ (or ‘partial’) life expectancy between birth and age 75 [e
(0-75)] rather than life expectancy at birth. Life expectancy was calculated using life table
techniques as proposed by Chiang.204 This gives slightly lower estimates than those
reported in the World Health Organisation’s Health for All database, which uses a different
method (Wiesler’s method) (Remis Prokhorskas, personal communication). Decomposition
of differences in life expectancy was undertaken using methods developed independently by
Andreev205, Arriaga206, and Pressat.207 Analyses were undertaken using Microsoft Excel.
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To examine changes in amenable mortality and their impact on changing temporary life
expectancy, we compared two periods, 1980 to 1989 and 1990 to 1998 as for most countries
most recent data were available to 1998 only. 
Age-standardised mortality rates by sex were calculated for all conditions and for all ages
(0-74) by direct standardisation to the European standard population.208
Results
Trends in life expectancy at birth 
In 1980, life expectancy at birth was highest among Greek men and Dutch women but the
order changed from 1989 onwards with Swedish men and French women experiencing on
average the longest lifespan in 1998, at 76.8 and 82.6 years, respectively (Table 11). In
contrast, life expectancy was consistently lowest in Portugal, for both men and women, at
71.6 and 78.9 years (1998), respectively. Although improving everywhere between 1980 and
1998 the pace of change differed between the two periods and between countries. The
largest improvements were seen in Austria, Italy, west Germany, the UK (men), Finland
(men) and Portugal (women). 
These changes meant that a female life expectancy gap of 4.8 years between the ‘best’ and
the ‘worst’ country in 1980 had narrowed to 3.7 years in 1998. While initially also declining
among men, from 5.6 years in 1980 to 4.1 in 1989, the mortality differential has been
increasing again, to 5.2 years between Portugal and Sweden in 1998.
Looking at life expectancy between birth and age 75, the picture is somewhat similar, at
least for men, with figures consistently lowest in Portugal and highest in Sweden (Table 12).
For women, from 1989, temporary life expectancy was lowest in Denmark, with Portugal
coming a close second while the highest figures were again seen in Sweden. In 1998,
however, life expectancy was highest among Spanish women although differences between
countries were small. 
As with life expectancy at birth, size and pace of improvements in temporary life expectancy
differed between the two periods and between countries. In the 1980s, the largest
improvements were seen in Portugal, Austria and west Germany (Table 12). In the 1990s
this pattern had changed somewhat, at least for men, with the largest improvements now
seen in Finland, Denmark and Austria, whereas among women, increases were again highest
in Austria and Portugal but also in Finland.
Among men, much of the observed changes in life expectancy at birth between 1980 and
1998 were due to mortality declines among the under 75s, accounting for 55% (Greece,
Sweden, UK) to 71% (Portugal) of the overall change. In women, this proportion was
considerably less, accounting for 32% (Finland) to 52% (Portugal). It is important to keep
this in mind when interpreting the following figures on changes in temporary life expectancy.
Amenable mortality in the 1980s and 1990s
For clarity, subsequent sections will examine changes in amenable mortality in the 1980s
and 1990s on a country by country basis. Table 14 at the end of this chapter gives an
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1980 1989 1990 1998 1980-89 1990-98
change change 
m f m f m f m f m f m f
Austria 68.96 76.05 71.97 78.77 72.37 79.00 74.74 80.98 3.01 2.72 2.37 1.98
Denmark 71.15 77.27 72.13 77.90 72.15 77.87 74.11 79.08 0.98 0.63 1.96 1.21
Finland 69.18 77.93 70.86 78.98 70.93 78.94 73.56 80.99 1.68 1.05 2.63 2.05
France 70.68 78.97 72.99 81.34 73.31 81.67 74.90 82.55 2.31 2.37 1.59 0.88
Germany west 69.88 76.69 72.55 79.08 72.69 79.11 74.47 80.63 2.67 2.39 1.78 1.52
Greece 73.02 77.51 74.49 79.41 74.68 79.51 75.65 80.69 1.47 1.90 0.97 1.18
Italy 70.98 77.63 73.59 80.27 73.68 80.37 75.73 82.09 2.61 2.64 2.05 1.72
Netherlands 72.47 79.36 73.65 80.03 73.81 80.21 75.18 80.75 1.18 0.67 1.37 0.54
Portugal 67.44 74.56 70.64 77.70 70.38 77.35 71.63 78.85 3.20 3.14 1.25 1.50
Spain 72.41 78.57 73.36 80.41 73.31 80.44 75.00 82.17 0.95 1.84 1.69 1.73
Sweden 72.75 78.94 74.78 80.69 74.80 80.50 76.82 82.03 2.03 1.75 2.02 1.53
UK 70.40 76.47 72.63 78.14 72.95 78.60 74.87 79.85 2.23 1.67 1.92 1.25
Table 11 Life expectancy at birth in selected European countries in 1980, 1989, 1990
and 1998 (in years)
1980 1989 1990 1998 change change
1980-89 1990-98 
m f m f m f m f m f m f
Austria 65.64 69.92 67.59 71.15 67.85 71.22 69.17 71.97 1.95 1.23 1.32 0.76
Denmark 67.25 70.09 67.77 70.34 67.91 70.43 69.11 71.09 0.52 0.25 1.21 0.66
Finland 66.05 71.04 66.90 71.37 67.00 71.31 68.61 72.02 0.86 0.33 1.61 0.71
France 66.49 70.75 67.66 71.54 67.80 71.68 68.85 72.06 1.17 0.79 1.05 0.38
Germany west 66.43 70.14 68.15 71.23 68.24 71.28 69.12 71.78 1.73 1.09 0.89 0.50
Greece 67.93 70.58 68.87 71.58 69.05 71.61 69.36 72.05 0.94 1.00 0.31 0.44
Italy 66.98 70.54 68.59 71.61 68.62 71.69 69.77 72.20 1.62 1.07 1.16 0.51
Netherlands 68.14 71.14 69.05 71.44 69.09 71.50 69.88 71.83 0.91 0.30 0.79 0.31
Portugal 64.34 69.09 66.49 70.50 66.39 70.52 67.33 71.30 2.14 1.42 0.93 0.78
Spain 67.72 70.95 68.08 71.65 68.11 71.68 69.24 72.37 0.37 0.71 1.13 0.68
Sweden 68.28 71.18 69.34 71.75 69.45 71.71 70.52 72.27 1.06 0.57 1.08 0.57
UK 67.04 69.96 68.36 70.76 68.46 70.89 69.49 71.49 1.32 0.80 1.04 0.60
Table 12 Life expectancy between birth and age 75 in selected European countries in
1980, 1989, 1990 and 1998 (in years)
overview on levels of mortality from selected causes and cause groups in each country for
ages 0 to 74 by sex for the years 1980, 1990 and 1998. The numbers subsequent figures are
based on are given in Table 15 and Table 16.
Austria
Figure 3 illustrates how different causes of death contributed to changes in temporary life
expectancy in Austria between 1980 and 1989 and between 1990 and 1998. The sum of
values, negative and positive, represents the change in life expectancy between birth and age
75 in years (delta e (0-75)). Bars extending below the horizontal axis indicate that mortality
rates in the age group concerned actually increased and thus contributed negatively to the
overall change in temporary life expectancy, while bars above the axis indicate that
mortality rates in an age group fell and therefore contributed positively.
This shows that in Austria, in the 1980s, improvements in amenable mortality made
substantial positive contributions to the overall increase in temporary life expectancy,
accounting for 40-44% in men and women. About 20% of this improvement was due to a
decline in infant mortality, with another 13-16% attributable to declining mortality among
those aged 40+. If ischaemic heart disease was to be included with amenable conditions,
their impact on life expectancy would be somewhat higher, contributing 1.14 years in men
and 0.65 of a year in women. 
However, declining mortality from ‘other causes’ made the largest contribution, at almost
50% in both sexes, largely because of declining mortality among the young and middle-aged
(15-64 years). 
In the 1990s, changes in amenable causes made a smaller contribution to the changes in life
expectancy than they had in the 1980s, especially among men, where falling amenable
mortality now accounted for 19% of the overall increase of 1.32 years (Figure 3). However,
unlike in the 1980s, much of the improvement in amenable mortality was now due to
declining death rates among the middle-aged. For women, falling amenable mortality
remained an important contributor, still accounting for almost 40% of the increase in life
expectancy. As with men, this was largely due to fewer deaths among the middle-aged
although falling infant mortality remained an important contributor.
Although declining IHD mortality also contributed to the overall improvement in temporary
life expectancy, its impact was somewhat less than in the 1980s, accounting for less than
10% in both sexes. Consequently  falling mortality from other conditions became more
important, in relative terms, in explaining improvements in temporary life expectancy in the
1990s in both sexes, but especially so in men, accounting for almost three quarters of the
change, again, mostly because of declining death rates among the middle-aged.
Denmark
Unlike Austria, changes in temporary life expectancy in Denmark in the 1980s were much
less, especially among women, at 0.25 of a year (Table 12). Figure 4 shows that the
underlying mortality pattern also differed quite considerably from that seen in Austria.
Among men, falling mortality from amenable conditions contributed only 17% to the
overall increase in life expectancy of 0.52 of a year. However, adding the decline in death
rates from IHD, the relative impact of amenable causes increased to almost 90%, indicating
that much of the improvement in temporary life expectancy among Danish men in the
1980s was actually due to falling IHD mortality. There was also considerable decline in
mortality from ‘other causes’ at younger ages. Its relative impact was, however,
counterbalanced by an actual increase in deaths from these causes at ages 50+.
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Figure 3 Age- and cause specific contributions to changes in temporary life expectancy in Austria: 1980-1989 and 1990-1998 
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72 Figure 4 Age- and cause specific contributions to changes in temporary life expectancy in Denmark: 1980-1989 and 1990-1998 
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
Denmark, men
Total change e(0-75): 0.52 years
1980-1989
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
Denmark, women
Total change e(0-75): 0.25 years
1980-1989
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
Denmark, men
Total change e(0-75): 1.21 years
1990-1998
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
Denmark, women
Total change e(0-75): 0.66 years
1990-1998
This last observation was even more pronounced among women, thus concealing
improvements seen at younger ages that were due, in part, to declining mortality from
amenable conditions (Figure 4). Falling infant mortality was an important contributor to
the favourable changes in amenable morality as were fewer amenable deaths among women
aged 40-49.
Again unlike Austria, changes in temporary life expectancy in Denmark in the 1990s were
substantially higher than they were in the 1980s, at 1.2 years in men and 0.66 of a year in
women. These changes were due to improvements in mortality at all ages with the
exception of 15-19 year old men and women over 65, but especially among infants and the
middle-aged. As with Austria, the impact of falling mortality from amenable conditions was
less than in the 1980s, at 15% in men and 30% in women. However, much of the
improvement in amenable mortality seen among women occurred among the middle-aged,
who accounted for 0.1 of a year or 17% of the overall change in temporary life expectancy
in the 1990s. Adding declining mortality from IHD increases the relative impact of
amenable mortality to about 55% of the overall change in both sexes. 
Finland
The mortality pattern underlying changing temporary life expectancy in Finland appears
somewhat similar to that seen in Denmark, with smaller changes in the 1980s, especially
among women, and substantial improvements among men in the 1990s (Figure 5). Also,
the improvements in life expectancy in the 1980s were driven largely by declining amenable
mortality and mortality from ischaemic heart disease. Compared with Denmark, the decline
in amenable mortality had a larger impact in Finland, accounting for 30% of the overall
increase in life expectancy among men and for over 60% among women. Adding falling IHD
mortality, its contribution increases to almost 100% of the change in both men and women.
Unlike in Denmark there were little improvements in death rates from ‘other causes’. In fact,
both men and women recorded a net increase in mortality at ages 15-39 that was largely due
to deaths in this category. 
By the 1990s this last pattern had, however, changed with particularly young men now
showing substantial improvements in mortality, mainly from ‘other causes’. As with Austria
and Denmark, falling mortality from amenable causes now made a smaller contribution to
the overall change in temporary life expectancy, accounting for 18% in men and 28% in
women. In both men and women, much of this improvement was due to fewer amenable
deaths among those over 40 years of age, contributing 10% and 15% of the total change,
respectively. Again, as with Denmark, adding the decline in mortality from IHD causes the
the relative impact of amenable mortality to increase even further, contributing about half of
the total change in life expectancy in the 1990s.
France
An again different mortality pattern was observed in France, which, as in Austria, saw
considerable improvements in temporary life expectancy for men in both periods although
there were only small changes among women in the 1990s (Figure 6). As with the other 
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Figure 5 Age- and cause specific contributions to changes in temporary life expectancy in Finland: 1980-1989 and 1990-1998
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Figure 6 Age- and cause specific contributions to changes in temporary life expectancy in France: 1980-1989 and 1990-1998
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countries described thus far, declining mortality from amenable causes made considerable
positive contributions to the overall change in life expectancy in the 1980s, accounting for
about one third of the observed improvements in both sexes. As can be inferred from Figure
6, falling death rates among infants and the middle-aged contributed equally to these gains,
at about 10% each. As in Austria, declining mortality from IHD contributed only little to the
total change in life expectancy, at 11% in men and 5% in women, thus increasing the
potential impact of amenable mortality to 35-40%. 
However, declining mortality from ‘other causes’ was the most important contributor to
changing life expectancy in France, accounting for about two thirds of the total change.
This contribution was not entirely beneficial, though, as men aged 25-39 years experienced
an actual net increase in mortality from ‘other causes’.
In contrast, in the 1990s, all age groups contributed positively to the changes in temporary
life expectancy, at 1.1 years in men and 0.38 of a year in women. As with what has been
described earlier, amenable conditions now had a smaller impact on these changes,
accounting for 15% in men and 21% in women. For women, this was the smallest
contribution by amenable conditions observed thus far. However, as in the 1980s, the
changes were equally due to declining mortality among infants and among the middle-aged,
together accounting for 10-12% of the total improvement in temporary life expectancy in
the 1990s. 
Again, as in the 1980s, declining IHD mortality had only little impact on the overall
changes in life expectancy whereas falling mortality from ‘other causes’ had become more
important in the 1990s, now accounting for about 75% of the total change in temporary life
expectancy in both sexes.
Germany, west
Turning to west Germany, the picture is very similar to that seen in Austria, particularly in
the 1980s (Figure 7). Thus, between 1980 and 1989 improvements in amenable mortality
made substantial positive contributions to the overall increase in temporary life expectancy,
accounting for 0.58 of a year or 34% in men and 0.49 of a year or 45% in women. About
one fifth of the total improvement was due to a decline in infant mortality, with another 12-
14% attributable to declining mortality among those aged 40+. However, among men,
declining IHD mortality had a higher impact on life expectancy than among Austrian men,
at 19% compared with 11%. Among women, the impact of IHD was similar, at about 6% in
both countries. 
As in Austria, mortality from ‘other causes’ declined at all ages, especially among young
men, and made the largest contribution to the total change in life expectancy, at almost 50%
in both sexes. 
In the 1990s, changes in amenable causes again made a smaller contribution to the changes
in life expectancy than they had in the 1980s, especially among men, where falling
amenable mortality accounted for 14% of the overall increase of 0.89 of a year (Figure 7).
However, as with Danish men, declining infant mortality remained the most important
contributor for increasing male life expectancy. Among women, in contrast, falling amenable 
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Figure 7 Age- and cause specific contributions to changes in temporary life expectancy in west Germany: 1980-1989 and 1990-1998
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
west Germany, men
Total change e(0-75): 1.73 years
1980-1989
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
west Germany, women
Total change e(0-75): 1.09 years
1980-1989
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
west Germany, men
Total change e(0-75): 0.89 years
1990-1998
-0.10
0.00
0.10
0.20
0.30
0.40
Age
IHD
amenable
other
west Germany, women
Total change e(0-75): 0.50 years
1990-1998
Figure 8 Age- and cause specific contributions to changes in temporary life expectancy in Greece: 1980-1989 and 1990-1998
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mortality among the over 40s became more important in the 1990s, now accounting for
15% of the total change in life expectancy although falling infant mortality remained an
important contributor, at 6%.
The impact of declining IHD mortality increased slightly in both sexes, now accounting for
20% of the increase in life expectancy in men and 9% in women. Combined with amenable
mortality, the potential impact of health care would thus amount to 35% of the total change
in temporary life expectancy in west Germany in the 1990s.
Greece
Compared with the countries analysed thus far, Greece displayed a very different mortality
pattern. Firstly, increases in temporary life expectancy were higher in women than in men
in both the 1980s and 1990s (Table 12). Secondly, in the 1980s, at least 70% of the total
improvements in life expectancy were due to falling amenable mortality in both sexes, with
about half of this improvement due to declining infant mortality (Figure 8). In contrast,
mortality from ischaemic heart disease increased slightly in both sexes, thus diminishing the
impact of health care to changing life expectancy in Greece in the 1980s to some extent. At
the same time, men aged 20-39 years recorded a net increase in mortality, largely from ‘other
causes’, thus counterbalancing the overall mortality improvements seen in men. Net
increases in mortality among young men were also observed in Finland and France, as
described above. 
Turning to the 1990s, there were only small further improvements in temporary life
expectancy in both men and women, at 0.31 and 0.44 of a year, respectively. As with the
other countries, amenable mortality made a somewhat smaller contribution than it had in
the 1980s, although its impact was still substantial, accounting for a about two thirds of the
total increase in life expectancy in both sexes. Again, much of this change was driven by
falling death rates in infancy, accounting for 36% in women to 47% in men of the observed
improvements. 
In contrast with all other countries analysed so far, there remained an increase in IHD
mortality among the middle-aged, especially men. This was, however, counterbalanced by a
simultaneous improvement in IHD death rates among the over 55s. As a result of these
diverging trends, there was a net decline in IHD mortality that accounted for 4-6% of the
total increase in temporary life expectancy in Greece in the 1990s.
Compared with the 1980s, falling mortality from ‘other causes’ also became an increasingly
important contributor to changing life expectancy. However its impact remained less than
that of amenable mortality, accounting for 28% of the total change in temporary life
expectancy in men and 38% in women. Interestingly and contrary to what has been
observed for the other countries analysed so far, changing amenable mortality had a
somewhat higher impact among men than among women in both time periods.
Italy
Italy, on the other hand, seemed to have some similarities to the mortality patterns seen in
Austria and west Germany, at least among women. It recorded comparatively large increases
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in temporary life expectancy in the 1980s, at 1.6 years in men and 1.1 years in women, and
somewhat lower improvements in the 1990s, at 1.2 and 0.51 of a year, respectively (Table
12). However, in the 1980s, changing mortality from amenable conditions exerted only little
impact on the overall improvements in life expectancy, at least in men (Figure 9). In fact,
there was an actual increase in male infant mortality attributable to amenable conditions
that was, however, more than compensated for by falling mortality from ‘other causes’. As a
consequence, there was a net decline in infant mortality that accounted for 0.45 of a year or
28% of the total increase in male life expectancy in the 1980s. Falling mortality at other
ages was also mainly due to ‘other causes’, with declining IHD mortality only having a
relatively small impact.
In contrast, the mortality pattern among women was very similar to that seen in Austria and
west Germany, with 0.50 of a year or 45% of the total change in female temporary life
expectancy due to falling amenable mortality, largely infant mortality at about 20%, and
another 7% attributable to declining IHD mortality. 
In the 1990s, while the overall changes in temporary life expectancy were less, unlike in the
other countries analysed so far, the impact of amenable mortality actually increased in both
men and women. This was especially apparent in men where falling amenable mortality
now accounted for 28% (0.32 of a year) of the total increase in life expectancy, 17% of
which was due to declining infant mortality. Among women, its impact was considerably
higher, at 50%, with falling amenable mortality among infants and the over 40s being
equally important, at about 20% each. 
In addition, the impact of declining IHD mortality increased slightly in both sexes, now
accounting for 13% of the increase in life expectancy in men and 9% in women. Combined
with amenable mortality, the potential impact of health care would thus amount to 41% of
the total change in temporary life expectancy among men and almost 60% among women in
Italy in the 1990s.
Netherlands
In The Netherlands the mortality pattern underlying changing temporary life expectancy
appears to have more in common with those seen in Denmark and Finland, at least in the
1980s. Temporary life expectancy improved in both periods, with very similar changes in
both the 1980s and the 1990s, at 0.8-0.9 of a year in men and 0.3 of a year in women (Table
12). Among men, falling mortality from amenable conditions accounted for about 20% of
the overall life expectancy increase in the 1980s, largely due to both declining infant
mortality and fewer deaths among those aged 40-64 (Figure 10). Adding declining mortality
from ischaemic heart disease, the impact of amenable mortality rises to over 60%. This was
less than in Danish and Finnish men, largely because, in the 1980s, Dutch men did not
experience net increases in mortality from ‘other causes’ as did their Danish and Finnish
counterparts. 
Turning to women, the picture is again very similar to that seen in Denmark and Finland,
with much of the improvement in temporary life expectancy in the 1980s driven by falling
amenable mortality, accounting for almost 70% of the total increase. One quarter of this 
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Figure 9 Age- and cause specific contributions to changes in temporary life expectancy in Italy: 1980-1989 and 1990-1998
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82 Figure 10 Age- and cause specific contributions to changes in temporary life expectancy in The Netherlands: 1980-1989 and 1990-1998
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improvement was due to falling amenable mortality among middle-aged women with
another 20% attributable to declining infant mortality. Combined with declining IHD
mortality, amenable mortality contributes almost 100% of the total change in temporary life
expectancy. As in Finland, there were only small improvements in death rates from ‘other
causes’. In fact, women over 40 experienced a net increase in deaths in this category.
By the 1990s, this pattern had changed markedly, especially among men. Falling amenable
mortality now accounted for less than 10% of the total increase in male temporary life
expectancy between 1990 and 1998. Instead, the overall improvement was mainly driven by
declining mortality from ‘other causes’, although falling IHD mortality remained an
important contributor, accounting for 36% of the total improvement. For women, although
a somewhat less important contributor in the 1990s, falling amenable mortality still
accounted for 35% of the total change in temporary life expectancy in the 1990s. As can be
inferred from Figure 10 this was mainly because of declining infant mortality although the
smaller rate of amenable deaths among women aged over 40 remained important (13%).
However, as with Denmark and Finland, adding falling mortality from IHD increases the
relative impact of amenable mortality even further, contributing about half of the total
change in female temporary life expectancy in the 1990s. 
Portugal
Portugal displayed a mortality pattern that was similar to that seen in Greece although on a
very different scale (Figure 11). Thus, Portugal recorded the largest improvements in
temporary life expectancy in the 1980s, at 2.1 years in men and 1.4 years in women. As
with Greece, these improvements were mainly due to changing amenable mortality, largely
falling infant mortality, which accounted for 35% of the total increase in life expectancy in
both sexes (or 0.75 of a year in men and 0.53 of a year in women). Another 20% was
attributable to falling amenable mortality among men and women aged 40 and more. Unlike
in Greece there was no increase in mortality from ischaemic heart disease although there
was not much improvement either, thus exerting a small impact only, at 6% in men and 3%
in women.
On the other hand, young Portuguese men experienced a net increase in mortality, as did
Greek men at that age, mostly from ‘other causes’ thus counterbalancing improvements in
mortality from these conditions seen at other ages.
By the 1990s, while still improving, the pace of the increase in male temporary life
expectancy had substantially slowed down, falling to less than one year. Portuguese women,
however, still showed the largest increase in life expectancy, at 0.78 of a year between 1990
and 1998. As with all other countries analysed so far, the impact of amenable mortality on
changing life expectancy was now somewhat less than it had been in the 1980s. However, as
with Greece, falling amenable mortality remained the largest contributor to increasing life
expectancy, accounting for over 50% of the total change in both sexes. Again, this was
mainly driven by falling infant mortality although for women, declining deaths among those
aged 40-64 years became increasingly important. This last group accounted for 15% of the
total change in temporary life expectancy among women in Portugal in the 1990s. 
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84 Figure 11 Age- and cause specific contributions to changes in temporary life expectancy in Portugal: 1980-1989 and 1990-1998
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As with Greece, the net mortality increase among men aged 20-24 seen in the 1980s had
reversed by the 1990s (Figure 11). Instead, the unfavourable mortality pattern had moved
towards somewhat higher ages, now affecting men aged 30-40, thus offsetting the overall
improvement in temporary life expectancy among Portuguese men in the 1990s.
Spain
In Spain somewhat similar issues to those in Portugal arise although there were also
important differences. In the 1980s, Spanish men experienced the lowest increase in
temporary life expectancy among the EU member states under study, at 0.37 of a year
(Table 12). This was mainly because of a net increase in mortality among men aged 15-39
that offset much of the improvements seen at other ages (Figure 12). 
Otherwise the mortality pattern among Spanish men looks very similar to that seen among
men in Greece (Figure 8), with a substantial impact of declining amenable mortality on the
total increase in life expectancy, largely due to falling infant mortality but also fewer deaths
among the over 40s. Falling IHD mortality was also of some importance for changing life
expectancy, although its impact was generally small. 
The mortality pattern among women also showed some striking similarities to that seen in
Greece. The only exceptions were declining infant mortality that had a somewhat smaller
impact on the total increase in life expectancy among Spanish women in the 1980s, at 23%
(compared with 45% in Greece) and, importantly, a net increase in mortality among young
women aged 15-29 years.
By the 1990s, the unfavourable mortality trend among young Spanish men had resolved,
thus adding 0.4 years to an overall increase in temporary life expectancy of 1.1 years
between 1990 and 1998, which was almost three times that in the 1980s. About one third of
this change was due to falling amenable mortality, with declining infant mortality
accounting for 0.14 or a year or 12% of the total increase in temporary life expectancy as
did declining mortality amongst men aged 15-64. For women, declining amenable mortality,
while somewhat less important compared with the 1980s also continued to exert a
substantial impact, accounting for 40% of the total change in temporary life expectancy in
the 1990s. A sustained decline was also seen in mortality from ischaemic heart disease in
both men and women, however its impact on changes in life expectancy remained relatively
small. 
As a consequence, and in contrast to Greece and Portugal, falling mortality from ‘other
causes’ became the most important contributor to changing life expectancy in Spain in the
1990s, accounting for 56% in women to 68% in men.
Sweden
Not unexpectedly, the mortality pattern underlying changing temporary life expectancy in
Sweden was very different from that seen in southern Europe. It had rather more in
common with The Netherlands, except that it did not experience the rise in female
mortality. Thus, temporary life expectancy improved consistently in both sexes and in both
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86 Figure 12 Age- and cause specific contributions to changes in temporary life expectancy in Spain: 1980-1989 and 1990-1998
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Figure 13 Age- and cause specific contributions to changes in temporary life expectancy in Sweden: 1980-1989 and 1990-1998
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the 1980s and the 1990s, at 1.1 years in men and 0.57 years in women (Figure 13). As in
The Netherlands, in the 1980s, falling amenable mortality did have a noticeable impact on
changing temporary life expectancy, accounting for 0.26 of a year or 25% of the total
increase in men and 45% (0.25 of a year) in women. While infant mortality was an
important contributor to these changes, falling amenable mortality among women aged over
40 years had a somewhat greater impact, accounting for just over 22% of the overall
increase in life expectancy.
Again as in The Netherlands, adding declining mortality from ischaemic heart disease
makes the impact of amenable mortality rise further, quite substantially so for men, to about
70% in both sexes. For women, this increase was less than that seen for Dutch women,
mainly because Swedish women did not record a net increase in mortality from ‘other
causes’ as did Dutch women over 40 years of age. 
By the 1990s this pattern had changed. As seen elsewhere, falling amenable mortality now
contributed less to the overall change in temporary life expectancy than it had in the 1980s,
especially among women where its impact had fallen to less than 20%, similar to that seen
in men but even lower than in French women. Instead the overall improvement was now
mainly driven by ‘other causes’ although falling IHD mortality remained an important
contributor, accounting for 0.10 of a year or 18% of the total change in temporary life
expectancy in women and 32% (0.35 or a year) in men.
Thus, if ischaemic heart disease was to be included with amenable conditions, their impact
on life expectancy would be considerably higher, accounting for about 40% of the overall
improvement in women and 50% in men.
United Kingdom
Turning finally to the United Kingdom, we find a pattern that looks somewhat similar to
that seen in Austria and west Germany, at least in the 1980s (Figure 14). Thus, declining
amenable mortality made substantial contributions to the overall change in temporary life
expectancy, at 37% of the total increase of 1.32 years in men and 58% of 0.8 years in
women. However, unlike in Austria and Germany, this was mainly due to falling mortality
among adults aged over 40, accounting for 0.24 of a year or 18% in men and, again, 0.24 of
a year or 30% in women. Only Finnish women experienced a higher impact of falling
amenable mortality among adults in the 1980s.
However, among men, declining IHD mortality was as important a contributor, accounting
for another 37% of the total change in temporary life expectancy. Thus, if IHD was to be
combined with amenable mortality it would increase the potential impact of health care to
75%. This proportion was somewhat less in women, at 70%.
As with many other countries analysed thus far, this pattern had changed by the 1990s,
with, among men, amenable mortality now accounting for much less than it had in the
1980s, at only 16% of the improvement in temporary life expectancy. This figure was very
similar to that seen in France, Finland, west Germany and Sweden. Whilst also declining in
women, amenable mortality remained an important contributor to changing life expectancy
in the 1990s, accounting for 0.26 of a year or 43% of the total change, still mainly women
over 40, contributing 24%. 
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Figure 14 Age- and cause specific contributions to changes in temporary life expectancy in the United Kingdom: 1980-1989 and 1990-1998
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Importantly, both men and women recorded a sustained decline in mortality from ischaemic
heart disease. In men, falling IHD mortality became the most important contributor to
changing temporary life expectancy in the 1990s, accounting for almost half of the total
change of 1.04 years between 1990 and 1998. Among women, falling IHD mortality
contributed about one third to the total change. Thus, if IHD mortality was to be combined
with amenable mortality its impact remains very high in the UK in the 1990s, at about 60%
in men and 70% in women.
Discussion
This analysis of the contribution of amenable mortality to changing life expectancy in
countries of the European Union in the 1980s and 1990s demonstrated that, while men and
women in all countries experienced increases in life expectancy between birth and age 75,
the pace of these changes differed between the two time periods and between countries. It is
not possible, within the scope of this report, to comment in detail on the changes in
particular causes of death observed in each country so the following sections will
concentrate on some major issues, highlighting findings common to a number of countries
and, specifically, focusing on the role of amenable mortality.  
Trends in temporary life expectancy
The improvements in temporary life expectancy were generally due to declining mortality at
all ages. However, there were some important exceptions. In the 1980s, the southern
European countries as well as France and Finland recorded a net increase in mortality
among young men aged 15-39, offsetting some of the improvements seen at other ages. This
was most notable in Spain, where the loss in temporary life expectancy due to increasing
mortality among young men was as large as the overall increase in life expectancy in that
country between 1980 and 1989. Spain was also among the two countries that, along with
Finland, also recorded a net increase in mortality among young women. Elsewhere it was
shown that the worsening in young adult mortality in Spain in the 1980s was largely
attributable to rising mortality from traffic related injuries, and, among men, possibly
AIDS.209 AIDS was also put forward as the main explanation for unfavourable mortality
pattern among young men in Italy in the 1980s, with traffic related injuries coming a close
second.210 Somewhat less is known about the causes of the mortality increases in Greece
and Portugal but rising mortality from external causes, especially traffic related injuries
among young men has been observed in both countries, with only little recent improvement
in Greece.211 However, in all countries except Greece and Portugal the deterioration in
mortality among young men had resolved in the 1990s.
The other exception was a net increase in mortality among women aged over 55 in
Denmark in the 1980s, and, to a smaller extent, in the 1990s, mainly reflecting rising death
rates from smoking related diseases.212 Smoking-related deaths also account for much of the
increase in mortality among Dutch women in that age group.213
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The contribution of amenable mortality to changing life expectancy
In the 1980s in all countries improvements in mortality from amenable conditions made
substantial positive contributions to the overall change in temporary life expectancy. In
most cases this was driven by falling infant mortality. The only exceptions were Denmark,
The Netherlands, the United Kingdom, France (men) and Sweden (women) where falling
amenable mortality among the middle-aged was equally or even more important. 
In contrast, in the 1990s, changes in amenable mortality made a somewhat smaller
contribution to improvements in temporary life expectancy than they had in the 1980s.
Among men, falling amenable mortality now accounted for only 8% in the Netherlands and
around 15% in west Germany, France, Sweden and the UK. However it remained an
important contributor in southern Europe, especially in Portugal and Greece. Among
women, the impact of amenable mortality on changing temporary life expectancy had also
declined somewhat in the 1990s but still accounted for at least 20% of the total
improvement. As in the 1980s, the impact of amenable mortality among men was largely
attributable to a continuous decline in infant mortality in most countries. However, among
women, declining amenable mortality among the middle-aged was more important in all
countries except the southern European ones.
Next steps
What do these findings say about the use of the concept of “avoidable mortality” in Europe
in the 21st century? There is clear evidence that improvements in access to effective health
care have had a measureable impact in many countries during the 1980s and 1990s, in
particular through reductions in infant mortality and in deaths among the middle aged and
elderly, especially women. However the scale of impact has, to a considerable extent,
reflected the starting point. Thus, those countries where infant mortality was relatively high
at the beginning of the 1980s, and which had the greatest scope for improvement, such as
Greece and Portugal, unsurprisingly saw the greatest reductions in amenable mortality in
infancy. In contrast, in countries with infant mortality rates that had already reached very
low rates by the beginning of the 1990s, such as Sweden, the scope for further improvement
was small.
Similarly, the scope for improvement in amenable deaths in adulthood was greatest in those
countries where initial rates were highest. The corollary of this is that as rates fall in all
countries, the extent of variation decreases. As a consequence, it seems likely that, in the
21st century, the ability to compare health system performance at this aggregate level is
likely to be very limited, simply because the differences will be relatively small. This clearly
has implications for the attempts being made by the WHO to develop rankings of health
systems based on health attainment, at least when applied to countries in western Europe.
This approach has, at its heart, an important contradiction, which relates to the definition of
the boundaries of the health care system. For two of the three dimensions being assessed,
responsiveness and fairness of financing, the health care system consists, implicitly, of
personal health services. It is the interaction with these services that is being assessed when
judging responsiveness; similarly it is the cost of these services that is being assessed when
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judging fairness of financing. In contrast, when assessing health attainment, using
disability-adjusted life expectancy, it is by implication the entire range of policies that
impact on health, whether they are in the housing, transport, economic development or
other sectors (arguably education is taken into account in the process of stochastic frontier
analysis used to assess what level is theoretically attainable). 
Elsewhere we have argued that a preferable approach to assessing health attainment
attributable to health systems would be to compare outcomes from only those causes where
there is demonstrable evidence that health care will have an impact.214
The results of such an exercise are shown in Table 13, which shows, for the countries
included in this study, three measure, life expectancy at birth (1998), disability adjusted life
expectancy (1999; as used in the 2000 World Health Report), and the age standardised
death rate from amenable causes between birth and age 75 in 1998. 
As in the World Health Report, these figures can be used to generate rankings of
performance. The consequences of using avoidable mortality, rather than disability adjusted
life expectancy, is shown in Figure 15. Although, for some countries, the ranking changes
little, for some it differs considerably. Finland improves from ninth to third place and
Denmark improves from eleventh to fifth place, although it has to be noted that certain
conditions were excluded (see table 13). Greece falls from fifth to eighth place and the
United Kingdom from seventh to eleventh place. 
To some extent this is a reflection of the greater weight given to cardiovascular disease (and
by extension the risk factors that cause it, which have their roots in broader health policies)
in estimation of disability-adjusted life expectancy, which tends to disadvantage some
northern European countries. However there are clearly other factors involved. In particular 
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Table 13 Selected measures of population health outcome
Country Life expectancy Disability-adjusted Age standardised   
life expectancy death rates from 
amenable causes
Austria 78.1 71.6 72.90
Denmark 76.7 69.4 68.37
Finland 77.5 70.5 64.73
France 78.9 73.1 62.75
Germany 77.8 70.4 75.38
Greece 78.3 72.5 72.35
Italy 79.1 72.7 68.95
Netherlands 78.2 72.0 71.15
Portugal 75.4 69.3 113.64
Spain 78.7 72.8 66.24
Sweden 79.6 73.0 49.55
United Kingdom 77.5 71.7 87.43
‡
x
x
x
x  Selected amenable conditions excluded (see text)
‡  West Germany only (1997)
Source: WHO HFA database; WHR 2000; author’s calculations
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the change in ranking of the United Kingdom raises some important questions about timely
access to health care, which have already been echoed in the national debate about
thefuture of health care in the United Kingdom in the light of other evidence of relative
under-achievement in relation to other European countries. 
Returning to the question asked at the beginning of this section, what does this mean for
current efforts to revise the methodology used in the World Health Organisation’s rankings?
Clearly a more detailed study of causes of death where the link to health system
performance is stronger than it is with overall mortality and disability will generate different
rankings. Of course, this can only be done for those countries where appropriate data are
available and it is noteworthy that, even in the European Union, a country such as Belgium
is unable to produce timely mortality data. This approach will not be possible for the 130+
countries that at present fail to collect adequate mortality data. This argument does, of course,
also apply to the existing approach, which gets around this problem by estimating mortality. 
It can, of course, be argued that ‘avoidable’ mortality does not take into account disability,
and so will underestimate the burden of disease attributable to mental health. However, at
present most data on disability are extrapolated from observations in a relatively small
number of countries and other work that we have undertaken (paper submitted) shows that
these estimates can be very different from what is found when specific studies are
undertaken. In addition, measures of disability, especially in relation to mental health, are
very susceptible to cultural differences.
One striking finding has been the substantial decline in deaths from ischaemic heart disease
in the northern European countries. The reasons for this decline are complex and seem to
include both changes in lifestyle, in particular improved diet and reduced smoking, as well
as greater access to effective treatment. Disentangling these contributions is beyond the
scope of this report and anyway is likely to be extremely difficult.
What are the next steps? When the concept of “avoidable mortality” was first developed it
was seen as a way of identifying topics for further study, rather than being an end in itself.
Figure 15 Comparison of rankings based on DALE and amenable mortality rates
This is even more true now that it was then. While the results presented here provide much
new information on what has happened in the 1990s in each country, they can also be used
to identify areas for further exploration. For example, although there have been large
improvements among British women in the 1990s, their death rates remain higher than in
otherwise comparable countries, possibly suggesting relative under-treatment. Similarly,
there is scope for a better understanding of the continuing relatively high infant mortality in
southern Europe.
This study has been undertaken at the level of entire countries. As the earlier review noted,
where it has been looked for, deaths from amenable mortality have been higher among the
poor. There is scope for further analysis within countries, both by socio-economic group
and, especially in the larger countries, by region. Thus, overall death rates vary considerably
between the constituent parts of the United Kingdom or among the German Länder, with
death rates in Scotland or in Mecklenburg-Vorpommern especially high. Similarly, there is
substantial diversity within both Italy and France.
What is now needed is more detailed examination of specific causes of death, recognising
that, especially where numbers are small, variations may be due to chance but they may also
indicate areas of concern that might otherwise be overlooked. Once identified, it will then
be possible to examine such tracer conditions to identify differences in processes and
outcomes of care.
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Table 14 Age-standardised death rates (per 100 000) for selected causes and cause groups in EU countries in 1980, 1990 and 1998: age 0-74
Austria Denmark* Finland* France Germany west Greece
1980 1990 1998 1980 1990 1998 1980 1990 1998 1980 1990 1998 1980 1990 1997 1980 1990 1998
men
amenable
causes 164.05 100.94 76.39 82.81 71.18 60.54 118.77 98.53 71.32 107.10 74.52 64.87 135.01 86.62 76.37 127.90 83.34 73.39
IHD 150.12 122.67 105.70 209.31 150.60 82.77 297.31 209.17 137.54 71.62 51.52 40.70 164.53 119.47 94.00 87.30 90.11 82.14
other causes 475.68 387.95 323.26 406.00 419.90 393.93 424.39 398.05 350.90 520.45 440.84 397.98 449.72 391.34 348.98 336.06 310.97 302.26
all causes 789.85 611.55 505.34 698.12 641.67 537.25 826.43 705.76 559.77 699.17 566.89 503.55 749.26 597.43 519.35 551.26 484.43 457.79
women
amenable
causes 128.54 89.30 69.41 97.15 88.05 76.19 94.01 76.09 58.14 86.31 65.92 60.62 118.44 85.38 74.39 127.08 86.81 71.32
IHD 47.37 39.11 32.65 66.75 50.74 29.30 76.02 59.38 37.67 19.32 13.12 9.65 46.90 36.89 30.30 24.90 27.50 23.46
other causes 215.07 165.35 138.74 226.02 243.29 241.09 165.22 164.46 143.26 197.31 154.41 145.06 208.93 174.36 155.15 176.60 145.08 132.39
all causes 390.98 293.76 240.81 389.92 382.09 346.59 335.26 299.93 239.08 302.94 233.46 215.33 374.27 296.63 259.84 328.58 259.39 227.16
Italy Netherlands Portugal Spain Sweden* United Kingdom
1980 1990 1998 1980 1990 1998 1980 1990 1998 1980 1990 1998 1980 1990 1998 1980 1990 1998
men
amenable
causes 143.10 89.12 70.00 87.92 69.34 67.31 251.39 160.74 130.42 128.79 88.94 70.54 75.40 57.97 47.23 146.16 95.36 85.58
IHD 107.60 77.35 61.02 167.09 115.97 78.33 83.86 69.66 58.69 73.80 63.69 57.99 209.39 138.68 89.83 250.72 188.72 126.20
other causes 437.41 376.81 318.76 372.13 356.74 321.78 488.93 444.30 422.52 389.40 396.54 347.18 305.26 283.64 256.15 347.01 315.14 280.51
all causes 688.12 543.27 449.78 627.13 542.05 467.41 824.18 674.70 611.63 591.98 549.16 475.71 590.06 480.30 393.21 743.89 599.23 492.28
women
amenable
causes 119.68 84.08 67.91 96.31 81.59 75.00 181.39 123.28 96.86 105.75 78.71 61.93 75.41 59.08 51.86 146.90 107.19 89.28
IHD 32.84 22.68 17.10 48.22 34.08 26.52 29.96 25.21 18.98 20.95 17.81 14.81 60.22 41.00 27.09 82.37 68.57 45.23
other causes 185.79 149.19 132.33 154.42 156.64 158.11 203.95 181.58 160.56 174.54 145.89 120.06 169.60 159.61 144.83 179.66 172.15 164.40
all causes 338.31 255.95 217.33 298.95 272.30 259.62 415.30 330.07 276.40 301.24 242.41 196.80 305.23 259.68 223.78 408.92 347.91 298.90
* selected amenable causes excluded (see text)
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Table 15 Life expectancy at birth in selected European countries in 1980, 1989, 1990
and 1998 (in years)
men 1980-1989 women 1980-1989
amenable IHD other all amenable IHD other all
Austria
0 0.4121 0.0000 0.0918 0.5040 0.2405 0.0032 0.1056 0.3493
1-14 0.0302 0.0000 0.0906 0.1208 0.0348 0.0000 0.0999 0.1347
15-39 0.0805 0.0121 0.3100 0.4026 0.0653 0.0060 0.0989 0.1703
40-64 0.1811 0.1710 0.3537 0.7059 0.1494 0.0538 0.2215 0.4246
65-74 0.0811 0.0222 0.1108 0.2141 0.0606 0.0164 0.0745 0.1516
all 0.7851 0.2053 0.9569 1.9473 0.5506 0.0795 0.6004 1.2305
Denmark
0 0.0268 0.0000 -0.0285 -0.0017 0.0420 0.0000 -0.0064 0.0356
1-14 0.0230 0.0000 0.0349 0.0579 0.0268 0.0000 -0.0074 0.0194
15-39 -0.0179 0.0110 0.1865 0.1796 -0.0017 -0.0049 0.1373 0.1306
40-64 0.0278 0.2664 -0.0817 0.2124 0.0530 0.0644 -0.0348 0.0826
65-74 0.0300 0.0913 -0.0451 0.0762 0.0094 0.0542 -0.0814 -0.0178
all 0.0897 0.3686 0.0660 0.5243 0.1294 0.1137 0.0073 0.2504
Finland
0 0.0912 0.0000 0.0273 0.1185 0.0528 0.0000 0.0437 0.0965
1-14 0.0251 0.0000 0.0388 0.0638 -0.0034 0.0000 0.0183 0.0149
15-39 0.0249 0.0388 -0.1292 -0.0656 0.0181 0.0057 -0.0361 -0.0122
40-64 0.0528 0.4729 -0.0065 0.5192 0.0935 0.0846 -0.0481 0.1300
65-74 0.0644 0.0896 0.0665 0.2206 0.0488 0.0373 0.0194 0.1055
all 0.2584 0.6013 -0.0030 0.8566 0.2098 0.1276 -0.0028 0.3346
France
0 0.1047 0.0000 0.1015 0.2062 0.0790 0.0000 0.0738 0.1528
1-14 0.0295 -0.0003 0.0972 0.1264 0.0225 0.0001 0.0569 0.0796
15-39 0.0307 0.0046 0.0671 0.1025 0.0264 0.0006 0.0926 0.1196
40-64 0.1113 0.0965 0.3410 0.5488 0.0828 0.0172 0.2057 0.3057
65-74 0.0480 0.0306 0.1055 0.1842 0.0384 0.0181 0.0672 0.1237
all 0.3243 0.1315 0.7123 1.1681 0.2491 0.0361 0.4962 0.7813
Germany, west
0 0.3019 0.0000 0.1039 0.4058 0.2530 0.0000 0.1078 0.3608
1-14 0.0288 0.0000 0.1185 0.1473 0.0289 0.0000 0.0814 0.1103
15-39 0.0446 0.0116 0.3256 0.3818 0.0475 0.0029 0.1120 0.1624
40-64 0.1381 0.2537 0.2027 0.5944 0.0987 0.0435 0.1923 0.3345
65-74 0.0711 0.0563 0.0699 0.1974 0.0579 0.0217 0.0434 0.1230
all 0.5846 0.3215 0.8207 1.7268 0.4861 0.0680 0.5369 1.0910
Greece
0 0.5621 0.0000 0.0869 0.6490 0.4521 0.0000 0.0912 0.5433
1-14 0.0211 0.0000 0.1032 0.1243 0.0225 0.0000 0.0506 0.0731
15-39 0.0194 -0.0140 -0.1484 -0.1431 0.0435 -0.0101 -0.0214 0.0120
40-64 0.0969 0.0160 0.1320 0.2449 0.1139 -0.0109 0.1478 0.2508
65-74 0.0558 -0.0225 0.0363 0.0696 0.0647 -0.0109 0.0656 0.1195
all 0.7553 -0.0206 0.2099 0.9446 0.6968 -0.0319 0.3338 0.9987
Italy
0 -1.5624 0.5635 1.4452 0.4464 0.2300 0.0000 0.0661 0.2961
1-14 0.0698 -0.0001 0.0865 0.1562 0.0300 0.0001 0.1125 0.1426
15-39 -0.0039 0.0129 0.0377 0.0467 0.0484 0.0028 0.0739 0.1251
40-64 0.0117 0.1198 0.6550 0.7865 0.1269 0.0439 0.1933 0.3641
65-74 0.0225 0.0196 0.1389 0.1810 0.0614 0.0243 0.0606 0.1463
all 0.1966 0.3700 0.3390 0.9056 0.2065 0.1017 -0.0108 0.2974
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Table 15 Life expectancy at birth in selected European countries in 1980, 1989, 1990
and 1998 (in years) (continued)
men 1980-1989 women 1980-1989
amenable IHD other all amenable IHD other all
Netherlands
0 0.0607 0.0000 0.0888 0.1495 0.0646 0.0000 0.0491 0.1136
1-14 0.0178 0.0000 0.0715 0.0893 0.0187 0.0000 0.0451 0.0638
15-39 0.0207 0.0217 0.1187 0.1612 0.0172 0.0042 0.0077 0.0291
40-64 0.0653 0.2782 0.0459 0.3894 0.0765 0.0588 -0.0899 0.0455
65-74 0.0321 0.0700 0.0142 0.1163 0.0295 0.0387 -0.0228 0.0454
all 0.1966 0.3700 0.3390 0.9056 0.2065 0.1017 -0.0108 0.2974
Portugal
0 0.7534 0.0000 0.1764 0.9298 0.5287 -0.0012 0.1397 0.6672
1-14 0.0730 0.0000 0.1328 0.2058 0.0796 0.0000 0.0831 0.1627
15-39 0.0674 0.0041 -0.1264 -0.0549 0.0645 0.0028 0.0058 0.0731
40-64 0.3045 0.0986 0.4457 0.8489 0.1768 0.0234 0.0967 0.2969
65-74 0.1306 0.0241 0.0603 0.2151 0.1362 0.0198 0.0626 0.2186
all 1.3289 0.1268 0.6889 2.1446 0.9858 0.0448 0.3879 1.4184
Spain
0 0.2495 -0.0002 0.0754 0.3247 0.1640 0.0005 0.0569 0.2214
1-14 0.0474 0.0008 0.0767 0.1250 0.0409 0.0006 0.0568 0.0983
15-39 0.0299 0.0178 -0.4217 -0.3739 0.0502 0.0033 -0.0629 -0.0094
40-64 0.1443 0.0776 -0.0080 0.2138 0.0784 0.0183 0.1717 0.2684
65-74 0.0601 0.0067 0.0099 0.0767 0.0554 0.0087 0.0632 0.1273
all 0.5313 0.1027 -0.2677 0.3664 0.3889 0.0314 0.2857 0.7059
Sweden
0 0.1073 0.0000 -0.0086 0.0987 0.0811 0.0000 -0.0317 0.0495
1-14 0.0249 0.0000 0.0424 0.0673 0.0117 0.0000 0.0445 0.0562
15-39 0.0415 -0.0032 0.0648 0.1030 0.0359 0.0006 0.0273 0.0638
40-64 0.0716 0.3373 0.2297 0.6385 0.0882 0.0562 0.1511 0.2955
65-74 0.0155 0.1491 -0.0106 0.1541 0.0351 0.0673 -0.0020 0.1004
all 0.2607 0.4831 0.3178 1.0616 0.2521 0.1240 0.1893 0.5654
United Kingdom
0 0.1772 -0.0005 0.0976 0.2743 0.1466 -0.0006 0.1131 0.2591
1-14 0.0305 -0.0004 0.0428 0.0730 0.0329 -0.0004 0.0214 0.0539
15-39 0.0478 0.0242 -0.0107 0.0614 0.0363 0.0037 0.0444 0.0844
40-64 0.1665 0.4059 0.1768 0.7492 0.1910 0.0898 0.0774 0.3582
65-74 0.0761 0.0603 0.0261 0.1625 0.0551 0.0163 -0.0278 0.0437
all 0.4921 0.4895 0.3388 1.3204 0.4593 0.1088 0.2312 0.7993
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Table 16 Age- and cause specific contributions (in years) to changes in temporary
life expectancy in selected countries of the European Union between 1990 and 1998
men 1990-1998 women 1990-1998
amenable IHD other all amenable IHD other all
Austria
0 0.0674 0.0000 0.1534 0.2208 0.1044 0.0000 0.0893 0.1937
1-14 0.0132 0.0000 0.0714 0.0846 0.0059 0.0000 0.0348 0.0408
15-39 0.0222 -0.0103 0.2824 0.2943 0.0344 -0.0076 0.0850 0.1117
40-64 0.1104 0.0917 0.3928 0.5949 0.1024 0.0243 0.1611 0.2878
65-74 0.0403 0.0320 0.0579 0.1301 0.0453 0.0268 0.0498 0.1219
all 0.2534 0.1134 0.9580 1.3248 0.2924 0.0434 0.4201 0.7559
Denmark
0 0.0926 0.0000 0.1923 0.2849 0.0405 0.0000 0.0942 0.1347
1-14 0.0376 0.0000 0.0565 0.0941 0.0201 0.0000 0.0270 0.0472
15-39 0.0060 0.0053 0.1552 0.1665 0.0155 0.0043 0.0773 0.0971
40-64 0.0266 0.3305 0.1603 0.5174 0.1115 0.1099 0.1801 0.4014
65-74 0.0151 0.1321 -0.0028 0.1445 0.0074 0.0542 -0.0830 -0.0214
all 0.1780 0.4679 0.5616 1.2075 0.1950 0.1684 0.2956 0.6590
Finland
0 0.0707 0.0000 0.0145 0.0852 0.0602 0.0000 0.0870 0.1471
1-14 0.0124 0.0000 0.0778 0.0902 0.0075 0.0000 0.0352 0.0427
15-39 0.0390 0.0232 0.4809 0.5431 0.0194 -0.0024 0.1091 0.1262
40-64 0.1218 0.4100 0.1486 0.6804 0.0678 0.0636 0.0916 0.2231
65-74 0.0388 0.1178 0.0516 0.2082 0.0459 0.0789 0.0496 0.1744
all 0.2826 0.5510 0.7734 1.6071 0.2007 0.1402 0.3725 0.7134
France
0 0.0481 0.0000 0.1820 0.2301 0.0241 0.0000 0.1277 0.1518
1-14 0.0187 0.0003 0.0552 0.0742 0.0169 -0.0004 0.0359 0.0524
15-39 0.0297 0.0082 0.3295 0.3674 0.0023 -0.0011 0.0767 0.0779
40-64 0.0538 0.0486 0.2236 0.3259 0.0254 0.0126 0.0416 0.0796
65-74 0.0087 0.0254 0.0193 0.0534 0.0115 0.0116 -0.0017 0.0214
all 0.1591 0.0825 0.8094 1.0510 0.0803 0.0227 0.2802 0.3831
Germany, west
0 0.0652 0.0000 0.1183 0.1835 0.0325 0.0000 0.0958 0.1283
1-14 0.0021 0.0000 0.0572 0.0592 0.0099 0.0000 0.0455 0.0555
15-39 0.0096 0.0017 0.1587 0.1700 0.0214 -0.0012 0.0712 0.0913
40-64 0.0295 0.1311 0.2003 0.3609 0.0507 0.0222 0.0692 0.1421
65-74 0.0186 0.0488 0.0464 0.1138 0.0261 0.0229 0.0381 0.0871
all 0.1249 0.1816 0.5809 0.8875 0.1406 0.0438 0.3198 0.5042
Greece
0 0.1434 0.0000 0.0302 0.1736 0.1592 0.0000 0.0696 0.2289
1-14 0.0102 0.0000 0.0568 0.0669 0.0262 0.0000 -0.0198 0.0063
15-39 0.0336 0.0020 -0.0386 -0.0030 0.0140 -0.0005 0.0142 0.0277
40-64 0.0010 -0.0174 0.0233 0.0069 0.0272 -0.0052 0.0784 0.1003
65-74 0.0174 0.0332 0.0134 0.0640 0.0324 0.0211 0.0248 0.0783
all 0.2055 0.0178 0.0851 0.3084 0.2589 0.0154 0.1672 0.4415
Italy
0 0.1951 0.0000 0.0463 0.2414 0.1125 0.0000 0.0479 0.1604
1-14 0.0095 0.0000 0.0356 0.0450 0.0111 0.0003 0.0229 0.0343
15-39 0.0197 0.0160 0.1795 0.2152 0.0245 0.0014 0.0206 0.0466
40-64 0.0638 0.1004 0.3481 0.5124 0.0715 0.0238 0.0803 0.1756
65-74 0.0309 0.0295 0.0811 0.1415 0.0351 0.0180 0.0398 0.0929
all 0.3189 0.1459 0.6907 1.1554 0.2546 0.0436 0.2116 0.5098
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Table 16 Age- and cause specific contributions (in years) to changes in temporary
life expectancy in selected countries of the European Union between 1990 and 1998
(continued)
men 1990-1998 women 1990-1998
amenable IHD other all amenable IHD other all
Netherlands
0 0.0455 0.0000 0.1023 0.1478 0.0355 0.0008 0.0959 0.1321
1-14 0.0066 0.0000 0.0636 0.0702 0.0135 -0.0013 0.0807 0.0929
15-39 0.0111 0.0060 0.0732 0.0902 0.0202 -0.0027 0.0385 0.0560
40-64 0.0005 0.1932 0.1502 0.3440 0.0249 0.0292 -0.0396 0.0146
65-74 0.0009 0.0800 0.0532 0.1340 0.0144 0.0213 -0.0193 0.0164
all 0.0646 0.2792 0.4424 0.7861 0.1085 0.0473 0.1562 0.3120
Portugal
0 0.3328 -0.0011 0.0866 0.4183 0.1969 0.0000 0.1214 0.3183
1-14 0.0298 -0.0008 0.0970 0.1260 0.0025 -0.0018 0.0669 0.0677
15-39 0.0019 0.0022 0.0646 0.0686 0.0033 0.0011 0.0340 0.0384
40-64 0.1072 0.0536 0.0823 0.2431 0.1199 0.0286 0.0817 0.2302
65-74 0.0550 0.0182 0.0041 0.0773 0.0715 0.0176 0.0356 0.1247
all 0.5266 0.0722 0.3345 0.9333 0.3940 0.0455 0.3397 0.7792
Spain
0 0.1392 -0.0003 0.0711 0.2099 0.1094 0.0003 0.0739 0.1836
1-14 0.0218 -0.0001 0.0758 0.0974 0.0217 -0.0009 0.0539 0.0747
15-39 0.0568 0.0054 0.3581 0.4203 0.0451 0.0014 0.0851 0.1317
40-64 0.0724 0.0230 0.1973 0.2927 0.0655 0.0135 0.1147 0.1936
65-74 0.0240 0.0163 0.0702 0.1106 0.0329 0.0096 0.0584 0.1009
all 0.3142 0.0442 0.7726 1.1310 0.2746 0.0239 0.3860 0.6845
Sweden
0 0.0761 0.0000 0.1201 0.1962 0.0266 0.0000 0.1477 0.1744
1-14 0.0192 0.0000 0.0229 0.0421 0.0172 0.0000 0.0262 0.0434
15-39 0.0147 -0.0013 0.2103 0.2236 0.0106 0.0009 0.0937 0.1052
40-64 0.0493 0.2388 0.1995 0.4877 0.0359 0.0578 0.0832 0.1770
65-74 0.0113 0.1118 0.0057 0.1289 0.0102 0.0447 0.0137 0.0686
all 0.1705 0.3494 0.5586 1.0785 0.1005 0.1035 0.3646 0.5685
United Kingdom
0 0.0711 0.0012 0.1155 0.1877 0.0609 0.0005 0.0799 0.1414
1-14 0.0253 0.0005 0.0410 0.0669 0.0207 0.0000 0.0260 0.0467
15-39 0.0177 0.0142 0.0566 0.0885 0.0304 0.0013 -0.0059 0.0258
40-64 0.0200 0.3350 0.1130 0.4679 0.1014 0.1116 0.0693 0.2823
65-74 0.0201 0.1268 0.0773 0.2241 0.0350 0.0641 0.0052 0.1042
all 0.1611 0.4777 0.3964 1.0352 0.2570 0.1775 0.1660 0.6005
PART III:
EMPIRICAL STUDIES OF 
‘AVOIDABLE’ MORTALITY
ANNOTATED REVIEW
Introduction
This part gives an overview of 70 studies that have empirically applied the concept of
avoidable mortality. Studies were analysed using a structured protocol, extracting
information on (1) study region, (2) time period under investigation, (3) aim of study and
definition of ‘avoidable mortality’, (4) causes of death and age group(s) under study, (5)
analytical design and (6) main results. This information was drawn together in the form of
an annotated bibliography. Studies are ordered according to the main objective of their
analysis, thus distinguishing four broad groups: (1) geographical variation of ‘avoidable’
mortality, (2) assessment of regional/national level of ‘avoidable’ mortality, (3) variation by
socio-economic and/or socio-demographic factors and (4) variation over time. Within each
cluster, studies are further organised according to the study region to enable an overview of
countries or regions within countries that have so far been subject to studies of ‘avoidable’
mortality.
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102 Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’)
Author country / region time period Topic/aim of study number of causes Design/method Results
Charlton et
al. 198320
England & Wales
by 98 Area
Health
Authorities
(AHA)
1974-78 Small area variation in mortality
considered 'avoidable' with
“appropriate medical intervention”
excl. conditions amenable to primary
prevention (e.g. lung cancer); ‘non-
preventable causes’: little effect of
medical intervention on likelihood of
fatal outcome
basis: Rutstein et al.
• 14 conditions/groups of
conditions plus perinatal deaths
• ages 5-64; respiratory causes: 5-
49, maternal causes: 10-44,
Hodgkin’s disease: 5-34
Cross-sectional
SMR by AHA, adjusted for
socio-economic factors
(%unskilled employed; % home
renting; % car ownership)
Considerable variation between 98 AHAs in
mortality from most of the diseases
considered ‘avoidable’ with medical care
even after adjustment for socio-economic
factors; social indicators explain 8%
(maternal deaths) to 64% (TB) of  variance of
‘avoidable’ deaths and about 40% of all-cause
and ‘non-preventable’ mortality
Carr-Hill et
al. 198764
E&W by 15
Regional Health
Authorities
(RHA)
1976-83 Small area variation in ‘avoidable'
mortality in relation to socioeconomic
factors and health care resources;
‘avoidable’  mortality: mortality
“apparently avoidable given
appropriate medical intervention”
• 4 major causes of avoidable
death (hypertensive disease, cancer
of cervix/uterus, selected
respiratory diseases, perinatal
mortality)
• no age given
Cross-sectional
Correlation of mortality rates and
socioeconomic factors / health
care expenditure [capital/
recurrent]; hospital services for
diagnosis & treatment; family
practitioner services; # nurses &
midwifes/patient
Social factors unemployment, average
domestic rateable value & no. cars/person
explain 40-91% of variance of 3 indicators
(perinatal, respiratory, cancer) of avoidable
mortality and 28-40% of variance in total
mortality; correlation between avoidable
deaths & health care resources positive for
most variables except cervical ca, pneumonia
& perinatal mortality with capital &
practitioner services
Bauer &
Charlton
198665
E&W by 98 Area
Health
Authorities
(AHAs)
1974-78 Evaluation of contribution of varying
morbidity to area variation in mortality
from diseases amenable to medical
intervention
basis: Charlton et al. (1983)
• 13 conditions/groups of
conditions excl. maternal and
perinatal mortality
• no age given
Cross-sectional
Multiple regression of SMR,
morbidity indicators (registration
ratios, hospital discharge rates)
and socioeconomic factors (see
Chalton et al. 1983) by AHA
Social factors explained up to 42.9% (cervical
ca) of area variation in SMRs, morbidity up to
37.4% (chron rheum heart disease);
significant improvement in variation
explained after adjusting for social factors and
morbidity combined with significant
heterogeneity persisting
Poikolainen
& Eskola
198826
25 developed
countries
1975-1978 Association of health service resources
with mortality amenable to
interventions by health services
basis: Rutstein et al.
• 4 categories: amenable (74
conditions); non-amenable (31),
partly amenable (20); violent
causes (13)
• ages <65; diabetes, respiratory:
0-49
Cross-sectional
Linear regression of SDR, GDP
(indicator socioeconomic
development), health services
resources [US$/capita; # medical
doctors, # nurses, # hospital
beds], other [alcohol & tobacco
consumption, military
expenditure]
Mortality from amenable causes significantly
negatively associated with GDP but not with
no. doctors/nurses, hospital beds, alcohol
consumption (neg. association with non-
amenable in men) [even after excluding
socialist countries]
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Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Buck & Bull
198661
A. 17 developed
countries; B.
England & Wales
A. 1971-
1974
B. 1974/5-
1977/8
A. Cross-country analysis of
association between preventable deaths
& health services input (expenditure)
B. ‘Micro-analysis’ of association
between preventable deaths & training
of GPs in E&W by local authority
‘preventable’ deaths: conditions that
are amenable to treatment
basis: Rutstein et al.
• 27 conditions/groups of
conditions plus infant mortality as
separate category; similar to
Charlton’s list excl. hypertensive
disease & Hodgkin’s disease, incl.
skin cancer, benign neoplasm,
venous thrombosis & some
infectious diseases
• ages 0-64
Cross-sectional
A. Age-sex adjusted DR;
correlation with 5 indicators for
health services input (public
investment in health facilities,
total health expend, public health
expend. [all: %GDP], % medical
graduates passing exam,
income/capita)
B. death rates & IMR adjusted
for socioeconomic factors;
correlation with 13 indicators of
GP training; regression (GLS)
A. significant (negative) correlation
between preventable deaths & public
investment in health facilities [-0.49]
(correlation higher for IMR: -0.74); &
with per capita income [-0.56] (IMR: -
0.39)
B. significant correlation between
preventable deaths & 1 indicator of GP
training (IMR: sign. correlation with 5
indicators); in GLS multiple regression
analysis 8 indicators in total explained
22% of variation in IMR and 10% of
preventable mortality
Holland
198828
10 EC member
states (with UK
separated into
England &
Wales, N. Ireland
and Scotland) by
administrative
area (total: 360)
1974-1978 Examination of selected ‘unnecessary
untimely deaths’ with causes
distinguished into those “for which it is
reasonably certain that effective
treatment or secondary prevention are
available” and those mainly amenable
to primary preventive intervention
“usually outside the control of health
services”, by region; comparison
between and within countries; relation
between variation in avoidable deaths
and levels of health services inputs
basis: Charlton et al. (1983)
• 17 conditions/groups of
conditions (primary prevention: 3
causes)
• ages 5-64; cervical ca: 15-64;
chron. rheum. heart dis: 5-44;
respiratory: 1-14; asthma: 5-44;
hypertensive & cerebrovascular:
35-64; whooping cough: 0-14;
tetanus: 0-64; measles: 1-14;
osteomyelitis: 1-64; liver cirrhosis:
15-74; maternal mortality & motor
vehicle accidents: all ages
Cross-sectional
SMR for each country (within-
country variation) and EC in
total (between-country
variation);  heterogeneity
between areas; summary scores
by administrative area (excess of
‘avoidable’ mortality using (1)
own country’s or (2) EC
standard); indicators of health
services input (# GPs/100k, #
acute hospital beds/100k, #
consultants/100k) & socio-
economic indicators (%
households with fixed
bath/shower, average #
persons/room, # cars/100
inhabitants) by region
Substantial within- and between-country-
variation for most avoidable conditions, esp.
tuberculosis, cervical cancer, hypertensive &
cerebrovascular disease, perinatal deaths and
all-cause mortality (ages 5-64 and all ages)
[for details see country-specific studies
below]
Holland
199329
12 EC member
states (with UK
separated into
England &
Wales, N. Ireland
and Scotland) by
administrative
area (total: 554)
1980-1984 Expanding the work of Holland 1988 &
1991 by analysing mortality from
conditions that “reflect extensions of
the abilities of health services and their
technical and administrative
infrastructures”, specifically conditions
for which it is “reasonably certain that
effective treatment or primary or
secondary prevention could be
provided by health care services”
• 8 conditions/groups of
conditions
• ages 0-64; intestinal infect: 0-
14; breast ca: 25-64; skin ca: 35-
64; testis ca: 0-64; leukaemia: 0-
44; IHD: 35-64; peptic ulcer: 25-
64; congenital heart disease:1-14
Cross-sectional
SMR for each country (within-
country variation) and EC in
total (between-country
variation);  degree of
heterogeneity between areas
Substantial between-country variation for all
avoidable conditions, esp. IHD with national
SMRs lowest in France (51), Spain (60),
Portugal (62) & highest in Scotland (255) &
N. Ireland (258); also: breast cancer lowest in
Mediterranean  countries (73-81) & highest in
UK (134-137); very high SMR in intestinal
infections in Portugal (1094) but well below
100 in all other EC countries; sign. within-
country variation esp. for IHD (all regions),
peptic ulcer & breast cancer (most regions)
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104 Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Jougla et al.
198733
France by 95
departments
1973-1977 Analysis of regional variation in
‘avoidable’ mortality and its
association with indicators of health
services (input), divided into causes
‘avoidable’ by ‘curative’ measures or
by ‘primary prevention’ (3 causes)
basis: EC (1988) list
• 21 conditions/groups of
conditions incl. cancer of oral
cavity, infectious dis, nephritis &
other dis of kidney, other accidents
(primary prevention: 4 causes)
• ages 5-64; appendicitis/
hernia/cholelithiasis: 20-64;
nephritis: 30-49; maternal
mortality: 10-44; cirrhosis & motor
vehicle accidents: 15-64; other
accidents: 1-14
Cross-sectional
Regional SMR; score
‘avoidable’ mortality;
factor analysis of explanatory
variables: 6 health services
supply indicators (physician &
bed density, % specialists &
private beds, hospital
admissions, presence of regional
hospital) & 12 socio-economic
indicators; multiple regression
Associations between ‘avoidable’ mortality
and generally stronger with socio-economic
variables than indicators of health services
supply; substantial geographical variation
with mortality from causes amenable to
curative measures concentrated in the North-
East (esp. among females)
Kunst et al.
198834
10 EC member
states (with UK
separated into
England &
Wales, N. Ireland
and Scotland) by
administrative
area (total: 360)
1974-78 Analysis of within and between-
country differences in mortality from
avoidable conditions in EC with
‘avoidable’ referring to conditions
amenable to medical intervention; main
questions:
(1) common pattern of regional
variation in avoidable causes within EC
countries?
(2) regional differences in cause-
specific mortality explainable by
differences in medical care supply?
basis: EC (1988) list
• 12 conditions/groups of
conditions excl. infectious diseases
• ages: see Holland 1988
Cross-sectional
SMRs by administrative area;
heterogeneity within countries;
principal component analysis of
avoidable causes; rank-
correlation for selected causes;
multiple regression of SMR,
independent variables: medical
care supply (# GPs/1000, #
hospital beds/1000, #
consultants/ 1000); socio-
economic: % households with
fixed shower/bath, average #
persons/room, # private cars/100
(1) sign. within-country heterogeneity for TB,
cervical cancer, rheumatic heart dis,
hypertensive & cerebrovascular dis, perinatal
mortality; common pattern of regional
mortality for selected conditions largely
resembling pattern of regional variation in all-
cause mortality; no specific intercorrelations
between causes of death that refer to same
type of medical care
(2) association between avoidable causes &
medical care supply not consistent and rarely
significant; no important differences to all-
cause mortality
Mackenbach
et al. 1988a66
The Netherlands
by 28 regions
1950-1984 Geographical variation in mortality
from conditions amenable to medical
intervention in relation to medical care
supply in 4 time periods (1950-54,
1960-64, 1970-74, 1980-84)
basis: Rutstein et al.
• 13 conditions/groups of
conditions [ordered accord. to time
of introduction of medical care
intervention];
• age limit 0-74 (cancer at young
ages: 0-34)
Cross-sectional
Regional SMRs, regression
analysis of logarithm of SMR,
independent variables: medical
supply characteristics (4, e.g. #
GPs/hospital beds), socio-
demographic factors (average
income, net immigration,
urbanisation), fertility rate
Sign. regional variation for all conditions
except cancer in children in all 4 periods with
indication of increasing homogeneity of
mortality from some causes; few sign.
associations between mortality & medical
supply (1980/84), e.g. TB & hospital bed
density [positive], CVA & % bed in
university hospital [negative]; associations
time dependent, e.g. largest association
between TB & medical care in 1980/84;
overall association between amenable
mortality & medical care supply weak and
inconsistent
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Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Mackenbach
199167
11 EC countries:
Belgium,
Denmark, France,
Germany (west),
Greece, Italy,
Ireland,
Netherlands,
Portugal, Spain,
UK
1980-84
(Greece:
1980-82;
Italy: 1979-
83; Spain:
1979-83)
Association of level of national health
care expenditure and mortality from
conditions considered to be “sensitive
to variations in effectiveness of health
services”; includes both preventable
(e.g. TB, cervical ca) and curable
conditions (e.g. appendicitis)
basis: EC (1988)
• 12 conditions/groups of
conditions excl. infectious diseases
• see Holland
Cross-sectional
SMR for each condition; average
SMR for 2 subgroups: (1) related
to GDP (TB, chron rheum heart
dis, resp dis, hypertensive/
cerebrovasc, perinatal deaths);
(2) not related to GDP; GDP-
adjusted ‘observed’ & ‘expected’
[least square regression] SMR
(1st grp); weighted overall
average SMR by country;
correlation with health
expenditure (US$/capita)
GDP-adjusted amenable mortality was lowest
in Greece, NL and DK and highest in
Portugal, Italy & Germany (indicative of cost-
effectiveness); mortality from conditions in 1st
subgroup generally lower in countries with
higher level of health care expenditure; no
association between per capita health care
expenditure and GPD-adjusted average SMR
from amenable conditions
Westerling
199350
Sweden by 26
health
administrative
areas
1974-1979,
1980-1985
Analysis of variation in death rates for
selected indicators of avoidable
mortality among health administrative
areas, divided into ‘medical care
indicators’ and ‘health policy indictors’
basis: Rutstein et al.
• 13 conditions/groups of
conditions (medical care: 10,
health policy: 3)
• ages 0-64
Cross-sectional
regional SMR; analysis of levels
of systematic (nonrandom)
variance between regions
Systematic variance accounted for at least
85% of observed variance for health policy
indicators (& total mortality) and up to 80%
for medical care indicators with remainder
due to random variation (most medical care
indicators); sign. differences between regional
SMR and national standard for all health
policy indicators and selected medical care
ind. (bronchitis, pneumonia, colon ca, cervix
ca, CVA, ulcer, perinatal mortality, asthma)
Westerling
1996153
Sweden by 26
health
administrative
areas
1987-1990 Analysis of whether proportion of
deaths outside hospital from selected
‘avoidable’ causes can explain regional
variations in mortality from these
causes; ‘avoidable’ causes: conditions
for which acute medical management
may be important to the outcome
• 5 causes of ‘avoidable’ death:
diabetes, ischaemic heart disease,
cerebrovascular disease, asthma,
ulcer of duodenum
• ages 0-69
Cross-sectional
(age-sex-standardised) mean
annual death rate for deaths in
and outside hospital, unknown
place, total; analysis of variation
between regions; correlation
between proportion deaths
outside hospital with all deaths
for each cause and by region
58% of deaths from asthma & 54% from IHD
occurred outside hospital (ulcer: 44%,
diabetes: 31%, CVA: 16%); sign. correlation
between in-hospital & outside hospital deaths
(CVA, IHD, diabetes: 0.5); sign. [but
moderate] correlation between outside
hospital deaths and all deaths for ulcer &
diabetes only (coeff: 0.4)
Suarez-
Varela et al.
1996215
Valencia, Spain 1982-1990 Analysis of regional variations in
avoidable mortality by level of
urbanisation and health care resources;
‘avoidable’ mortality: causes of death
“amenable to intervention by health
services”
basis: Rutstein et al.
• 14 conditions/groups of
conditions (see Holland 1988 excl.
causes amenable to primary
prevention)
• no age given
Cross-sectional
Age-standardised death rates by
level of urbanisation (= proxy for
health care resources, such as
number of hospitals)
Among men levels of pneumonia
tuberculosis, rheumatic heart disease,
bacterial disease, Hodgkin’s disease sign.
higher in urban areas (women: cervical
cancer, pneumonia, abdominal hernia,
cholecystitis); CVA sign. higher in rural areas
(both sexes)
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106 Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Humblet et
al. 198732,60
Belgium by 43
districts
1974-78 Analysis of geographical variations of
‘avoidable’ mortality as defined by
Holland (1988)
basis: EC (1988)
• 12 conditions/groups of
conditions excl. maternal &
perinatal mortality, infectious
diseases, motor vehicle accidents
• ages 5-64; hypertensive &
cerebrovascular disease: 35-64;
respiratory: 1-14; asthma: 5-49;
liver cirrhosis: 15-64
Cross-sectional
Regional SMR; multiple
correspondence analysis of
avoidable causes; multiple
regression analysis of thus
identified ‘types of mortality’
against socio-economic
indicators (index of social well-
being; index of industrial growth
1961-1970; mean income level)
& indicators of health services
(age-morbidity-standardised rate
of GP consultations, specialist
consultations; ‘technical coeff’)
Two types of mortality: (1) loading highest on
mortality from tuberculosis, liver cirrhosis,
hypertension, (2) lung cancer, cervical cancer,
hypertension; both showing specific regional
pattern (north-south or east-west gradient);
sig. & strong neg. association of factor 1
mortality with industrial growth and (pos.)
‘technical coefficient’, also specialist
consultations; factor 2 with mean income
(neg.) and specialist consultations (neg.)
Lorant
2000216
Belgium by 557
communities
1985-1993 Analysis of the association between
socio-economic deprivation and
mortality from all causes and from
causes avoidable by primary and
secondary prevention
basis: Simonato et al. (1998)
• 11 conditions/groups of
conditions
• ages < 65
Cross-sectional
SMR by community; SES:
Townsend & Carstairs index,
factor analysis of 11 socio-
economic indicators; regression
analysis & ‘concentration illness
index’ and P90/P10 ratio
Strong positive association between
deprivation & all-cause mortality <65
(B=0.71), mortality from liver cirrhosis
(0.57), lung cancer (0.49), suicide (0.35), falls
(9.34); concentration of mortality (sign.
unequal distribution): liver cirrhosis (14%),
falls (7%), suicide (4%), lung cancer (6%)
Marshall &
Keating
198946
Auckland, New
Zealand
1977-1985 Geographical variation in mortality
burden that is ‘avoidable’ by
appropriate medical intervention and
treatment
basis: Rutstein et al/
• 16 conditions/groups of
conditions
• ages 0-64; asthma, cervical ca,
respiratory dis, diabetes,
bronchitis/ emphysema, peptic
ulcer, meningitis, viral hepatitis,
pregnancy complications: 0-49
Cross-sectional
SMRs by census unit
Avoidable deaths accounted for 2.4% of all
deaths & 8% of all deaths <65; substantial
regional variation in amenable mortality with
indication of rates being highest in deprived
areas (correlation avoidable mortality rates &
% Maori population: 0.53, with % Pacific
Islanders: 0.65; with % unemployed: 0.57;
with % blue collar worker: 0.45; with % car
owner: -0.60, with average income: -0.54
Velkova et al.
199782
12 Countries of
central and
eastern Europe
(CCEE), 16
countries of
western Europe
(CWE)
1985-1991 Contribution of differences in mortality
from conditions amenable to medical
intervention to difference in life
expectancy between CCEE and CWE
in comparison with contribution of
differences in mortality from 4 major
cause of death groups (cancer, CVD,
respiratory diseases, external causes)
basis: Rutstein et al.
• 9 conditions/groups of
conditions, perinatal mortality
replaced by early neonatal
mortality
• ages 0-75
Cross-sectional
Age-adjusted death rates;
decomposition of life expectancy
between birth & age 75 by cause
of death between each CCEE
and average of CWE
Amenable causes accounted for 11-50% of
the difference in temporary LE between
CCEE & CWE in men and 24-59% in women
(excluding early neonatal deaths); for all
CCEE, amenable causes contributed 1.2 years
of the overall gap of 4.8 years (24%) in men
and 0.9 of 2.3 years in women (40%);
contribution of amenable causes of similar
magnitude as that of CVD (1.5 yrs in men, 1
yr in women) and much larger as that from
neoplasms (0.5 & 0.2), respiratory diseases
(0.7 & 0.4) or external causes in women (0.3)
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Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Treurniet et
al. 199962
The Netherlands 1984-1994 Association between regional
variations in ‘avoidable’ mortality and
variations in disease incidence (as
measured by hospital discharge data);
‘avoidable’ conditions: “(excess)
occurrence of these outcomes points to
potential problems in health care”
basis: Rutstein et al.
• 12 conditions/groups of
conditions plus 4 perinatal causes
• ages 5-64; cervical ca: 15-64,
cancer testis: 0-64, leukaemia: 0-
44, rheumatic heart disease: 5-44,
hypertensive/ cerebrovasc disease
(CVA): 35-64,  influenza/
pneumonia: 0-74, benign prostatic
hyperplasia: 0-74, congenital
cardiovasc anomalies: 1-14
Cross-sectional
Log-linear regression to estimate
RR for mortality, incidence,
incidence-adjusted mortality and
in-hospital mortality; linear
regression examining the
association between mortality &
incidence, and incidence-
adjusted mortality & in-hospital
mortality
Significant regional mortality variations for 7
out of 16 conditions, e.g. cervical cancer,
cancer of testis, CVA, influenza/pneumonia,
perinatal causes; with exception of cervical
cancer regional differences only partly
accounted for by variation in incidence; also
regional variation in in-hospital mortality that
explained 60% of mortality variation in CVA,
29% in appendicitis, i.e. high death rate is
associated with high risk of dying in hospital
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108 Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’ and time trend)
Author country / region time period Topic/aim of study number of causes Design/method Results
Holland
199129
12 EC member
states by
administrative
area (total: 451)
1980-1984
(1974-78)
See Holland 1988 plus analysis of
changes in ‘avoidable’ mortality
between 1974/78 & 1980/84 (except
for Portugal & Spain who became EC
member states in 1986)
see Holland 1988 Cross-sectional & time trend
SMR for each country (within-
country variation) and EC in
total (between-country
variation);  degree of
heterogeneity between areas;
ranks of SMRs in 2 periods
(relative change) by cause &
region, age-standardised death
rates by cause & region; excess
mortality relative to EC rates by
region
Between 1974/78 & 1980/84 standardised
death rates from all causes (ages 5-64) fell in
all EC countries, by 3.5% in Greece to 10% in
France (EC: -7.8%) except DK (+4.4%);
deaths from avoidable causes (EC) fell more
steeply, by at least 20% (hypertensive/
cerebrovascular disease) to 67% (chron.
rheum. Heart disease) except asthma (+24%),
rates were however small (e.g. asthma:
0.62/100k); as in 1974/78 there was
considerable between- and within country
variation regarding avoidable causes of death
Holland
199731
12 EC member
states by
administrative
area (total: 554)
1985-1989
(1980-84)
Expanding the work of Holland 1988,
1991 & 1993 plus analysis of trends in
avoidable deaths between 1980/84 &
1985/89
basis: EC (1988, 1993)
• 16 conditions/groups of
conditions
• ages: see Holland 1988 & 1993
Cross-sectional & time trend
SMR for each country (within-
country variation) and EC in
total (between-country
variation);  degree of
heterogeneity between areas;
annual % change in avoidable
mortality (SDR) by cause &
area/country
Between 1980/84 & 1985/89 SDR from all
causes (ages 5-64) fell in all EC countries, by
0.4%/year in DK to 3.2/year in Lux (EC: -
1.7%/year); deaths from avoidable causes fell
more rapidly than for all causes, from at least
10%/yr for TB , appendicitis, cholelithiasis %
chronic rheum heart disease to about 3%/yr
for IHD & cervical ca; increase in asthma
(+1.6%/yr) & breast cancer (+0.4%/yr); small
increases in SDR from IHD in Greece
(+2.2%/yr), cervical ca in E&W (+0.3%/yr),
cholelithiasis in DK (+4.1%/yr); as in
1974/78 & 1980/84 there was considerable
between- and within country variation
regarding avoidable causes of death
Carstairs
198936
10 EC member
states, focus:
Scotland
1974-78
(1979-84)
Based on EC Atlas Vol. 1  (see Holland
1988)
see Holland 1988 Cross-sectional & time trend
see Holland 1988 + comparison
with age-standardised death rates
1979-84; %-change between
1974-78 & 1979-84
In 1974/78 Scotland had highest death rates
from asthma and CVA [exceeding EC
average by 81% and 51%], within-Scotland
variation esp. high for tuberculosis (highest in
Greater Glasgow); between 1974/78 and
1979/84 decline in no. of deaths from all
avoidable causes, by 8%, but increase in
deaths from all causes (ages 5-64), by 10%
Barry 199235 12 EC member
states, focus:
Ireland
1980-1984
(1974-78)
Based on EC Atlas Vol. 2  (see Holland
1991)
see Holland 1991 Cross-sectional & time trend
see Holland 1991
Between 1974/78 &1980/84 crude DR for
avoidable conditions fell by 20% for cervical
ca to 60% for appendicitis; asthma mortality
increased by 30%; In 1974/78 death rates
from tuberculosis highest in Ireland & rel.
high for asthma, considerable within-country
variation for both; despite 42% decline in TB
mortality between 1974/78 & 1980/84 death
rates remained highest in Ireland
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Empirical studies of ‘avoidable’ mortality: Analyses of geographical variation (‘cross-sectional’ and time trend) – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Pampalon
199343
Québec, Canada,
by 15 (+2) health
regions
1969-73 &
1982-90
Temporal and geographical
(international, regional) differences in
‘avoidable’ mortality, defined as being
“reasonably certain that effective
treatment or secondary prevention are
available for these […] diseases [apart
from tuberculosis, which is, however,
amenable to primary prevention)”
basis: EC (1988)
• 13 conditions/groups of
conditions excl. infectious diseases
& conditions amenable to primary
prevention
• ages: see Holland 1998
Cross-sectional & time trend
Regional SMR [standard:
1982/90 mortality]; factor
analysis of explanatory
variables: 10 health services
indicators (GP, specialist &
hospital bed density, use &
supply of ambulatory services,
hospital use) & 10 SES
indicators; plus incidence of
prematurity, prevalence of
hypertensive & cerebrovascular
disease (ages 35-64); multiple
regression
Between 1969/73 & 1982/90 avoidable
mortality [except asthma] fell on average by
300% compared with 28% decline in
mortality from all other causes [both sexes];
avoidable death rates in Quebec as low as in
Sweden & Japan in 1984/1988; within
Quebec, sign. regional variation for
tuberculosis, hypertensive disease & perinatal
mortality only; regional variation in these
avoidable causes largely explained by socio-
economic factors (TB: 26%, hypertension/
CVA: 42%, periantal mortality: 83%), only
perinatal mortality also related to services
provided by GPs (variation explained: 5%)
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110 Empirical studies of ‘avoidable’ mortality: Analyses of ‘avoidable’ mortality at regional/national level 
Author country / region time period Topic/aim of study number of causes Design/method Results
Westerling
1992a14
Sweden 1974-1985 Proportion of mortality in Sweden
covered by Rutstein’s original list of
avoidable causes; identification of most
common potentially avoidable causes
of death, divided into ‘preventable’ and
‘treatable’ causes of death as defined
by Rutstein
basis: Rutstein et al.
• 68 causes of death in men, 66
causes of death in women
• ages 0-64
Cross-sectional
Crude and age-standardised
death rates
18% of deaths in men classified as
‘avoidable’ (women: 22%) with neoplasms &
respiratory diseases being the most common
[avoidable] causes (at 50% and 15-17%);
large number of ‘avoidable’ causes relatively
rare (men: 63%, women: 82%), 14
‘avoidable’ causes accounted for 16% of total
mortality in men aged 0-64 (women: 12
causes)
Benavides et
al. 199252
Valencia, Spain 1988 Estimation of years of life expectancy
to be gained by preventing ‘avoidable’
deaths by dividing deaths into those
‘avoidable’ by primary or by secondary
prevention as defined by Holland
(1988)
basis: EC (1988)
• 16 conditions/groups of
conditions (perinatal mortality
excluded) (primary prevention: 3
conditions)
• no age restriction (life
expectancy at birth)
Cross-sectional
Life expectancy at birth (LE) for
(1) all causes, (2) excl. all
avoidable causes, (3) excl.
causes avoidable by primary
prevention; (4) excl. causes
avoidable by secondary
prevention
LE at birth: 72.5 in men & 79.7 in women
(1988); removing all avoidable deaths would
increase LE by 2.01 (men) & 0.8 (women); of
these, 1.59 yrs [78%] (men) attributable to
primary prevention (women: 0.46 yrs [58%]);
total gain (both sexes): 1.47 (1.09 primary
prevention [74%]; 0.37 secondary prevention)
Sanchez et al.
199338
Spain 1983-1986 Analysis of ‘avoidable’ mortality using
measure of life expectancy LEFAM
(“Life Expectancy Free of Avoidable
Mortality”), defined as mean years one
can be expected to live if health system
were as efficient as it ought to be;
‘avoidable’ causes: causes “directly due
to the health system”
basis: EC (1988)
• 14 conditions/groups of
conditions (perinatal mortality
excluded) plus anaemia
• age restriction as in Holland
1988 (anaemia: age 0-64)
Cross-sectional
Life expectancy at ages 0, 1, 5,
14, 35, 44, 64, with & without
avoidable deaths; correlation of
LE & LEFAM with annual
changes in GDP, IMR, mortality
rate, hospital beds, health
personnel, ambulatory contacts
(1975-1986)
LEFAM was about 1.1-1.2 years (men: 1.5-
1.8; women: 0.6) higher than LE at birth with
difference declining with increasing age;
(sign.) correlation between LEFAM & GDP
(R=0.98), IMR (-0.98), health human
resources (0.96), hospital beds (-0.86)
stronger than between LE & these measures;
no sign. correlation with ambulatory contacts
for both
Adler 197819 USA 1968-71 Evaluation of preventable mortality in
the USA; ‘preventable’ mortality:
includes preventable and treatable
conditions as defined by Rutstein
basis: Rutstein et al.
• all conditions/groups of
conditions as in Rutstein’s list A
• no age restriction
Cross-sectional
Total deaths, proportion of
deaths
Conditions classified as ‘sentinel health
events’ [“only if the occurrence of a single
case…would justify…an immediate inquiry
into the question, ‘Why did it happen?’”]
accounted for 14% of all deaths in US
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Empirical studies of ‘avoidable’ mortality: Analyses of variation by socio-demographic factors 
Author country / region time period Topic/aim of study Number of causes Design/method Results
Westerling et
al. 199651
Sweden 1986-1990 Analysis of socio-economic differences
in ‘avoidable’ mortality in Sweden,
divided into ‘medical care indicators’
and ‘health policy indictors’ plus
‘others’ including causes for which
health services intervention programs
had been recommended (suicide, breast
cancer)
basis: Rutstein et al.
• 18 conditions/groups of
conditions (medical care: 12;
health policy: 4; other: 2)
• ages 21-64
Cross-sectional
Linked mortality-census data;
SMR for selected causes/cause
groups by SES (=occupied vs.
non-occupied; blue- vs. white
collar; level of training
[unskilled-skilled blue collar;
low-medium-high white collar])
SMRs for non-occupied were higher for all
causes studied, medical care SMR: 212,
health policy: 186, all: 210; (occupied: 73, 80,
75); esp. high rates for bronchitis (346),
diabetes (335), meningitis (361), liver
cirrhosis (333) [healthy worker effect?];
smaller differences between blue & white
collar workers (medical care- blue: 107,
white: 95; health policy – blue: 116, white:
85; other-blue: 114, white: 88); only
exception ulcer death rates with blue collars
almost 3 times those of  white collars
Westerling &
Rosen
2002217
Sweden 1986-1990 Analysis of differences in ‘avoidable’
mortality among immigrants in
Sweden; ‘avoidable’ conditions divided
into ‘medical care indicators’ (MCI)
and ‘health policy indictors’ (HPI) plus
‘others’ including causes for which
health services intervention programs
had been recommended (suicide, breast
cancer)
basis: Rutstein, EC (1988)
• 18 conditions/groups of
conditions (medical care: 12;
health policy: 4; other: 2)
• ages 21-69
Cross-sectional
Linked mortality-census data;
SMR for selected causes/cause
groups by country of birth
SMRs for  avoidable/all causes highest in
population born in Nordic countries other than
Sweden, SMR MCI: 119, HPI: 163, all: 133
(Sweden: 100, 95, 98; countries other than
Nordic/Sweden: 83, 117, 91);  SMR variation
for MCI smaller than HPI; high rates among
Nordic immigrants for, e.g. CVA (Finland:
143), chronic bronchitis (DK & Iceland: 252),
rectal CA (DK & Iceland: 311); for other
countries of birth also chronic rheumatic heart
disease (SMR 345); immigrants from Finland
had highest SMR for all causes (by 41) and
for MCI (21%); HPI highest for immigrants
from DK/Iceland (106%)
Woolhandler
et al. 198568
Alameda County,
CA, USA
1978 Racial differences in mortality from
preventable and manageable causes
compared with ‘non-preventable’
causes; definition of death as
‘preventable’ or ‘manageable’ if
resulted from a condition as listed by
Rutstein’s list A or B
basis: Rutstein et al.
• all conditions/groups of
conditions as in Rutstein’s lists A
& B excl. those where
preventable/manageable proportion
<50%, plus all diagnoses primarily
associated with drug & alcohol
abuse, mental disorders, accidents,
suicides, homicides, other external
causes
• all ages; acute resp infect: <45;
hernia: <65; Hodgkin’s dis: <25;
neuroblastoma, nutritional
marasmus, congenital anom of
heart: <1
Cross-sectional
Age-adjusted death rates for all
ages and <65; death rate ratios;
potential years of life lost before
age 65 (PYLL)
Total death rates under 65 among blacks
exceeded those of whites by 58% (m: 65%, f:
48%); mortality from preventable/
manageable conditions [list A+B] under 65
was 77% higher in blacks (m: 85%, f: 64%);
33% of excess mortality (<65) in black men
attributable to potentially preventable
conditions (f: 37%); 44% of PYLL in blacks
attributable to potentially preventable deaths
(whites: 32%); sig. excess black rates for
IMR, cancer of thoracic organs, hypertension,
acute pulmonary infection; elevated: cervical
ca, diabetes, peptic ulcer amongst others
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Author country / region time period Topic/aim of study number of causes Design/method Results
Carr et al.
198963
New York State,
USA
1983 Occurrence of ‘sentinel health events’
among hospitalised residents and
differences among population
subgroups’: “negative health states –
diseases, disabilities, and deaths – that
are deemed to be avoidable given
current medical and public health
knowledge and technology”
basis: Rutstein et al.
• no age limits
Cross-sectional
Age-adjusted disease and death
rates based on hospital discharge
data by population subgroup
(racial/ethnic), social class
(proxy: Medicaid, Blue Cross),
hospital type (municipal,
voluntary); case-fatality ratio
Approx. 10% of all hospital deaths were
potentially avoidable, 1/3 of which occurring
under age 65; 50-80% of these deaths
possibly avoidable through primary
prevention; case-fatality higher among blacks,
Medicaid enrolees & NY municipal hospitals
René et al.
199569
Texas, USA 1980-1989 Ethnic differences in “sentinel causes
of mortality” as a measure of access
and availability of health-care delivery
services
basis: Schwartz et al. (1990)
• 12 conditions/groups of
conditions excl. bacterial
infections, anaemia, perinatal &
maternal mortality but incl.
influenza
• ages 15-64
Cross-sectional
Age-standardised death rates;
SMRs (comparing with white
population) and by region
Amenable mortality among Texas African
Americans was >3 times that of white
Americans [SMR: 3.4], especially
hypertension but also tuberculosis, asthma,
appendicitis & cervical cancer; for Spanish-
speaking Americans rates only slightly higher
[SMR: 1.1] (mainly TB  & cervical cancer)
Wood et al.
199973
British Columbia,
Canada
1981-1991 Socio-economic differences in male
mortality from causes of death
amenable to medical care
basis: Charlton et a. (1983)
• 12 conditions/groups of
conditions excl. cervical cancer &
perinatal mortality
• ages 15-64
Cross-sectional
Age-standardised death rates;
classification into social levels
by occupation (adapted from UK
system), education, median
income, combined index; rate
ratios between lowest and
highest social level; weighted
regression to assess strength of
social class gradient
Mortality from amenable causes highest in
lowest occupational class [ratio: 1.9; sign.];
similar associations for education, income and
education & income combined with sign.
gradients for hypertensive disease (2.9),
tuberculosis (2.7), asthma (2.2), pneumonia
(2.3) and all amenable causes (2.1)
Malcolm
199442
New Zealand 1985-1987 Avoidable mortality among Maori and
non-Maori New Zealanders with deaths
divided into causes avoidable by
primary or secondary prevention
See Holland (1988) Cross-sectional
Potential gains in life expectancy
(YLG)
Excluding all preventable deaths, YLG in
Maori men was 2.6 years compared with 2.3
in non-Maori men (women: 2.7 & 1.7); excl.
deaths avoidable by secondary prevention
only, potential gain would be 1.15 yrs in
Maori and 1.0 in non-Maori men (44% of
total gain in both) (women: 1.74 & 1.04 yrs [
62-65% of total gain])
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Empirical studies of ‘avoidable’ mortality: Analyses of variation by socio-demographic factors  – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Schwartz et
al. 199070
USA and District
of Columbia
1980-1986 Race-specific analysis of conditions for
which mortality is largely avoidable
given timely and appropriate medical
care; ‘avoidable’ mortality as indicator
of access or quality of health care
(“causes preventable by medical
intervention”)
basis: Charlton et al. (1983)
• 12 conditions/groups of
conditions excl. bacterial
infections, anaemia, perinatal &
maternal mortality but incl.
influenza
• ages 15-64
Cross-sectional & time trend
Age-adjusted cause and race
specific death rates; YPLL < age
65; excess number of
preventable deaths by indirect
standardisation (standard: death
rates of US White population)
Non-significant decline in mortality from all
avoidable causes by 8.7% between 1980&
1986 (US); SDR from avoidable causes 4.5
times sign. higher in Blacks than Whites, esp.
TB (ratio:8.9), hypertension (6.5), asthma
(4.4); of all avoidable deaths among Blacks
78% in excess of Whites, mostly
hypertension, pneumonia, cervical ca,
tuberculosis; DC rates higher for Blacks &
Whites compared with US, B/W ratio within
DC 3.6 for all avoidable causes
Tobias &
Jackson
200159
New Zealand 1981-1997 Trends in avoidable mortality in New
Zealand: ‘primary avoidable mortality’
(preventable at individual/population
level intervention, condition prevented
before it develops); ‘secondary
avoidable mortality’ (preventable
through early detection/intervention);
‘tertiary avoidable mortality’ (case
fatality can be significantly reduced by
existing medical or surgical treatment);
update of Charlton’s (1983) list, each
weighted for ‘preventability’ by level
of prevention; variation by ethnicity
and deprivation
basis: Charlton et al. (1983)
• 56 conditions/groups of
conditions with 24 considered
mainly amenable to primary
prevention, 16 mainly secondary
prevention and 16 mainly tertiary
prevention
• ages 0-75 (upper age limit to
reflect improvements in life
expectancy)
Cross-sectional & time trend
Age-standardised death rates;
‘avoidable’ conditions
partitioned among three
categories of prevention by
authors and external reviewers;
‘level of deprivation’ assessed
by factor analysis of 9 socio-
economic variables (1996/97)
Total avoidable mortality fell by 38%
compared with 9% drop in non-avoidable
mortality (all-causes: -31%); ‘excess’
reduction of 29% in avoidable mortality (or
1.5%/year) estimated ‘added value’ of health
system [health promotion, disease prevention,
treatment]; declines greatest for PAM & SAM
among <14, declines equally steep for all 3
measures for those aged 45-74 (where about
80% of all avoidable causes occur); ethnic
and socio-economic gradient for avoidable
causes greatest for PAM & SAM, with rates
more than twice as high among Maori vs.
non-Maori and the most deprived vs. the least
deprived
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Author country / region time period Topic/aim of study number of causes Design/method Results
Poikolainen
& Eskola
199572
City of Helsinki,
Finland
1980-1986 Analysis of regional and social class
differences in RR of death from
amenable causes (Rutstein’s list
adapted to state of medical knowledge
& preventability of death at beginning
of study period)
basis: Rutstein et al.
• 23 conditions/groups of
conditions
• ages 0-64; Hodgkin’s disease: 5-
64, diabetes: 5-39
Case-control study
1 case:4 controls, data by age,
marital status, area of residence
& social class/status
(occupation); multiple logistic
regression to estimate adjusted
OR’s
Regional differences in amenable mortality
very small after adjustment; significant
differences by social class with OR in lowest
being 8.5-fold that in highest; sign. elevated
risks for those with no address (OR 5.6),
mainly amenable heart disease & respiratory
disease
Song &
Byeon 200056
Korea 1992-1996 Socioeconomic mortality differentials
in Korean male civil servants, with
causes of death divided into
‘avoidable’, ‘partly avoidable’ and
‘external’ conditions; ‘avoidable’
conditions: preventable and treatable
conditions as defined by Rutstein
(Table A)
basis: Rutstein et al.
• all conditions/groups of
conditions as in Rutstein’s list A
(‘clear-cut, immediate use of
Quality-of-Care indexes’ –
‘avoidable deaths’) & B (‘limited
use of Quality-of-Care indexes’ –
‘partly avoidable deaths’) plus
external causes as separate
category
• ages 30-64
Prospective observational study
RR (Cox proportional hazard
regression) by SES (grade of
monthly salary), adjusted for
age, smoking status, drinking
habit, BMI, cholesterol level,
systolic blood pressure, area of
residence, type of occupation
Mortality from external & avoidable causes
accounted for 21 & 13% of overall mortality
in lowest SES compared with 14 & 12% in
high SES; fully adjusted RR for all cause
mortality: 1.59 (lowest vs. highest SES),
avoidable mortality: 1.65, external causes:
2.26, partly avoidable: 1.22, non-avoidable:
1.54; no SES differences in mortality from
IHD but cerebrovascular disease (1.67)
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Empirical studies of ‘avoidable’ mortality: Analyses of changes over time
Author country / region time period Topic/aim of study number of causes Design/method Results
Lakhani et al.
198622
England & Wales 1974/78-
1979/83
Changes in mortality amenable to
health services; update of Charlton et
al. 1983
basis: Charlton et al. (1983)
• 12 conditions/groups of
conditions incl. perinatal &
maternal deaths, stroke; excl.
pneumonia & bronchitis, bact
infect, anaemia; acute resp dis
replaced by all resp but limited to
age 1-14
• ages 5-64; hypertension &
stroke: 35-64, CA cervix uteri: 15-
64; asthma: 5-44; maternal deaths:
5-44
Time trend
Comparison of deaths and crude
death rates between 1974/78 &
1979/83 and expected changes
due to changes in ICD
Mortality from causes amenable to health
services fell by 23%, non-amenable by 6%
and all-cause mortality by 9% between
1974/78 and 1979/83
Charlton et al.
198623
England & Wales
by 98 Area
Health
Authorities
(AHAs)
1974/78-
1979/83
Changes in mortality amenable to
health services at national and local
level
basis: Charlton et al. (1983)
• 8 conditions/groups of
conditions incl. perinatal &
maternal deaths, stroke; excl.
pneumonia & bronchitis, acute
resp dis, bact infect, anaemia,
abdominal hernia, cholecystitis
• ages 5-64; hyperten. & stroke:
35-64, cervix ca: 15-64; asthma: 5-
44; maternal deaths: 5-44
Time trend
Comparison of SMR by AHA (&
District Health Authority) for
1974/79 & 1979/83; comparison
of geographical distribution of
each indicator in 2 time periods;
regional variation tested for
heterogeneity; summary score
based on standard deviation from
national death rate
Except for asthma (national) death rates of
conditions amenable to medical treatment fell
by 10% (cervical cancer) to 63% (chronic
rheumatic heart disease); observed increase in
asthma deaths (27%) higher, by 18%, than
expected from change in ICD in 1979; half of
decline in mortality from chronic rheumatic
heart disease explained by change in ICD;
degree of heterogeneity between AHAs over
time remained high although most AHAs
improved over time
Poikolainen
& Eskola
198625
Finland 1969-81 Impact of  health services on mortality
from natural causes amenable to
medical intervention excl. conditions
amenable to primary prevention;
‘partly amenable causes’: causes
changed from non-amenable to
amenable or partly amenable through
innovations in medical care over time
basis: Rutstein et al.
• 21 conditions/groups of
conditions (5 perinatal causes) + 7
partly amenable condistions (incl.
IHD, larynx cancer)
• ages 0-64; diabetes: 0-49,
respiratory causes: 0-49
Time trend
Linear regression of logarithm of
mortality rates (unadjusted as
similar to age-adjusted);
estimating ‘impact of medical
care’
Between 1969&1981mortality amenable to
medical intervention declined by 63% in men
& 68% in women (non-amenable causes: 24
& 29%; all causes: 24% & 34%);
approximately 50% of decline in amenable
causes attributable to health services (4.2%
p.a.)
McKee &
Rajaratnam
198791
England & Wales 1969-1978 Trends in mortality from conditions
amenable to medical intervention
basis: Rutstein et al.
• 17 conditions/groups of
conditions as analysed by
Poikolainen & Eskola 1986
Time trend
Comparison of deaths between
1969 and 1978
Between 1969 & 1978 deaths from amenable
causes fell by 44% in men and 34% in
women, non-amenable causes fell by 15% in
both sexes
Charlton &
Velez 198624
E&W, USA,
France, Japan,
Italy, Sweden
1950-80
(1956-78)
International comparison of mortality
amenable to medical care (‘avoidable’
with “appropriate and timely health
care”)
basis: Charlton et al. (1983)
• 9 conditions/groups of
conditions + stroke, excl.
pneumonia & acute resp dis;
perinatal deaths replaced by infant
deaths
• ages 5-64
Time trend
Trends in age-standardised
mortality rates
Between 1956 and 1978 mortality [both
sexes] from amenable causes (all other
causes; total) fell: E&W: 51% (4; 12); USA:
55% (9; 18) [67% recalculated]; France: 64%
(19; 26); Japan: 72% (43; 53); Italy: 57% (17;
25); Sweden: 61% (3; 12);
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Author country / region time period Topic/aim of study number of causes Design/method Results
McKee &
Bewley
198796
Northern Ireland 1969-1978 Trends in mortality from conditions
amenable to medical intervention
basis: Rutstein et al.
• 18 conditions/groups of
conditions as analysed by
Poikolainen & Eskola 1986
• ages 0-64; diabetes &
respiratory diseases: 0-49
Time trend
Linear regression of number of
deaths against time (1969=1);
estimating ‘impact of medical
care’
Deaths from amenable conditions declined by
58% in men & 44% in women, non-amenable
mortality remained stable in men & fell by
6% in women; 58% of decline in amenable
mortality in men attributable to health
services compared with 35% in women; excl.
perinatal mortality still shows sign. fall in
amenable mortality; declines especially
marked for TB, hypertension, infectious dis,
& perinatal mortality
Wiesner &
Zimmermann
199039,40
Former GDR 1980-1987 Analysis of ‘avoidable’ mortality with
respect to life expectancy; ‘avoidable’
causes defined according to Charlton et
al. (1983)
Basis: Charlton et al. (1983)
• 11 conditions/groups of
conditions (excl. maternal &
perinatal mortality)
Time trend
Life expectancy at birth with and
without ‘avoidable’ causes of
death; ‘avoidable’ loss of life
expectancy at birth
LE at birth excl. ‘avoidable’ causes improved
at pace similar to LE at birth incl. these
causes, by 0.7 yrs in men & 0.9 yrs in
women; ‘avoidable’ loss of life expectancy at
birth was 0.41 yrs in men and 0.45 yrs in
women
Mackenbach
et al. 1988b76
The Netherlands 1969-1984 Regional variation in mortality decline
within The Netherlands from selected
conditions including a selection of
conditions considered ‘amenable to
medical intervention’
basis: Charlton et al. (1983, 87)
• 13 conditions/groups of
conditions; perinatal mortality as
separate category
• ages 0-75
Time trend
Log-linear regression to estimate
national & regional mortality
levels & trends, controlled for
size & age/sex composition of
population; correlation of levels
& trends with health care (#
university hospitals, # beds,
#GPs) & socioeconomic
indicators (income/capita, %
primary education, %
unemployed)
Between 1969 & 1984 amenable mortality
declined by 4.5% per year compared with all
cause mortality at -1.6%/a; amenable (&
perinatal) mortality declined faster in less
urbanised, low income areas, decline not
associated with presence of university
hospital or changes in health care supply (#
beds, GPs) but with socioeconomic indictors:
declined faster in areas with higher increase
in average income and/or  educational level
(as did perinatal and total mortality)
Mackenbach
et al. 1988c47
The Netherlands 1950-1984
(1950-68,
1969-84)
Impact of medical care innovations on
mortality amenable to medical care
[”the application of biomedical
knowledge through a personal service
system”] excl. conditions amenable to
primary care, with small numbers or
high survival rates due to reasons other
than increasing effectiveness of
medical care (e.g. thyroid cancer)
basis: Rutstein et al.
• 35 conditions/groups of
conditions [ordered accord. to time
of introduction of medical care
intervention]; age limits for kidney
cancer and leukaemia (<15) and
diabetes (<25)
Time trend
Loglinear regression analysis of
observed no. of deaths in relation
to person-years at risk, age and
calendar year (slope of change)
Accelerated decline in mortality for many
conditions in 1969-84 period, reflecting
introduction of specific treatments; decline in
mortality amenable to medical intervention
added 2.96 years to male life expectancy
between 1950/54 and 1980/84 [mainly
infectious (+0.94) & perinatal (+0.72)] and
3.95 years to female life expectancy [mainly
hypertension/ cerebrovasc. (+1.32) & acute
respiratory (+1.13)]
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Empirical studies of ‘avoidable’ mortality: Analyses of changes over time – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Mackenbach
et al. 198975
England & Wales
The Netherlands
E&W:
1931,61,81
NL: 1952,
62, 72, 82
Contribution of medical care to
widening of mortality differences
between socio-economic groups:
analysis of differences in mortality
from conditions which have become
amenable to medical intervention
basis: Rutstein et al.
• 25 conditions/groups of
conditions grouped accord. to type
of innovation in medical care &
related to period of mortality effect
of innovation [1930-60; 1960-80]
• ages 15(16)-64 for E&W; 0-74
for NL
Time trend
E&W: absolute & relative
changes in cumulative mortality
rates; SES by occupation
NL: SMR (against national rate
for 1950-84); regression against
SES by geographic region,
classified using index of 6
indicators (e.g. average income,
average no. years education, %
unemployed)
E&W: between 1931&1961 declines in
amenable mortality were generally larger than
declines in all-cause mortality with rates
typically declining by about 80% compared
with 6-40% in men (40-50% in women),
declines were usually steeper in social classes
I+II than in classes IV+V; pattern less
consistent in 1961-1981 although proportional
declines in amenable mortality were steeper
than in total mortality
NL: differential mortality decline for peptic
ulcer only (1952-62) & 3 surgical conditions
and hypertensive & cerebrovascular disease
in 1962-82
Mackenbach
200049
The Netherlands 1980/84-
1991/95
Update of analysis of Mackenbach et
al. 1988b
See Mackenbach et al. 1998b + 3
‘new’ conditions for which there
have been important medical
advances (IHD, rectal cancer, hip
fracture)
Time trend
See Mackenbach et al. 1998b
Decline in mortality from amenable
conditions added an additional 0.23 years to
male life expectancy at birth (females: +0.41
yrs); adding in IHD, rectal cancer & hip
fracture results in overall addition of 1.07 yrs
in men & 0.82 yrs in women
Westerling &
Smedby
199237
Sweden 1974-1985 Analysis of ‘avoidable’ mortality in
Sweden using the EC Working Group
avoidable death indicators with causes
of death divided into indicators of
‘medical care intervention’ and of
‘national health policies’
See Holland 1988 Time trend
Linear (& log) regression
analysis of yearly change in
death rates, trends tested for
significance; SMR using EC
death rates as standard for
1974/78 & 1980/84
Health policy indicators constituted higher
proportion of total mortality (10-18%) than
medical care indicators at all ages except <0
(medical care: 40-43%) and women age 45-64
(11% vs. 7%); in 1980/84 10 out of 14
medical care indicators occurred in less than
50 cases (both sexes); significant decline in
most avoidable deaths from 1974-1985,
largest for CVA by 1.54%/a in men & 1.3%/a
in women; in women sign. increase in lung
cancer; levels of avoidable mortality in
Sweden sign. lower than in EC except asthma
(SMR: around 150 both periods)
Westerling
1992b218
Sweden 1974-1985 Trend analysis of potential avoidable
mortality in Sweden, divided into
‘preventable’ and ‘treatable’ causes of
death
basis: Rutstein et al.
• 63 causes of death (women: 65)
• ages 0-64
Time trend
Linear (& log) regression
analysis of yearly change in the
proportion of deaths, trends
tested for significance
Among men deaths from treatable causes
declined more than total mortality; the
proportion of treatable causes fell by 0.10%
units/a [proportion of all avoidable causes fell
by 0.11%/a]; excl. lung cancer preventable
mortality also declined more than total
mortality (at 0.11%/a in men and 0.16/a in
women); sign. increase in treatable mortality
in  boys aged 1-14 by 0.48%/a, mainly
asthma, bronchitis & leukaemia
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Author country / region time period Topic/aim of study number of causes Design/method Results
Bjerregaard
& Juel 199041
Greenland 1968-1985 Analysis of ‘avoidable’ deaths among
native Greenlanders, with causes
divided into those amenable to
treatment or primary prevention or
both; list mainly based on Rutstein’s
(1976) list but taking account of
mortality experience in Greenland
basis: Rutstein et al.
• 15 conditions/groups of
conditions; 5 treatable causes, 8
preventable causes, 2 causes
amenable to both (meningitis,
chronic bronchitis)
• ages 0-64; TB, lung ca, cervix
ca: 5-64; whooping cough,
measles: 0-14; chronic rheumatic
heart disease: 5-44; acute
respiratory infections, chronic
bronchitis: 5-49; maternal deaths:
15-49; suicide: 10+; alcohol related
deaths: 15+; boat accidents: all
Time trend
Poisson regression of mortality
rates
(Sign) fall in deaths from selected ‘treatable’
conditions (respiratory dis, chronic rheumatic
heart dis, chronic bronchitis) & measles,
cervical ca (‘preventable’) & alcohol related
accidents; increases in preventable conditions
(lung ca, suicides, alcohol related deaths &
boat accidents); regional differences for
selected conditions attributed, in part, to
differences in access to and quality of
medical/health care (vaccine-preventable
conditions, maternal deaths, appendicitis);
SDR higher than in Denmark for all
‘avoidable’ causes, esp. TB (ratio: 41.5),
whooping cough (43.9), measles (24.8);
median ratio: 9.6
Bernat Gil &
Rathwell
198978
Spain 1960-1984 Trends in mortality amenable to
medical care and non-amenable
mortality in light of major reforms in
Spanish health care system since 1982;
‘amenable conditions’: treatment
available and sufficient evidence for
mortality from being avoidable given
appropriate standards of medical care
basis: Rutstein et al.
• 13 conditions/groups of
conditions (incl. infant mortality
instead of perinatal mortality)
• ages 5-64
Time trend
Trends in age-standardised death
rates (1960, 1970, 1976-1984);
‘impact of health services’: _
between average decrease of
each amenable condition and
average decrease of all non-
avoidable conditions
Between 1960 and 1984 amenable mortality
declined by 67% (all causes: 29%, non-
amenable causes: 20%) [1976-1984: 36, 13,
10]; death rates declined for all amenable
causes except cervical cancer, rates relatively
low in international comparison (1982); 51%
of decline in avoidable causes attributable to
medical care (or 2.1%/a)
Albert et al.
199654
Valencia, Spain 1975-1990 Analysis of the evolution of avoidable
mortality between 1975-1990
comparing Holland’s and Charlton’s
lists and by dividing causes into those
amenable to secondary prevention or
treatment (‘medical care indicators’;
MCI) & those avoidable through
primary prevention (‘national health
policy indicators’; NHPI)
• EC (1988) list: 14 medical care
indictors; 3 national health policy
indictors
• Charlton (1983) list
• ages 5-64 for groups MCI,
NHPI, Holland Class [all],
Charlton Class [all]
Time trend
Age-standardised death rates;
linear & non-linear regression of
trends; estimating ‘impact of
medical care’
Amenable mortality (MCI) declined by 63%,
NHPI increased by 24%. Non-avoidable
mortality fell by 17% (total mortality: -24%);
NHPI rates increased by (ß=) 0.5 units/a, MCI
fell by 1.6 units/a; 46% of decline in MCI
(ages 5-64) estimated to be attributable to
health services (or 2.9%/a)
Humblet et al.
200055
Belgium (by 43
districts)
1974-78,
1980-84,
1985-89,
1990-94
Analysis of levels and trends in EC
avoidable deaths indicators (‘Holland’s
list’) and assessment of impact of
avoidable causes of death on premature
mortality, divided into ‘curative
indicators’ and ‘preventive indicators’
basis: EC (1988)
• 18 conditions/groups of
conditions plus cancer of testis,
peptic ulcer, skin cancer; excluding
perinatal mortality (13 curative
indicators, 5 preventive indicators)
• ages 1-64
Time trend
Age-adjusted Years of Potential
Life Lost (YPLL), ratio of YPLL
rates for changes between
1974/78 and 1990/94 in total and
by district
Between 1974/78 and 1990/94 YPLL for
curative indicators declined by 53% in men &
29.7% in women, YPLL for preventive
indictors fell by 30.8 & 26.7%, all avoidable:
-34.2 & 28.1%, all causes: -23.9 & 26.7%;
proportion of all avoidable causes to overall
YPLL in women around 40% & stable over
time (no improvement in breast cancer &
liver cirrhosis [as in men], increase in lung
cancer), declining in men from 47% in
1974/78 to 40% in 1990/94
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Empirical studies of ‘avoidable’ mortality: Analyses of changes over time – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Schwartz
1987219
New Hampshire,
USA
1970-1985 Distribution of deaths due to conditions
amenable to medical intervention
(“(t)hey generally do not lead to death
if appropriate medical intervention is
provided”)
basis: Charlton et al. (1983)
• 14 conditions/groups of
conditions excl. anaemia but incl.
influenza
• ages 15-64; pneumonia, asthma,
influenza & acute respiratory
infections: 15-54; maternal deaths:
15-44; rheumatic heart disease: 15-
44; Hodgkin’s disease: 15-34
Time trend
Age-standardised death rates;
YPLL
Age-standardised death rates from ‘avoidable’
conditions declined by 51% between 1970
and 1987 (no information on changes in all-
cause mortality); cervical cancer,
hypertension & pneumonia accounted for
69% of ‘avoidable’ deaths over 16 year
period & for 60% of YPLL
Hisnanick &
Coddington
199581
USA 1972-1987 Evaluation of the concept of “human
betterment” using measurable health
outcome ‘avoidable mortality’ among
American Indians/Alaska Natives
(AI/AN) [served by Indian Health
Service, IHS]; hypothesis that “reforms
leading to universal health care in US
could result in better access to care and
an increase in overall human
betterment through a reduction in
avoidable mortality”
basis: Rutstein et al.
• 8 conditions/groups of
conditions
•  ages 5-75
Time trend
Mortality rates [crude death rates
per 10000 population eligible for
HIS]; Linear regression
Total mortality among AI/AN declined by
3.7%/year between 1972 & 1987, avoidable
mortality fell by 7.5%/a (7% of all causes);
for those eligible for IHS, avoidable mortality
fell by 57% between 1972/79 and 1980/87
compared with decline of 28% in mortality
from all other causes [declines similar in men
& women]; reductions greatest at ages 45-74
(by 70-75%)
Manuel &
Mao 200244
USA, Canada 1980-1996 Comparison of avoidable mortality
trends in the USA and Canada as a
means to “encourage further evaluation
and improvement of health care
systems” if differences existed;
‘avoidable’ mortality classified
according to 1997 EC Atlas of
Avoidable Death (see Holland 1997)
basis: EC (1997)
• 11 conditions/groups of
conditions excl. chronic rheum
heart dis. & respiratory dis; incl.
IHD
•  ages 0/5-64; see Holland 1997
Time trend
SMR standardised to European
population of 1985-89
IHD accounted for _ of all deaths at ages 15-
64 & for _ of all avoidable deaths in US &
Can in 1985/89;  higher SMR for 9 out of 11
causes in US, esp. cervical ca , TB, asthma,
hypertension/CVA; avoidable mortality fell in
both US & Can except asthma in US; rate of
decline more rapid in Can than US esp. for
cervical ca, TB, hypertension/CVA, asthma
[changes not quantified]
Malcolm &
Salmond
199371
New Zealand 1968-1987 Time trends in amenable mortality
among Maori and non-Maori in New
Zealand; ‘amenable mortality’:
mortality amenable to medical
intervention
basis: Charlton et al. (1983)
• 15 conditions/groups of
conditions
• ages 0-64
Time trend
Age-standardised death rates;
trends modelled by linear or
quadratic regression; estimation
of impact of medical care
Mortality from amenable conditions declined
by 73% in Maori women & 54% in non-
Maori women compared with fall in non-
amenable mortality by 46 & 18% (men: 76 &
62%; 37 & 22%); about 37% of amenable
mortality decline in Maori women (men:
51%) attributable to medical care compared
with 66% in non-Maori (men: 64%); Maori to
non-Maori ratio in amenable mortality
declined from 2.3 to 2.0 in women (men: 2.5
& 2..0), ratio for non-amenable fell from 2.4
to 1.6 (men: 1.8 & 1.5)
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Author country / region time period Topic/aim of study number of causes Design/method Results
Marshall et
al. 199379
New Zealand 1975-1977,
1985-1987
Time trends and social class patterns of
mortality amenable to medical
intervention in New Zealand males
basis: Charlton et al. (1983)
• 12 conditions/groups of
conditions excl. cervical cancer,
pneumonia & bronchitis, perinatal
mortality
• ages 15-64
Time trend
Age-standardised death rates;
classification into socio-
economic groups by index of
median income & median
education; rate ratios between
each social level and pooled
rates for all social levels;
weighted regression to assess
strength of social class gradient
Pooled death rate for amenable causes fell by
30% compared with 14% for non-amenable
causes & 15% for all causes; strong social
gradient in amenable mortality fell from 34%
to 28% (all causes: 13% & 15%), gradient for
TB (40->61%), appendicitis & hernia
increased; amenable rate ratio for lowest
social class declined from 2.68 to 1.72
(highest social class: 0.70->0.50) [amenable
causes accounted for 5% of total mortality]
Niti & Ng
200145
Singapore 1965-1994
(1989-
1997)
Trends & ethnic differences in
amenable mortality with mortality
divided into ‘treatable’ (preventable by
‘timely therapeutic care’) &
‘preventable’ conditions (preventable
by ‘primary preventive policy
measures’)
basis: EC (1988, 1991, 1993)
• 9 ‘treatable’ conditions excl.
perinatal & maternal mortality,
plus diabetes, peptic ulcer; 6
‘preventable’ conditions incl. colon
cancer, liver cancer, cervical
cancer, cerebrovascular disease
• ages 5-64
Time trend
Age-standardised death rate, by
5 consecutive 5-year periods;
SMRs (1990 baseline); linear
regression for time trend; impact
of health care as differential %
decline in amenable mortality
after subtracting % decline of
non-amenable mortality
Total amenable mortality fell by 52%
between 1965/69 & 1990/94 (both sexes)
[annually: -1.77% men; -1.72% women]; non-
amenable: –27% (men) & -35% (women)
[annually: 0.91 & 1.17]; all causes:–40% &
43%; treatable causes fell by 78% [men] &
68% [women], preventable deaths by 29 &
34%; 51% of decline in avoidable mortality
attributable to medical care in men [women:
33%] [attributable to health policy: 1 & -1%]
amenable mortality almost twice as high in
men than in women 1990/94 (mainly
preventable causes); amenable mortality
highest among Malay with rate ratio 1.3-2
compared with Chinese, mainly treatable
mortality; increase in treatable mortality in
Malay and Indian men between 1989/91 &
1995/7 (10 & 14%), decline in Indian women
(-15%) and Chinese (-5 in men & -24 in
women); preventable & all cause mortality:
decline in all groups except Indian men
Gai_auskien_
& Gurevi_ius
199553
Lithuania 1970-1990 Trends in ‘avoidable’ mortality with
deaths divided into ‘treatable’ and
‘preventable’ causes according to
Rutstein
basis: Rutstein et al.
• 14 conditions/groups of
conditions (similar to Charlton’s
list); 11 treatable causes, 3
preventable causes
• ages 5-64; cervical cancer: 15-
64; respiratory diseases: 1-14;
asthma: 5-44; hypertens./
cerebrovascular disease: 35-64;
liver cirrhosis: 15-64
Time trend
Age-standardised death rates;
linear regression analysis of
trends (annual % change)
Treatable mortality fell sign. in both sexes, by
0.7%/a in men and 0.9/a in women (ages 0-
64); preventable causes sign. increased, by
0.9 & 1.3/a; total avoidable mortality
remained stable as did all-cause mortality in
both sexes; total avoidable mortality
accounted for 26-27% of total mortality
(1970-90) with male death rates > twice as
high as in women; main causes of avoidable
mortality were motor vehicle accidents (men:
29%, women: 13%), hypertensive/
cerebrovasc. disease (18 & 30%), perinatal
mortality (20%) and lung cancer (16%)
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Empirical studies of ‘avoidable’ mortality: Analyses of changes over time – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Gai_auskien_
& Westerling
1995220
Lithuania &
Sweden
1971-1990 Trends in avoidable mortality in
Lithuania and Sweden in 4 periods:
1971-75, 1976-80, 1981-85, 1986-90;
‘avoidable’ mortality as defined by
Holland (1988)
basis: EC (1988)
• 15 conditions/groups of
conditions excl. Hodgkin’s disease
• ages: see Holland (1988)
Time trend
Age-standardised death rates;
(indirect) standardised death
ratios (Swedish rates as
standard)
Lithuania: Increase in all-cause mortality by
12% between 1971/75 & 1980/85 &
subsequent fall; increase in mortality from
hypertensive/cerebrovasc disease by 19%
between 1971/75 & 1986/90; Sweden: all-
cause mortality fell by 18%, mortality from
hypert/cerebrovasc. fell by 44%; death rates
higher in Lithuania than in Sweden for most
avoidable causes (TB, rheumatic heart dis.,
appendicitis, respiratory diseases etc.) gap
widening over time (e.g. TB ratio from 10.7
in 1971/75 to 36.2 in 1986/90, appendicitis:
3.4 and 5.6; all causes: 1.6 and 1.9)
Jozan
&Forster
199974
Budapest,
Hungary
1980-83,
1990-93
Trends in ‘amenable’ and ‘non-
amenable’ mortality in Budapest
between 1980/3 and 1990/3 by ‘social
advantage’; amenable mortality defined
as deaths “potentially preventable by
direct, timely and appropriate medical
care”
basis: EC (1988)
• 12 conditions/groups of
conditions excl. infectious
diseases; perinatal mortality
replaced by infant mortality
• ages: 0-64; for specific causes
see Holland (1988)
Time trend
SMR standardised to 1980/3
rates comparing most to least
disadvantaged district
(composite indictor: % unskilled
workers among economically
active population; % resident
population > 25 without
completed college/ university
degree; overcrowding)
Between 1980/3 & 1990/3 SMR amenable
causes declined in ‘most disadvantaged’
districts (men: 109.2, 98.4; women: 105.2,
89.8) while SMR all causes & non-amenable
causes increased in men (non-amenable:115.0
& 124.1) but not women (109.6, 105.7);
general decline in ‘least disadvantaged’
districts for all categories (amenable:
men:81.5, 74.8; women: 89.2, 74.4 / non-
amenable: men: 81.3, 77.9; women: 89.2,
78.3); ratio most-to-least disadvantaged
increased for all categories, from 1.3 to 1.7
for amenable and 1.3 to 1.5 for non-amenable
Boys et al.
199177
Hungary,
Czechoslovakia,
Poland, GDR,
FRG, England &
Wales, USA,
Canada
1955/1959,
1970/1974,
1985/1987
Trends in mortality from conditions
amenable to timely, appropriate
medical care and from non-amenable
conditions between 1955/59 and
1970/74 and between 1974/79 and
1985/87
basis: Rutstein et al.
• 22 conditions/groups of
conditions plus IHD as separate
category (from 1968)
• ages 0-64; cervical cancer: 15-
64; Hodgkin’s disease: 0-34;
diabetes, rheumatic fever/heart
disease, pneumonia: 0-49,
hypertens./ cerebrovascular
disease: 35-64; peptic ulcer,
cholelithiasis: 5-64;  maternal
mortality: all ages
Time trend
Age-standardised death rates for
ages 0-64 and 65+
(data Poland from 1959; DDR
for 1973 & 1974 and 1985-1987
only)
Amenable mortality fell in all countries, by in
33.5% in Hungary, 28.3 in Czech, 42.2 in
Poland compared with 42.5 in FRG, 40.4 in
E&W, 50.7 in Canada, 46.4 in US between
1955/59 & 1970/74; between 1970/74 &
1985/87 decline less steep in eastern countries
at 14.7% (Hun), 28.2 (Cz), 22.6 (Pol), 26.5
(DDR), 61.6 (FRG), 49.7 (E&W), 60.1 (Can),
51.2 (US); non-amenable mortality incl IHD
fell slightly in 1st period and increased in 2nd
period in east (Hun: 29%; Cz: 2.2; Pol: 16.5,
DDR: 2.9), fell in west (FRG: 19%, E&W:
15.5, Can: 22.9, US: 21.7); all cause mortality
fell in 1st period in all countries, by about 8-
15% but increased in Hun & Pol in 2nd period
[17 & 7%], declined otherwise, by 3.2 (Cz),
3.8 (DDR), 27.3 (FRG), 22 (E&W), 28.4
(Can), 26.2 (US)
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122 Empirical studies of ‘avoidable’ mortality: Analyses of changes over time – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Bojan et al.
1991221
Hungary,
Czechoslovakia,
England &
Wales, France,
Italy, Japan,
Portugal, USA
1979-1988 Pattern of avoidable mortality in
Hungary in international comparison;
‘avoidable’ mortality: “causes of death
avoidable with medical treatment”
basis: Rutstein et al.
• 13 conditions/groups of
conditions
• ages 5-64; cervical cancer: 15-
64; Hodgkin’s disease: 5-34;
rheumatic heart disease: 0-44,
acute respiratory disease,
pneumonia: 5-49
Time trend
Age-standardised mortality rates
Between 1981 & 1988 amenable mortality
fell by 35% in Japan, 20 in Italy, 20-30 in
E&W, 15-20 in France, 10 in US, 30 in
Portugal compared with all other causes at
about 5-10%; except Hungary & Czech where
amenable mortality first increased (4-10 &
10% ), declined from 1985 in Hun (15-20%)
and from 1983 in Czech (15%), all-cause
mortality increased similarly but rate of
decline was less rapid (about 5%; ages 5-64)
by 1988 amenable mortality was below 1981
level, non-amenable mortality remained
elevated
Nolte et al.
200257
East & west
Germany, Poland
1980/83-
1988,
1991/92-
1996/97
Trends in avoidable mortality with
causes of death divided into those
responsive to medical care
(‘amenable’) and those responsive to
health policy (‘preventable’)
basis: Mackenbach et al. (1988) &
EC (1988, 1993, 1997)
• 32 conditions/groups of
conditions; 28 ‘amenable’, 3
‘preventable’ plus IHD as separate
group
• ages 0-74
Time trend
Age-standardised death rates;
decomposition of life expectancy
[0-75] by age & cause of death
Between 1980/83 & 1988 improvements in
amenable mortality contributed 34 & 44% in
west German men and women to total
increase in temp. LE (east Germany: 62-63%;
Poland: decline in amenable mortality offset
by increase in IHD; still small increase in
temp. LE); in 1990s, amenable mortality
accounted for 12-16% in German men
(Poland: 21%), women: 26, 27 & 32%;
contribution of IHD- men: 21, 17 & 24%;
women: 7, 10 & 13%; preventable conditions
in men: 16, 23 & 16%; women: 8, 9 & 3%; 16
(men) – 25% (women) of gap in LE between
E+W Germany in 1997 attributable to
amenable conditions; preventable conditions:
46-50%
Kjellstrand et
al. 199880
Australia,
Canada, France,
Germany, Italy,
Japan, New
Zealand, Sweden,
UK, US
1980-1990 Trends in mortality from ‘avoidable’
[“amenable to treatment by modern
medicine”] and ‘unavoidable’ diseases
and in cost of health care; relation
between life expectancy,
avoidable/unavoidable, infant and
maternal mortality, acceptance rates for
dialysis and transplantation and health
expenditure; efficiency of health care
basis: Rutstein et al.
• 2 categories: ‘avoidable’ (6
causes of death); ‘unavoidable’
(remainder) (ages 5-64)
• life expectancy, maternal &
infant mortality, acceptance rates
for dialysis and renal
transplantation
Time trend
Slope of mortality & acceptance
rates; regression analysis of life
expectancy, mortality,
acceptance rates as dependent
and per capita cost & %GDP
spent on health as independent
variable (best fit); Efficiency-
index: (avoidable mortality rate
x mean $ expenditure per
capita)/(individual country
avoidable death rate x
expenditures for country)
Avoidable death rate declined by 34% &
unavoidable by 9%; cost/capita increased by
107%, health expenditure as % GDP by 10%;
correlation between health expenditure and
avoidable mortality strongest with 10 yr delay
(1970 exp & 1980 avoid. mortality: R2=0.71;
1980 exp. & 1990 avoid. mort.: R2=0.33); no
correlation between expenditure &
unavoidable mortality, infant & maternal
mortality; limited correlation between
expenditure & acceptance rates; Australia
most and US least efficient
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Empirical studies of ‘avoidable’ mortality: Analyses of changes over time – continued
Author country / region time period Topic/aim of study number of causes Design/method Results
Simonato et
al. 199858
21 countries in
Europe, divided
into Southern
Europe, Central
Europe, Northern
Europe & Nordic
countries
1955-1994
(varies by
country)
Trends of avoidable mortality in
Europe: causes amenable to primary
prevention through reduction of
exposures, secondary prevention
through early detection and treatment,
and tertiary prevention through
improved treatment and medical care
basis: Rutstein et al.
• (1) causes avoidable through
primary prevention (7 causes of
death); (2) causes avoidable
through secondary prevention (4
(mainly female) conditions); (3)
causes avoidable through improved
treatment and medical care (12
conditions = Charlton’s list)
• ages 5-64
Time trend
Age-standardised 5-year death
rates (standardised to world
population)
Between 1955/59 and 1990/94 mortality from
all avoidable causes declined by 45.8% in
women and 39.3% in men (all-cause
mortality: 45.1 and 32.6%); reduction greatest
in causes amenable to medical care (grp 3),
by 76-78% in both sexes while preventable
causes declined by 17% in men and 29% in
women; among women also decline in group
2 causes, by 11%; for men, main causes of
avoidable mortality related to preventable
conditions (tobacco, diet, occupational
exposures), for women main avoidable causes
were cancers that are considered preventable
by screening
G L O S S A R Y
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GLOSSARY
AHA  . . . . . . . . . . . . . . . . . Area Health Authority
Anaemia  . . . . . . . . . . . . . Deficiency anaemia
Bact  . . . . . . . . . . . . . . . . . Bacterial 
CA . . . . . . . . . . . . . . . . . . . Cancer
CVA  . . . . . . . . . . . . . . . . . Cerebrovascular disease
dis  . . . . . . . . . . . . . . . . . . . Disease(s)
E&W  . . . . . . . . . . . . . . . . England & Wales
EC  . . . . . . . . . . . . . . . . . . . European Community
EU  . . . . . . . . . . . . . . . . . . . European Union
GP  . . . . . . . . . . . . . . . . . . . General Practitioner
IHD . . . . . . . . . . . . . . . . . . Ischaemic heart disease
IMR  . . . . . . . . . . . . . . . . . Infant mortality rate
infect  . . . . . . . . . . . . . . . . Infection(s)
LE  . . . . . . . . . . . . . . . . . . . Life expectancy
MCI  . . . . . . . . . . . . . . . . . Medical care indicator
(N)HPI . . . . . . . . . . . . . . . (National) health policy indicator
resp . . . . . . . . . . . . . . . . . . respiratory
SES  . . . . . . . . . . . . . . . . . . Socio-economic status
SMR  . . . . . . . . . . . . . . . . . Standardised Mortality Ratio
TB  . . . . . . . . . . . . . . . . . . . Tuberculosis
YPLL / PYLL  . . . . . . . . . Years of Potential Life Lost
R E F E R E N C E S
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